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FOREWORDForeword
This 2013 edition of Health at a Glance – OECD Indicators presents the most recent comparable
data on key indicators of health and health systems across the 34 OECD member countries. Where
possible, it also reports comparable data for Brazil, China, India, Indonesia, the Russian Federation,
and South Africa, as key emerging countries.
The production of Health at a Glance would not have been possible without the contribution
of OECD Health Data National Correspondents, Health Accounts Experts, and Health Care Quality
Indicators Experts from the 34 OECD countries. The OECD gratefully acknowledges their effort in
supplying most of the data contained in this publication. The OECD also acknowledges the
contribution of other international organisations, especially the World Health Organization, the
World Bank and Eurostat, for sharing some of the data presented here, and the European
Commission for supporting data development.
This publication was prepared by a team from the OECD Health Division under the co-
ordination of Gaétan Lafortune. Chapter 1 was prepared by Gaétan Lafortune, Kees van Gool and
Nelly Biondi; Chapter 2 by Franco Sassi, Marion Devaux, Michele Cecchini and Nelly Biondi; Chapter
3 by Michael Schoenstein, Gaétan Lafortune, Gaëlle Balestat and Anne Durand; Chapter 4 by Gaétan
Lafortune, Valérie Paris, Gaëlle Balestat, Marie-Clémence Canaud and Jessica Farebrother;
Chapter 5 by Kees van Gool, Ian Forde, Rie Fujisawa, Nelly Biondi, Evianne van der Kruk and Niek
Klazinga; Chapter 6 by Marion Devaux, Valérie Paris, Gaétan Lafortune, Michael Schoenstein,
Tomoko Ono, Michael Mueller, Emily Hewlett and Alessia Forti; Chapter 7 by David Morgan, Michael
Mueller and Alan Diener; and Chapter 8 by Francesca Colombo, Yuki Murakami, Marie-Clémence
Canaud, Nelly Biondi, Michael Mueller and Martin Salomon. This publication benefited from many
comments and suggestions from Mark Pearson (Head of the OECD Health Division).HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013 3
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EDITORIAL: FROM EXPENDITURE GROWTH TO PRODUCTIVITY GROWTH IN THE HEALTH SECTOREditorial:
From expenditure growth to productivity growth
in the health sector
Almost six years since the start of the global financial and economic crisis, economic
conditions vary widely across OECD countries, with the United States, Canada and Japan
on a path to recovery, while the economic prospects of many European countries remain
subdued. After a period in which, as part of the stimulus packages, greater resources were
channelled to welfare and social protection programmes, the shift towards restoring sound
fiscal conditions has often implied substantial cuts in public spending. Like other government
programmes, health care has been the target of spending cuts in many OECD countries.
The crisis has had a profound impact on the lives of citizens across the world, and has
tested the resilience of many families as they see their wealth and incomes decline.
Millions of people have joined the ranks of the unemployed and millions more are
experiencing financial stress. The combined effects of the crisis with the associated recent
expenditure cuts as well as health care reforms have led to uncertainty about the impact
on the health and well-being of the population. The most recent OECD health statistics,
presented in this edition of Health at a Glance, provide a comprehensive picture of how
health systems have evolved during the crisis and the challenges which lie ahead.
Most OECD countries have moved to lower health spending
Growth in health spending has slowedmarkedly in almost all OECD countries since 2008.
After years of continuous growth of over 4% per annum, average health spending across the
OECD grew at only 0.2% between 2009 and 2011. Total health spending fell in 11 out of the 34
OECD countries between 2009 and 2011, compared to pre-crisis levels. Not surprisingly, the
countries hit hardest by the economic crisis have witnessed the biggest cuts in health
expenditure growth. For example, Greece and Ireland experienced the sharpest declines, with
per capita health care spending falling by 11.1% and 6.6%, respectively, between 2009 and 2011.
Health spending growth also slowed significantly in Canada and the United States. Only in
Israel and Japan has health spending growth accelerated since 2009.
In order to limit or reduce public health expenditures, countries have worked to lower the
prices paid for publicly financed health care, including cutting the price of medical goods,
particularly pharmaceuticals. Governments have targeted hospital spending through
budgetary restrictions and cuts to wages. Several countries including Greece, Ireland, Iceland
and Estonia have reduced nursing wages in response to the crisis as well as those of salaried
GPs. Expenditure on prevention and public health has also been cut since 2009. Further, in
several OECD countries, patients are now expected to assume a greater share of health costs.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013 9
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10The crisis has had a mixed impact on health indicators
What has been the effect of the crisis on health? The results are mixed. For example,
while suicide rates rose slightly at the start of the crisis, they appear to have stabilised
since then. There are also indications that Greece’s infant mortality rate, long in decline,
has been rising since the crisis started. Neither is good news. But other health indicators
tell a different story: mortality from road traffic accidents, for example, has declined. Such
deaths had already been steadily falling in most OECD countries, but the rate of decline
accelerated after 2008 in some countries that were hard hit by the recession, likely because
less economic activity means fewer cars on the roads, and so fewer accidents.
The crisismay also have led to positive changes in certain health behaviours. In particular,
alcohol and tobacco consumption in a number of OECD countries fell in the immediate
aftermath of the crisis. This was already a long-standing trend inmost countries, but the drop
in consumption has accelerated due to the combined impact of lower incomes and more
stringent policies around purchasing and use. It remains a question as to whether these gains
can be maintained once economic growth and household budgets improve.
As the short-term impact of the crisis on health is both bad (mental health) and good
(accidents, alcohol), it is not surprising to find that there is no evidence yet of a widespread
health impact in the countries hardest hit by the crisis. As with so many things in health, the
pathways by which economic crisis and policies affect health outcomes are complex to
evaluate. Moreover, most countries, including those most heavily affected by the crisis,
continue to make progress in primary health care and the quality of acute care for life-
threatening conditions. There are no signs that the crisis is raising cancer-related mortality
rates, for example, andmost countries have continued to raise survival rates for cardiovascular
disease.
Nevertheless, the direction that policies have taken in some countries raises some
concern. For instance, prevention is often a more cost-effective way of improving health than
spending money once a disease takes root. However, prevention expenditures have been
reduced since 2009 (although they only account for around 3-4% of total health expenditure).
One example of the consequences is the dramatic rise in the number of new HIV cases
reported since 2010 in Athens, Greece, among injecting drug users. Although opioid
substitution and needle exchange programmes have expanded since the start of the outbreak,
the initial response fell well short of recommended levels of access, illustrating the potential
long-term impact on health and spending when highly cost-effective prevention programmes
are not fully implemented. Cuts in spending on preventing obesity, harmful use of alcohol, and
tobacco consumption are cases of “penny-wise, pound foolish” thinking.
Likewise, cuts to the supply of health care services and changes in health care financing
arrangements are also affecting access to care. After years of steady decline, average waiting
times for some operations in Portugal, Spain, England, and Ireland show a small increase.
There is evidence thatmore people in countries such as Greece and Italy are foregoingmedical
care due to financial constraints, reflecting reduced household incomes, but also perhaps
rising out-of-pocket costs. Low-income groups are the worst affected, although they are likely
to have the highest health care needs, and they may be foregoing necessary care such as
medicines or routine medical check-ups for chronic conditions. This may have long-term
health and economic consequences for the most vulnerable groups in society.
Towards affordable, sustainable care
Pressures to reduce public spending are likely to persist well into the recovery phase.
Given the large fiscal imbalances built during the crisis, fiscal consolidation required to bringHEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013
EDITORIAL: FROM EXPENDITURE GROWTH TO PRODUCTIVITY GROWTH IN THE HEALTH SECTORdebt-to-GDP ratios back to sustainable levels would have to be pursued for a number of years,
as stressed in the 2013 OECD Economic Outlook. Countries’ main consolidation targets vary but
generally focus on inefficient public expenditures and include savings on health care.
In a climate of fiscal restraint and efficiency efforts, health expenditure growth should be
more aligned to a country’s economic growth and its ability to raise revenue. This was not the
case before the crisis, whenhealth care funding outpaced economic growth inmany countries.
The crisis has pushedmany countries to undertake structural reforms of their health systems,
aimed at changing the incentives or the way that prices are negotiated. Examples include
Greece’s introduction of a new output-based hospital funding system, Italy’s drive for greater
competiveness in the pharmaceutical distribution market, Portugal’s investment in health
care performance management systems and the centralisation of pharmaceutical purchasing
powers in Spain. These reforms could make important long-term contributions to the health
systems’ productivity and efficiency.
Governmentsmust continue to seek cleverways bywhich health systems can continue to
improve the well-being of patients within the new fiscal environment. Some countries are
moving towards greater labour productivity by re-examining the traditional functions of
general practitioners, specialists, nurses and allied health professionals. Other countries are
also looking at the extent to which medical practice variation points towards ineffective or
inefficient care. For example, there is a three-fold difference in the rate of caesarean sections
between Iceland and the Netherlands, which have the lowest number of caesareans, and
Mexicowhich has the highest rate. Some of this variationmay be justified by clinical need, but
it could alsomean that women are either having unnecessary operations, or being denied care
they should be getting. Evidence-based clinical pathways can improve health care productivity.
While the agenda for quality of care has now been firmly embedded in most health care
systems, countries can make further gains in patient safety, thereby reducing the costs and
health burdens associated with adverse events. Health care quality can also be improved by
strengthening primary care systems to better manage complex conditions. The increasing
prevalence of complex chronic diseases is one of the many challenges arising from ageing
populations andwill require constant vigilance andmultidisciplinary care to prevent the onset
of costly complications.
Many of the reforms implemented since the start of the crisis have had an immediate
impact on public expenditure. Some have been controversial, with considerable unrest and
political pressure from industry groups, and some may also have had undesirable
consequences for access, outcomes and equity. For example, greater out-of-pocket costs are
likely to reduce health care use among those in highest need, leading to greater inequity and
inefficiency over the longer term.
In the new,more constrained, fiscal climate, the challenge for health care policymakers is
to preserve quality health care coverage for the whole population while converting a system
built on notions of unconstrained growth to one that is based on greater productivity and fiscal
sustainability. This challenge is not new. Countries have pursued the twin objectives of
efficiency and equity in health for decades.The economic crisis means that health care policy
makers must swiftly and convincingly adopt a health care productivity agenda.
Stefano Scarpetta
Director for Employment, Labour and Social AffairsHEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013 11

EXECUTIVE SUMMARYExecutive summary
Health at a Glance 2013 presents the trends and influences shaping health status, services
and policies in OECD countries and the BRIICS. Although indicators such as life expectancy
or infant mortality suggest that things are improving overall, inequalities in wealth,
education and other social indicators still have a significant impact on health status and
access to health services.These health disparities may be explained by differences in living
and working conditions, as well as differences that show up in the health-related lifestyle
data presented here (e.g., smoking, harmful alcohol drinking, physical inactivity, and
obesity).
Health expenditures show considerable variations across countries, in terms of spending
per capita, as a share of GDP and recent trends. On average across the OECD, per capita
health spending grew by 4.1% annually in real terms over 2000-2009, but this slowed to 0.2%
in 2009-10 and 2010-11 as many countries reduced health spending to help cut budget
deficits and government debt, especially in Europe. Countries outside of Europe have
continued to see health spending grow, albeit at a reduced pace in many cases, notably in
Canada and the United States.
Different areas of spending have been affected in different ways: in 2010-11, spending on
pharmaceuticals and prevention dropped by 1.7%, while hospital costs rose by 1.0%.
Life expectancy in OECD countries is rising,
but so is the burden of chronic diseases
● Average life expectancy exceeded 80 years across OECD countries in 2011, an increase of
ten years since 1970. Those born in Switzerland, Japan and Italy can expect to live the
longest among OECD countries.
● Across OECD countries, women can expect to live 5.5 years longer thanmen. People with
the highest level of education can expect to live 6 years longer than those with the
lowest level of education.
● Chronic diseases such as diabetes and dementia are increasingly prevalent. In 2011,
close to 7% of 20-79 year-olds in OECD countries, or over 85 million people, had diabetes.
There are more doctors per capita in most
countries, but twice as many specialists
as generalists
● Since 2000, the number of doctors has grown in most OECD countries, both in absolute
number and on a per capita basis, with only a few exceptions. There was virtually no
growth in the number of doctors per capita in Estonia and France, and a decline in Israel.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013 13
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14● There were two specialists for every generalist on average across the OECD, in 2011. The
slow growth in, or reduction of, the number of generalists raises concerns about access
to primary care for all the population.
Shorter hospital stays and growing use of generic
drugs help to contain costs, but large variations
in medical practice point towards overuse
● The length of stay in hospital dropped from 9.2 days in 2000 to 8.0 days in 2011 in OECD
countries.
● The market share of generic drugs has increased significantly over the past decade in
many countries. However, generics still represent less than 25% of the market in
Luxembourg, Italy, Ireland, Switzerland, Japan and France, compared with about 75% in
Germany and the United Kingdom.
● Wide variations in the utilisation rate of different diagnostic and surgical procedures
cannot be explained by differences in clinical needs. For example, in 2011, caesarean
sections made up more than 45% of all births in Mexico and Turkey, triple the rate in
Iceland and the Netherlands, suggesting possible overuse.
The quality of acute care and primary care has
improved in most countries, but could improve
more
● Progress in the treatment of life-threatening conditions such as heart attack, stroke and
cancer has led to higher survival rates in most OECD countries. On average, mortality
rates following hospital admissions for heart attack fell by 30% between 2001 and 2011
and for stroke by almost 25%. Survival has also improved for many types of cancer,
including cervical cancer, breast cancer and colorectal cancer.
● The quality of primary care has also improved in most countries, as shown by the
reduction in avoidable hospital admissions for chronic diseases such as asthma and
diabetes. Still, there is room in all countries to improve primary care to further reduce
costly hospital admissions for these conditions.
Nearly all OECD countries have achieved
universal health coverage, but the scope
and degree of coverage varies
● All OECD countries have universal (or quasi-universal) health coverage for a core set of
health services and goods, except Mexico and the United States. Following the 2004
reforms in Mexico, the proportion of the population covered has grown rapidly to reach
nearly 90%. In the United States, where 15% of the population was still uninsured in
2011, the Affordable Care Act will further expand health insurance coverage, from
January 2014.
● The burden of out-of-pocket spending creates barriers to health care access in some
countries. On average, 20% of health spending is paid directly by patients; this ranges
from less than 10% in the Netherlands and France to over 35% in Chile, Korea and
Mexico.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013
EXECUTIVE SUMMARY● Around 19% of out-of-pocket medical expenditure across OECD countries in 2011 was for
dental care, while another 12% was for eyeglasses, hearing aids and other therapeutic
appliances.
● People in low-income groups are more likely to report unmet medical and dental needs
than people in higher-income groups, and are also less likely to consult a medical
specialist or a dentist.
Population ageing increases demand for long-term
care and puts pressures on public spending,
despite informal care
● The life expectancy of people at age 65 has continued to increase, reaching nearly
21 years for women and 18 years for men across OECD countries in 2011. However, many
of these additional years are lived with some chronic conditions. For example, over a
quarter of people aged 85 years and older suffers from dementia.
● Across OECD countries, more than 15% of people aged 50 and older provide care for a
dependent relative or friend, and most informal carers are women.
● Public expenditures on long-term care grew by 4.8% annually between 2005 and 2011
across OECD countries, higher than the growth in health care spending.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013 15

READER’S GUIDEReader’s guide
Health at a Glance 2013 presents comparisons of key indicators of health and health
systems across the 34 OECD countries, as well as for key emerging countries (Brazil, China,
India, Indonesia, the Russian Federation and SouthAfrica). The indicators presented in this
publication have been selected on the basis of their policy relevance as well as data
availability and comparability. The data come mainly from official national statistics,
unless otherwise indicated.
Structure of the publication
The framework underlying this publication assesses the performance of health
systems in the context of a broader view of public health (Figure 0.1). It is based on a
framework that was endorsed for the OECD Health Care Quality Indicators project (Kelley
and Hurst, 2006; Arah et al., 2006).
This framework recognises that the goal of health systems is to improve the health
status of the population. Many factors influence the health status of the population,
including a number that fall outside health care systems, such as the physical environment
in which people live, and individual lifestyles and behaviours. The performance of health
care systems also contributes obviously to the health status of the population. This
performance includes several dimensions, including the degree of access to care and the
quality of care provided.
Performance measurement also needs to take into account the financial resources
required to achieve these access and quality goals. The performance of health systems
depends on the people providing the services, and the training, technology and equipment
at their disposal.
Finally, a number of contextual factors that also affect the health status of the
population and the demand for and supply of health services also need to be taken into
account, including the demographic context, and economic and social development.
Health at a Glance 2013 compares OECD countries on each component of this
framework. It is structured around eight chapters.
Chapter 1 on Health Status highlights large variations across countries in life
expectancy, mortality and other measures of population health status. Compared with the
previous edition, this chapter includes new measures of inequality in health status by
education and income level for key indicators such as life expectancy and perceived health
status.
Chapter 2 on Non-medical Determinants of Health focuses on health-related lifestyles
and behaviours among children and adults, including tobacco smoking, alcohol drinking,
physical activity, nutrition, and overweight and obesity problems. Most of these factors can
be modified by public health and prevention policies.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013 17
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18Chapter 3 looks at the Health Workforce, providing data on the supply and
remuneration of doctors and nurses in OECD countries. It also presents trends on the
number of new graduates from medical and nursing education programmes, a key
determinant of future supply.
Chapter 4 on Health Care Activities describes some of the main characteristics of health
service delivery in different OECD countries. It begins by looking at consultations with
doctors, and the supply and use of diagnostic technologies such as medical resonance
imaging and computed tomography scanners. The hospital sector continues to absorb the
largest share of health spending in OECD countries, hence a focus on the availability of
hospital beds, their utilisation rate, the number of hospital discharges and average length
of stay. The chapter also looks at variations in the use of high-volume and high-cost
procedures, such as caesarean sections, cardiac procedures, and hip and knee
replacement. It concludes by looking at the pharmaceutical market, comparing the use of
certain pharmaceutical drugs and the share of the generic market in different countries.
Chapter 5 examines Quality of Care or the degree to which care is delivered in
accordance with established standards and improves health outcomes. It provides
comparisons on quality of care for chronic conditions and pharmaceutical prescriptions,
acute care for life-threatening diseases, patient safety, care for mental disorders, cancer
care, the prevention of communicable diseases and, for the first time, some important
aspects of patient experiences.
Chapter 6 on Access to Care presents a set of indicators that can be used to assess to
what extent OECD countries are meeting their policy goal of ensuring adequate access to
essential health services on the basis of individual need. It begins by describing the
proportion of population covered by public or private health insurance and the share of
Figure 0.1. Conceptual framework for health system performance assessment
Source: Adapted from Kelley, E. and J. Hurst (2006), “Health Care Quality Indicators Project: Conceptual Framework”,
OECD Health Working Paper, No. 23, OECD Publishing, http://dx.doi.org/10.1787/440134737301.
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Health care activities
(Chapter 4)
Demographic, economic and social context
(Annex A)HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013
READER’S GUIDEout-of-pocket spending in household consumption. The chapter then discusses issues
around geographic access to care, focusing in particular on the “density” of doctors in
different regions in each country. Another approach to measuring access to care is to look
at inequalities among different socioeconomic groups in the use of health services. Three
indicators look at the use of doctors, dentists and screening rates for cancer, either by
income group or education level. The last indicator relates to timely access to care,
comparing waiting times for certain elective surgery in a group of OECD countries where
this is considered to be an important issue.
Chapter 7 on Health Expenditure and Financing compares how much OECD countries
spend on health, both on a per capita basis and in relation to GDP. The chapter also
provides an analysis of the different types of health services and goods consumed across
OECD countries, including a separate focus on pharmaceuticals. It also looks at how these
health services and goods are paid for in different countries (i.e. the mix between public
funding, private health insurance where it exists, and direct out-of-pocket payments).
Lastly, in the context of the growth in medical tourism and international trade in health
services, current levels and trends are examined.
Chapter 8 focuses on Ageing and Long-term Care, starting by a review of demographic
trends and the rising share of the population aged over 65 and 80 in all OECD countries.The
chapter presents the most recent data on life expectancy and life expectancy in good
health at age 65, self-reported health and disability status, as important factors affecting
the current and future demand for long-term care. This is followed by a set of indicators on
older persons currently receiving long-term care at home or in institutions, on care
providers (including both formal and informal caregivers), and on the capacity to provide
long-term care in institutions in different countries. The final indicator reviews levels and
trends in long-term care expenditure over the past decade.
A Statistical Annex provides additional information on the demographic and economic
context within which health and long-term care systems operate.
Presentation of indicators
Each of the topics covered in the different chapters of this publication is presented
over two pages. The first provides a brief commentary highlighting the key findings
conveyed by the data, defines the indicator and signals any significant national variation
from the definition which might affect data comparability. On the facing page is a set of
figures. These typically show current levels of the indicator and, where possible, trends
over time. Where an OECD average is included in a figure, it is the unweighted average of
the OECD countries presented, unless otherwise specified.
Data limitations
Limitations in data comparability are indicated both in the text (in the box related to
“Definition and comparability”) as well as in footnotes to figures.
Data sources
Readers interested in using the data presented in this publication for further analysis
and research are encouraged to consult the full documentation of definitions, sources and
methods presented in OECD Health Statistics on OECD.Stat (http://stats.oecd.org/index.aspx,
then choose “Health”). More information on OECD Health Statistics is available at
www.oecd.org/health/healthdata. Information about data sources used for non-OECD
countries is available at www.oecd.org/health/healthataglance.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013 19
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20Population figures
The population figures presented in Annex A and used to calculate rates per capita
throughout this publication come from the OECD Historical Population Data and
Projections (as of end of May 2013), and refer to mid-year estimates. Population estimates
are subject to revision, so they may differ from the latest population figures released by the
national statistical offices of OECD member countries.
Note that some countries such as France, the United Kingdom and the United States
have overseas colonies, protectorates or territories. These populations are generally
excluded. The calculation of GDP per capita and other economic measures may, however,
be based on a different population in these countries, depending on the data coverage.
OECD country ISO codes
Emerging country ISO codes
Australia AUS Japan JPN
Austria AUT Korea KOR
Belgium BEL Luxembourg LUX
Canada CAN Mexico MEX
Chile CHL Netherlands NLD
Czech Republic CZE New Zealand NZL
Denmark DNK Norway NOR
Estonia EST Poland POL
Finland FIN Portugal PRT
France FRA Slovak Republic SVK
Germany DEU Slovenia SVN
Greece GRC Spain ESP
Hungary HUN Sweden SWE
Iceland ISL Switzerland CHE
Ireland IRL Turkey TUR
Israel ISR United Kingdom GBR
Italy ITA United States USA
Brazil BRA Indonesia IDN
China CHN Russian Federation RUS
India IND South Africa ZAFHEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013
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1.5. Mortality from transport accidents
1.6. Suicide
1.7. Infant mortality
1.8. Infant health: Low birth weight
1.9. Perceived health status
1.10. Diabetes prevalence and incidence
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1. HEALTH STATUS1.1. Life expectancy at birthLife expectancy has increased greatly over the past few
decades in all OECD countries and many emerging econo-
mies. Improvement in living conditions, a reduction of cer-
tain risk factors (e.g., smoking rates) and progress in health
care are the main factors explaining increased longevity.
For the first time in history, in 2011, life expectancy on aver-
age across OECD countries exceeded 80 years, an increase
of ten years since 1970 (Figure 1.1.1). Switzerland, Japan
and Italy lead a large group of over two-thirds of OECD
countries in which life expectancy at birth now exceeds
80 years. A second group, including the United States, Chile
and a number of central and eastern European countries,
have a life expectancy between 75 and 80 years. Among
OECD countries life expectancy was lowest in Mexico and
Turkey. While life expectancy in Turkey has increased rap-
idly and steadily over the past four decades, the increase in
Mexico has slowed down markedly since 2000.
Emerging countries such as Brazil, China, Indonesia and
India have also achieved large gains in longevity over the
past decades, with life expectancy in these countries con-
verging rapidly towards the OECD average. There has been
much less progress in South Africa (due mainly to the epi-
demic of HIV/AIDS) and the Russian Federation (duemainly
to the impact of the economic transition in the 1990s and
the rise in risky behaviors among men).
In the United States, the gains in life expectancy since 1970
have also been much more modest than in most other
OECD countries. While life expectancy in the United States
used to be one year above the OECD average in 1970, it is
now more than one year below the average. Many possible
explanations have been suggested for these lower gains in
life expectancy, including: 1) the highly fragmented nature
of the US health system, with relatively few resources
devoted to public health and primary care, and a large
share of the population uninsured; 2) health-related behav-
iours, including higher calorie consumption per capita and
obesity rates, higher consumption of prescription and ille-
gal drugs, higher deaths from road traffic accidents and
higher homicide rates; and 3) adverse socio-economic con-
ditions affecting a large segment of the US population, with
higher rates of poverty and income inequality than in most
other OECD countries (National Research Council and Insti-
tute of Medicine, 2013).
Higher national income (as measured by GDP per capita) is
generally associated with higher life expectancy at birth,
although the relationship is less pronounced at the highest
levels of national income (Figure 1.1.2). There are also nota-
ble differences in life expectancy between countries with
similar income per capita. For example, Japan and Italy
have higher, and the United States and the Russian
Federation have lower life expectancies than would be pre-
dicted by their GDP per capita alone.
Figure 1.1.3 shows the relationship between life expectancy
at birth and health expenditure per capita across OECD
countries and emerging countries. Higher health spending
per capita is generally associated with higher life expec-
tancy at birth, although this relationship tends to be less
pronounced in countries with the highest health spending
per capita. Japan, Italy and Spain stand out as having rela-
tively high life expectancies, and the United States and the
Russian Federation relatively low life expectancies, given
their levels of health spending.
Many other factors, beyond national income and total
health spending, affect life expectancy and explain varia-
tions across countries.
Definition and comparability
Life expectancy at birth measures how long, on aver-
age, people would live based on a given set of age-
specific death rates. However, the actual age-specific
death rates of any particular birth cohort cannot be
known in advance. If age-specific death rates are fall-
ing (as has been the case over the past decades),
actual life spans will be higher than life expectancy
calculated with current death rates.
The methodology used to calculate life expectancy
can vary slightly between countries. This can change
a country’s estimates by a fraction of a year.
Life expectancy at birth for the total population is
calculated by the OECD Secretariat for all OECD coun-
tries, using the unweighted average of life expectancy
of men and women.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 201324
1. HEALTH STATUS
1.1. Life expectancy at birth1.1.2. Life expectancy at birth and GDP per capita, 2011
(or nearest year)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932916021
1.1.3. Life expectancy at birth and health spending
per capita, 2011 (or nearest year)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en;
World Bank for non-OECD countries.
1 2 http://dx.doi.org/10.1787/888932916040
1.1.1. Life expectancy at birth, 1970 and 2011 (or nearest year)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en; World Bank for non-OECD countries.
1 2 http://dx.doi.org/10.1787/888932916002
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1. HEALTH STATUS1.2. Life expectancy by sex and education levelThere remain large gaps in life expectancy between women
and men in all OECD countries. On average across OECD
countries, life expectancy at birth for women reached
82.8 years in 2011, compared with 77.3 years for men, a gap
of 5.5 years (Figure 1.2.1).
The gender gap in life expectancy increased substantially
in many OECD countries during the 1970s and early 1980s
to reach a peak of almost seven years in the mid-1980s, but
it has narrowed during the past 25 years, reflecting higher
gains in life expectancy among men than among women.
This can be attributed at least partly to the narrowing of
differences in risk-increasing behaviours, such as smoking,
accompanied by sharp reductions in mortality rates from
cardiovascular diseases among men.
In 2011, the life expectancy for women in OECD countries
varied from a low of 77 years in Turkey and Mexico to a
high of nearly 86 years in Japan and France. Life expec-
tancy for men ranged from 71 years in Estonia, Hungary
and Mexico, to over 80 years in Iceland, Switzerland and
Italy. The life expectancy for both women and men is
much shorter in South Africa (at only 53 and 52 years
respectively in 2011), due largely to the HIV/AIDS
epidemic.
In the United States, the life expectancy for both women
and men is now slightly shorter than the OECD average,
and the gap with leading countries has been widening.
The life expectancy for US men in 2011 was 4.2 years
shorter than in Switzerland (up from less than three years
in 1970); for US women, it was 4.8 years shorter than in
Japan in 2011 (there was no gap in 1970). Possible explana-
tions for this slower progress are provided in Indicator 1.1.
Among OECD countries, the gender gap in life expectancy
is relatively narrow in Iceland, Israel, New Zealand, the
Netherlands and Sweden (a gap of less than four years), but
much larger in Estonia (more than ten years), Hungary, the
Slovak Republic and Poland (7.5 years or more), and France
(seven years). In the Russian Federation, the gender gap in
life expectancy reached almost 12 years in 2011. This large
gap in life expectancy between Russian men and women
can be explained to a large extent by higher smoking rates
and alcohol consumption, and higher death rates from
road traffic accidents, homicides and suicides (OECD,
2012c).
Life expectancy in OECD countries varies not only by gen-
der, but also by socio-economic status as measured for
instance by education level (Figure 1.2.2). Higher education
level not only provides the means to improve the socio-
economic conditions in which people live and work, but
may also promote the adoption of more healthy lifestyles
and facilitate access to appropriate health care. On average
among 14 OECD countries for which data are available, peo-
ple with the highest level of education can expect to live six
years more than people with the lowest level of education
at age 30 (53 years versus 47 years). These differences in
life expectancy by education level are particularly pro-
nounced for men, with a gap of almost eight years on aver-
age. They are particularly large in central and eastern
European countries (Czech Republic, Estonia, Hungary,
Poland and Slovenia), where the life expectancy gap
between higher and lower educated men reaches more
than ten years. Differences in Portugal, Sweden,
Switzerland and Italy are less pronounced, although not
negligible.
Definition and comparability
Life expectancy at birth measures how long, on aver-
age, people would live based on a given set of age-
specific death rates. However, the actual age-specific
death rates of any particular birth cohort cannot be
known in advance. If age-specific death rates are fall-
ing (as has been the case over the past decades),
actual life spans will be higher than life expectancy
calculated with current death rates.
The methodology used to calculate life expectancy
can vary slightly between countries. This can change
a country’s estimates by a fraction of a year.
To calculate life expectancies by education level,
detailed data on deaths by sex, age and education
level are needed. However, not all countries have
information on education as part of their deaths data.
Data linkage to another source (e.g. a census) which
does have information on education may be required
(Corsini, 2010).HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 201326
1. HEALTH STATUS
1.2. Life expectancy by sex and education level1.2.1. Life expectancy at birth by sex, 2011 (or nearest year)
Note: Countries are ranked in descending order of life expectancy for the whole population.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en; World Bank for non-OECD countries.
1 2 http://dx.doi.org/10.1787/888932916059
1.2.2. Gap in life expectancy at age 30 by sex and education level, 2010 (or nearest year)
Note: The figures show the gap in the expected years of life remaining at age 30 between adults with the highest level (“tertiary education”) and the
lowest level (“below upper secondary education”) of education.
Source: Eurostat database complemented with national data for Austria, Netherlands and Switzerland.
1 2 http://dx.doi.org/10.1787/888932916078
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1. HEALTH STATUS1.3. Mortality from cardiovascular diseasesCardiovascular diseases are the main cause of mortality in
most OECD countries, and accounted for 33% of all deaths
in 2011. They cover a range of diseases related to the circu-
latory system, including ischemic heart disease (often
referred to as heart attack) and cerebrovascular diseases
such as stroke.
Ischemic heart disease (IHD) is caused by the accumulation
of fatty deposits lining the inner wall of a coronary artery,
restricting blood flow to the heart. IHD alone was responsi-
ble for 12% of all deaths in OECD countries in 2011. Mortality
from IHD varies considerably, however, across countries
(Figure 1.3.1). Central and eastern European countries
report the highest IHD mortality rates; Japan, Korea and
France are the countries with the lowest rates. Across OECD
countries, IHD mortality rates in 2011 were 90% higher for
men than women.
IHD mortality rates have declined in nearly all OECD coun-
tries, with an average fall of 40% since 1990. The decline
has been most remarkable in Denmark, the Netherlands,
and Norway, where rates fell by two-thirds or more. Declining
tobacco consumption contributed significantly to reducing
the incidence of IHD, and consequently to reducing mortality
rates. Improvements in medical care have also contributed
to reducedmortality rates (see Indicator 4.6 “Cardiac proce-
dures” and 5.3 “Mortality following acute myocardial
infarction”).
The Slovak Republic and Mexico as well as Korea have
witnessed a rise in IHD mortality rates. The increase was
particularly large in Korea; however IHD mortality remains
low in Korea and has started to fall after peaking in 2006.
The initial rise has been attributed to changes in lifestyle
and dietary patterns as well as environmental factors at the
time of birth, with people born between 1940 and 1950 fac-
ing higher relative risks (OECD, 2012b; Juhn et al., 2011; Lee
et al., 2012).
Cerebrovascular disease was the underlying cause for
about 8% of all deaths in OECD countries in 2011. Cerebro-
vascular diseases refer to a group of diseases that relate to
problems with the blood vessels that supply the brain.
Common types of cerebrovascular disease include ischemic
stroke, which develops when the brain’s blood supply is
blocked or interrupted, and haemorrhagic stroke which
occurs when blood leaks from blood vessels onto the
surface of the brain. In addition to being an important
cause of mortality, the disability burden from stroke and
other cerebrovascular diseases is also substantial (Murray
et al., 2013).
There are large variations in cerebrovascular disease
mortality rates across countries (Figure 1.3.2). Hungary and
the Slovak Republic report a cerebrovascular mortality that
is more than three times higher than that of Switzerland
and France. Many of the central and eastern European
countries including the Czech Republic and Estonia have
highmortality rates for both IHD and cerebrovascular disease.
The high prevalence of risk factors common to both diseases
(e.g. smoking and high blood pressure) helps explain this
link.
Since 1990, cerebrovascular disease mortality has
decreased in all OECD countries, although only marginally
in Poland and the Slovak Republic. On average, the mortal-
ity burden from cerebrovascular disease has been halved
across OECD countries. In Estonia, Luxembourg, Portugal
and Spain, the rates have been cut by at least two-thirds. As
with IHD, the reduction in mortality from cerebrovascular
disease can be attributed at least partly to a reduction in
risk factors as well as improvements in medical treatments
(see Indicator 5.4 “Mortality following stroke”).
Definition and comparability
Mortality rates are based on numbers of deaths regis-
tered in a country in a year divided by the size of the
corresponding population. The rates have been
directly age-standardised to the 2010 OECD popula-
tion to remove variations arising from differences in
age structures across countries and over time. The
source is the WHO Mortality Database.
Deaths from ischemic heart disease are classified to
ICD-10 codes I20-I25, and cerebrovascular disease to
I60-I69. Mathers et al. (2005) have provided a general
assessment of the coverage, completeness and reli-
ability of data on causes of death.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 201328
1. HEALTH STATUS
1.3. Mortality from cardiovascular diseases1.3.1. Ischemic heart disease mortality, 2011 and change between 1990 and 2011 (or nearest year)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932916097
1.3.2. Cerebrovascular disease mortality, 2011 and change between 1990 and 2011 (or nearest year)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932916116
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1. HEALTH STATUS1.4. Mortality from cancerCancer accounts for over one-fourth of all deaths in OECD
countries and, after diseases of the circulatory system, it is
the second leading cause of death. The proportion of
deaths that are due to cancer has increased over time, and
in countries such as Canada, Denmark, France, Japan and
the Netherlands it has become the number one cause of
death. This rise reflects the fact that mortality from other
causes, particularly circulatory diseases, has been declin-
ing at a faster pace than the mortality rate for cancer.
There are more than 100 different types of cancers, with
most named for the organ in which they start. Cancer
occurs when abnormal cells divide without control and are
able to invade other tissues. For a large number of cancer
types, the risk of developing the disease rises with age.
While genetics is a risk factor, only about 5% to 10% of all
cancers are inherited. Modifiable risk factors such as smok-
ing, obesity, exercise, and excess sun exposure, as well as
environmental exposures, explain as much as 90-95% of all
cancer cases (Anand et al., 2008). Prevention, early detec-
tion and treatment remain at the forefront in the battle to
reduce the burden of cancer.
In 2011, the average cancer mortality rate across OECD
countries was 211 per 100 000 population. Mortality was
lowest in Mexico, Brazil and Finland, with rates less than 180
per 100 000 population. Central and eastern European coun-
tries such as Hungary, Slovenia and the Slovak Republic
as well Denmark bear the biggest cancer burden with
mortality rates in excess of 240 per 100 000 population
(Figure 1.4.1).
Cancer mortality rates are persistently higher for men than
for women in all countries (Figure 1.4.1). The gender gap
was particularly wide in Korea, Spain and Estonia, along
with the Slovak Republic, Japan and France; with mortality
rates among men more than twice those for women. This
gender gap can be explained partly by the greater preva-
lence of risk factors among men, notably smoking rates.
Among men, lung cancer imposes the highest mortality
burden, accounting for 23% of all cancer-related deaths. In
Belgium and Greece, this percentage was in excess of 30%.
For women, lung cancer accounted for 16% of all cancer-
related deaths. In many countries, lung cancer mortality
rates for men have decreased over the last 20 years,
whereas the opposite trend can be observed for women.
These conflicting trends are, to a large degree, explained by
the large number of females who started smoking several
decades later than males (Ahmedin et al., 2011). Mortality,
survival and screening rates for cervical, breast and
colorectal cancer are discussed further in Chapter 5.
In most OECD countries, cancer-related death rates have
fallen since 1990. On average, cancer-related mortality
rates fel l by nearly 15% between 1990 and 2011
(Figure 1.4.2). Substantial declines in mortality from stom-
ach, colorectal, breast and cervical cancer for women, as
well as prostate and lung cancer for men contributed to
this reduction. However, these gains were partially offset by
increases in the number of deaths due to cancer of the pan-
creas and liver for both sexes as well as lung cancer for
women.
In the case of Brazil, Korea, South Africa and Slovenia, how-
ever, cancer-related mortality increased over this period
(Figure 1.4.2). In all other countries, mortality rates fell, but
there is substantial variation between countries in the rate
of decline. Mortality rates fell by a modest 2% to 5% in
Greece, the Slovak Republic and Estonia, but by more than
25% in Switzerland, Luxembourg and the Czech Republic.
Definition and comparability
Mortality rates are based on numbers of deaths regis-
tered in a country in a year divided by the size of the
corresponding population. The rates have been
directly age-standardised to the 2010 OECD popula-
tion to remove variations arising from differences in
age structures across countries and over time. The
source is the WHO Mortality Database.
Deaths from all cancers are classified to ICD-10 codes
C00-C97. Mathers et al. (2005) have provided a general
assessment of the coverage, completeness and reli-
ability of data on causes of death.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 201330
1. HEALTH STATUS
1.4. Mortality from cancer1.4.1. All cancer mortality rates, total and by gender, 2011 (or nearest year)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932916135
1.4.2. Change in all cancer mortality rates, 1990-2011 (or nearest year)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932916154
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1. HEALTH STATUS1.5. Mortality from transport accidentsWorldwide, an estimated 1.3 million people are killed in
transport accidents each year, most of which are due to
road traffic accidents. Globally, road transport accidents
account for 0.5% of deaths among women aged 15-45 but
over 10% for men in this age group (Lozano et al., 2012). In
OECD countries, 107 000 lives were lost due to transport
accidents in 2011. Seventy-four per cent of these fatalities
occurred amongmen.The largest number of road transport
accidents occurs among younger age groups with the risk
of dying due to a road accident peaking at ages 15-24 (Walls
et al., 2012; OECD/ITF, 2013).
The average OECDmortality rate due to transport accidents
was 7.7 per 100 000 population in 2011 (Figure 1.5.1). There
is great dispersion between countries with transport acci-
dents claiming more than five times as many lives per
100 000 population in Mexico compared to Sweden. Fatali-
ties were in excess of 14 deaths per 100 000 population in
Mexico and Chile, and were even higher in other large
emerging countries such as Brazil and the Russian Federation.
They were lowest in Sweden, the United Kingdom and
Denmark with four deaths or less per 100 000 population.
Most fatal traffic injuries occur in passenger vehicles,
although other road users also face substantial risks. In
Korea, Israel, Japan and Korea, pedestrians account for over
one third of all road user fatalities. Motorcyclists account
for over 25% of road transport accident deaths in Greece,
Italy and France (OECD/ITF, 2013).
Deaths due to transport accidents have decreased in
almost all countries over the last few decades. Since 1990,
the average OECD mortality rate due to transport accidents
has fallen by more than half (Figure 1.5.2). Spain, Estonia
and Iceland have slashed their mortality rates by more
than 75% over the 20-year period. These gains are even
more impressive when considering the increase in the
number of vehicle kilometres travelled over this period
(OECD/ITF, 2013). Chile is the only country where mortality
rates due to transport accidents have increased, and are
now at a similar level to countries such as Korea, the United
States and Greece. At the start of the 1990s, Chile’s mortal-
ity rate was comparatively low and its rise in road traffic
fatalities may be associated with its rapid economic growth
during this period (Nghiem et al., 2013).
Road safety for car occupants has increased greatly over
the past decades in many countries through improvements
of road systems, education and prevention campaigns as
well as vehicle design. In addition, the adoption of new
laws and regulations and the enforcement of these laws to
improve compliance with speed limits, seatbelt use and
drink-driving rules, have had a major impact on reducing
the burden of road transport accidents. More gains can be
made if countries can further improve seatbelt use (OECD/
ITF, 2013).
Declines in mortality rates for vulnerable road users such
as pedestrians, cyclists and motorcyclists were substan-
tially less than those for car occupants. Between 2000 and
2010, fatalities among motorcyclists fell by only 14% across
the OECD, with some countries such as the United States,
Poland and Finland witnessing significant increases among
this class of road users (although there have been reports of
recent reductions in deaths from motorcycle accidents in
Finland since 2010).
In some countries hard-hit by the economic recession, the
downward trend has accelerated after 2008. Preliminary
data suggests that the rate of decline between 2009 and
2012 in Greece and Ireland is even greater than the long-
term average observed in those countries. One possible
explanation for this is that the economic crisis has reduced
reliance on motor vehicle use. However, this impact is
likely to be short-lived and over the longer term, effective
road safety policies will remain the primary contributor to
reduced mortality (OECD/ITF, 2011).
Definition and comparability
Mortality rates are based on numbers of deaths regis-
tered in a country in a year divided by the size of the
corresponding population. The rates have been
directly age-standardised to the 2010 OECD popula-
tion to remove variations arising from differences in
age structures across countries and over time. The
source is the WHO Mortality Database.
Deaths from transport accidents are classified to
ICD-10 codes V01-V89. Mathers et al. (2005) have pro-
vided a general assessment of the coverage, com-
pleteness and reliability of data on causes of death.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 201332
1. HEALTH STATUS
1.5. Mortality from transport accidents1.5.1. Transport accident mortality rates, 2011 (or nearest year)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en; and Ministry of Health for New Zealand.
1 2 http://dx.doi.org/10.1787/888932916173
1.5.2. Trends in transport accident mortality rates, selected OECD countries, 1990-2011
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932916192
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1. HEALTH STATUS1.6. SuicideSuicide is a significant cause of death in many OECD coun-
tries, and accounted for over 150 000 deaths in 2011. There
is a complex set of reasons why some people choose to
attempt or commit suicide, with multiple risk factors that
can predispose a person to attempt to take their own life.
Over 90% of people who have attempted or committed sui-
cide have been diagnosed with psychiatric disorders such
as severe depression, bipolar disorder and schizophrenia
(Nock et al., 2008). The social context in which an individual
lives is also important. Low income, alcohol and drug
abuse, unemployment and unmarried status are all associ-
ated with higher rates of suicide (Qin et al., 2003; Crump et
al., 2013).
Figure 1.6.1 shows that suicide rates were lowest in Greece,
Turkey, Mexico, Brazil and Italy, at six or fewer deaths per
100 000 population. In Korea, Hungary, the Russian Federation
and Japan, on the other hand, suicide is responsible for
more than 20 deaths per 100 000 population. There is a ten-
fold difference between Korea and Greece, the two coun-
tries with the highest and lowest suicide rates. However,
the number of suicides in certain countries may be under-
reported because of the stigma that is associated with the
act, or because of data issues associated with reporting cri-
teria (see “Definition and comparability”).
Death rates from suicide are four times greater for men
than for women across OECD countries. In Greece and
Poland, men are at least seven times more likely to commit
suicide than women.The gender gap in those two countries
has widened in recent years.While in Luxembourg and the
Netherlands the gender gap is smaller, male suicide rates
are still twice those of females.
Since 1990, suicide rates have decreased by more than 20%
across OECD countries, with pronounced declines of over
40% in some countries such as Hungary (Figure 1.6.2). In
Estonia, rates fell by nearly 50% over the 20-year period, but
not before rising substantially in the mid-1990s. Death
rates from suicides have increased in countries such as
Korea and Japan. In Japan, there was a sharp rise in the
mid-to-late 1990s, coinciding with the Asian Financial
Crisis; but rates have remained stable since then. Suicide
rates also rose sharply at this time in Korea and, unlike in
Japan, have continued to increase. It is now the fourth lead-
ing cause of death in Korea (Jeon, 2011). Mental health ser-
vices in Korea lag behind those of other countries with
fragmented support, focused largely around institutions,
with insufficient or ineffective support provided to those
who remain in the community. Further efforts are also
needed to remove the stigma associated with seeking care
(OECD, forthcoming).
Previous studies have shown a strong link between adverse
economic conditions and higher levels of suicide
(Ceccherini-Nelli et al., 2011; Classen and Dunn, 2012; Zivin
et al., 2011). Figure 1.6.2 shows suicide rates for a number of
countries that have been hard hit by the recent economic
crisis. Suicide rates rose slightly at the start of the eco-
nomic crisis in a number of countries such as Ireland but
more recent data suggest that this trend did not persist. In
Greece, overall suicide rates were stable in 2009 and 2010,
despite worsening economic conditions. There is a need for
countries to continue monitoring developments closely in
order to be able to respond quickly, including monitoring
high-risk populations such as the unemployed and those
with psychiatric disorders (see Indicator 5.8 for further
information).
Definition and comparability
The World Health Organization defines suicide as an
act deliberately initiated and performed by a person
in the full knowledge or expectation of its fatal out-
come. Comparability of data between countries is
affected by a number of reporting criteria, including
how a person’s intention of killing themselves is
ascertained, who is responsible for completing the
death certificate, whether a forensic investigation is
carried out, and the provisions for confidentiality of
the cause of death. Caution is required therefore in
interpreting variations across countries.
Mortality rates are based on numbers of deaths regis-
tered in a country in a year divided by the size of the
corresponding population. The rates have been
directly age-standardised to the 2010 OECD popula-
tion to remove variations arising from differences in
age structures across countries and over time. The
source is the WHO Mortality Database. Deaths from
suicide are classified to ICD-10 codes X60-X84.
Mathers et al. (2005) have provided a general assess-
ment of the coverage, completeness and reliability of
data on causes of death.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 201334
1. HEALTH STATUS
1.6. Suicide1.6.1. Suicide mortality rates, 2011 (or nearest year)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932916211
1.6.2. Trends in suicide rates, selected OECD countries, 1990-2011
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932916230
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1. HEALTH STATUS1.7. Infant mortalityInfant mortality, the rate at which babies and children of
less than one year of age die, reflects the effect of economic
and social conditions on the health of mothers and new-
borns, the social environment, individual lifestyles as well
as the characteristics and effectiveness of health systems.
In most OECD countries, infant mortality is low and there is
little difference in rates (Figure 1.7.1). In 2011, the average
in OECD countries was just over four deaths per 1 000 live
births, with rates being the lowest in Nordic countries
(Iceland, Sweden, Finland, Norway), Japan and Estonia. A
small group of OECD countries still have relatively high
rates of infant mortality (Mexico, Turkey and Chile),
although in these three countries infant mortality rates
have come down rapidly over the past few decades
(Figure 1.7.2).
In some large non-member countries (India, South Africa
and Indonesia), infant mortality rates remain above
20 deaths per 1 000 live births. In India, nearly one-in-
twenty children die before their first birthday, although the
rates have fallen sharply over the past few decades. Infant
mortality rates have also been reduced greatly in Indonesia.
In OECD countries, around two-thirds of the deaths that
occur during the first year of life are neonatal deaths (i.e.,
during the first four weeks). Birth defects, prematurity and
other conditions arising during pregnancy are the principal
factors contributing to neonatal mortality in developed
countries. With an increasing number of women deferring
childbearing and a rise in multiple births linked with fertil-
ity treatments, the number of pre-term births has tended
to increase (see Indicator 1.8 “Infant health: Low birth
weight”). In a number of higher-income countries, this has
contributed to a levelling-off of the downward trend in
infant mortality rates over the past few years. For deaths
beyond a month (post-neonatal mortality), there tends to
be a greater range of causes – the most common being SIDS
(sudden infant death syndrome), birth defects, infections
and accidents.
All OECD countries have achieved remarkable progress in
reducing infant mortality rates from the levels of 1970,
when the average was approaching 30 deaths per 1 000 live
births, to the current average of just over four. Besides
Mexico, Chile and Turkey where the rates have converged
rapidly towards the OECD average (Figure 1.7.2), Portugal
and Korea have also achieved large reductions in infant
mortality rates, moving from countries that were well
above the OECD average in 1970 to being well below the
OECD average in 2011.
By contrast, in the United States, the reduction in infant
mortality has been slower than in most other OECD coun-
tries. In 1970, the US rate was well below the OECD average,
but it is now well above (Figure 1.7.1). Part of the explana-
tion for the relatively high infant mortality rates in the
United States is due to a more complete registration of very
premature or low birth weight babies than in other coun-
tries (see box on “Definition and comparability”). However,
this cannot explain why the post-neonatal mortality rate
(deaths after onemonth) is also greater in the United States
than in most other OECD countries. There are large differ-
ences in infant mortality rates among racial groups in the
United States, with black (or African-American) women
more likely to give birth to low birth weight infants, and
with an infant mortality rate more than double that for
white women (11.6 vs. 5.2 in 2010) (NCHS, 2013).
Many studies use infant mortality as a health outcome to
examine the effect of a variety of medical and non-medical
determinants of health (e.g., OECD, 2010a). Although most
analyses show that higher health spending tends to be
associated with lower infant mortality, the fact that some
countries with a high level of health expenditure do not
exhibit low levels of infant mortality suggests that more
health spending is not necessarily required to obtain better
results (Retzlaff-Roberts et al., 2004). A body of research
also suggests that many factors beyond the quality and
efficiency of the health system, such as income inequality,
the socio-economic environment and individual lifestyles,
influence infant mortality rates (Kiely et al., 1995).
Definition and comparability
The infant mortality rate is the number of deaths of
children under one year of age, expressed per
1 000 live births. Neonatal mortality refers to the
death of children during the first four weeks of life.
Post-neonatal mortality refers to deaths occurring
between the second and the twelfth months of life.
Some of the international variation in infant and neo-
natal mortality rates is due to variations among coun-
tries in registering practices for premature infants.
The United States and Canada are two countries
which register a much higher proportion of babies
weighing less than 500 g, with low odds of survival,
resulting in higher reported infant mortality (Joseph
et al., 2012). In Europe, several countries apply a min-
imum gestational age of 22 weeks (or a birth weight
threshold of 500g) for babies to be registered as live
births (Euro-Peristat, 2013).HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 201336
1. HEALTH STATUS
1.7. Infant mortality1.7.1. Infant mortality rates, 2011 (or nearest year)
1. Three-year average (2009-11).
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en; World Bank for non-OECD countries.
1 2 http://dx.doi.org/10.1787/888932916249
1.7.2. Infant mortality rates, selected OECD countries, 1970-2011
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932916268
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1. HEALTH STATUS1.8. Infant health: Low birth weightLow birth weight – defined as newborns weighing less than
2 500 grams – is an important indicator of infant health
because of the close relationship between birth weight and
infant morbidity and mortality. There are two categories of
low birth weight babies: those occurring as a result of
restricted foetal growth and those resulting from pre-term
birth. Low birth weight infants have a greater risk of poor
health or death, require a longer period of hospitalisation
after birth, and are more likely to develop significant dis-
abilities (UNICEF andWHO, 2004). Risk factors for low birth
weight include maternal smoking and excessive alcohol
consumption, poor nutrition, low body mass index, lower
socio-economic status, and having had in-vitro fertilisation
treatment and multiple births.
One in 15 babies born in OECD countries in 2011 – or 6.8%
of all births – weighed less than 2 500 grams at birth
(Figure 1.8.1). The proportions of low-weight births were
lowest in Nordic countries (Iceland, Finland, Sweden,
Norway, with the exception of Denmark) and Estonia, with
less than 5% of live births defined as low birth weight.
Alongside a number of key emerging countries (India,
South Africa and Indonesia), Turkey, Greece and Japan
have the highest proportions among OECD countries, with
rates of low birth weight infants above 9%. Some of these
variations across countries may be due to physiological
differences in size between populations (Euro-Peristat,
2013). In some emerging countries, the high proportion of
low birth weight infants is mainly associated with mater-
nal malnutrition before and during pregnancy, poor
health and limited access to proper health care during
pregnancy.
In almost all OECD countries, the proportion of low birth
weight infants has increased over the past two decades
(Figure 1.8.1, right panel and Figure 1.8.2). There are several
reasons for this rise. The number of multiple births, with
the increased risks of pre-term births and low birth weight,
has risen steadily, partly as a result of the rise in fertility
treatments. Other factors whichmay explain the rise in low
birth weight are older age at childbearing, and increases in
the use of delivery management techniques such as induc-
tion of labour and caesarean delivery, which have
increased the survival rates of low birth weight babies.
Korea, Spain, Greece, Japan and Portugal have seen large
increases of low birth weight babies over the past two
decades. In Japan, this increase can be explained by
changes in obstetric interventions, in particular the greater
use of caesarean sections, along with changes in maternal
socio-demographic and behavioural factors (Yorifuji et al.,
2012). This contrasts with sharp decreases in Poland and
Hungary, although most of the reduction in these two
countries occurred in the first half of the 1990s, with little
change since then.
Comparisons of different population groups within coun-
tries indicate that the proportion of low birth weight
infants may also be influenced by differences in education
level, income and associated living conditions. In the
United States, there are marked differences in the propor-
tion of low birth weight infants among racial groups, with
black infants having a rate almost double that of white
infants (13.2% versus 7.1% in 2010) (NCHS, 2013). Similar
differences have also been observed among the indigenous
and non-indigenous populations in Australia, Mexico and
New Zealand, often reflecting the disadvantaged living
conditions of many of these mothers.
The proportion of low birth weight infants is also much
higher among women who smoke than for non-smokers.
In the United States, the rate reached 12.0% for cigarette
smokers compared with 7.4% for non-smokers in 2010
(NCHS, 2013).
Definition and comparability
Low birth weight is defined by the World Health
Organization (WHO) as the weight of an infant at
birth of less than 2 500 grams (5.5 pounds) irrespec-
tive of the gestational age of the infant. This thresh-
old is based on epidemiological observations
regarding the increased risk of death to the infant and
serves for international comparative health statistics.
The number of low weight births is then expressed as
a percentage of total live births.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 201338
1. HEALTH STATUS
1.8. Infant health: Low birth weight1.8.1. Low birth weight infants, 2011 and change between 1990 and 2011 (or nearest year)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en; World Bank andWHO for key partners.
1 2 http://dx.doi.org/10.1787/888932916287
1.8.2. Trends in low birth weight infants, selected OECD countries, 1990-2011
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932916306
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1. HEALTH STATUS1.9. Perceived health statusMost OECD countries conduct regular health surveys which
allow respondents to report on different aspects of their
health. A commonly asked question relates to self-
perceived health status, of the type: “How is your health in
general?”. Despite the subjective nature of this question,
indicators of perceived general health have been found to
be a good predictor of people’s future health care use and
mortality (DeSalvo et al., 2005; Bond et al., 2006).
For the purpose of international comparisons, cross-country
variations in perceived health status are difficult to inter-
pret because responses may be affected by the formulation
of survey questions and responses, and by social and
cultural factors. Since they rely on the subjective views of
the respondents, self-reported health status will reflect
cultural biases or other influences.
With these limitations in mind, in almost all OECD coun-
tries, a majority of the adult population reports their health
as good or better (Figure 1.9.1; left panel). The United
States, New Zealand and Canada are the three leading
countries, with about nine out of ten people reporting to be
in good health. However, the response categories offered to
survey respondents in these three countries are different
from those used in European countries and Asian OECD
countries, which introduce an upward bias in the results
(see box on “Definition and comparability”).
On the other hand, less than half of adults in Japan, Korea
and Portugal rate their health as good or very good. The
proportion is also relatively low in Estonia, Hungary,
Poland, Chile and the Czech Republic, where less than 60%
of adults consider themselves to be in good health.
The percentage of adults rating their health as good or very
good has remained fairly stable over the past few decades
in most countries, although Japan has seen some decline
since the mid-1990s.
In all OECD countries, men are more likely than women to
report being in good health, except in Australia where the
proportion is equal. The gender gap is especially large in
Chile, Portugal and Turkey (Figure 1.9.1; right panel).
There are also large disparities in self-reported health
across different socio-economic groups, as measured for
instance by income level. Figure 1.9.2 shows that, in all
countries, people with a lower level of income tend to
report poorer health than people with higher income,
although the gap varies. On average across OECD countries,
nearly 80% of people in the highest income quintile reports
being in good health, compared with just over 60% for peo-
ple in the lowest income group. These disparities may be
explained by differences in living and working conditions,
as well as differences in health-related lifestyles (e.g.,
smoking, harmful alcohol drinking, physical inactivity, and
obesity problems). In addition, people in low-income
households may havemore limited access to certain health
services, for financial or non-financial reasons (see
Chapter 6 on “Access to care”). It is also possible that the
causal link goes the other way around, with poor health
status in the first place leading to lower employment and
lower income.
Greater emphasis on public health and disease prevention
among disadvantaged groups, and improving access to
health services may contribute to further improvements in
population health status and reducing health inequalities.
Definition and comparability
Perceived health status reflects people’s overall per-
ception of their health, including both physical and
psychological dimensions. Typically ascertained
through health interview surveys, respondents are
asked a question such as: “How is your health in gen-
eral? Is it very good, good, fair, poor, very poor.” OECD
Health Statistics provides figures related to the propor-
tion of people rating their health to be “good/very
good” combined.
Caution is required in making cross-country compar-
isons of perceived health status, for at least two rea-
sons. First, people’s assessment of their health is
subjective and can be affected by factors such as cul-
tural background and national traits. Second, there
are variations in the question and answer categories
used to measure perceived health across surveys and
countries. In particular, the response scale used in the
United States, Canada, New Zealand and Australia is
asymmetric (skewed on the positive side), including
the following response categories: “excellent, very
good, good, fair, poor.” The data in OECD Health Statistics
refer to respondents answering one of the three posi-
tive responses (“excellent, very good or good”). By
contrast, in most other OECD countries, the response
scale is symmetric, with response categories being:
“very good, good, fair, poor, very poor.” The data
reported from these countries refer only to the first
two categories (“very good, good”). Such a difference
in response categories biases upward the results from
those countries that are using an asymmetric scale by
about 5-8%.
Self-reported health by income level is reported for
the first quintile (lowest 20% of income group) and the
fifth quintile (highest 20%). Depending on the sur-
veys, the incomemay relate either to the individual or
the household (in which case the income is equiv-
alised to take into account the number of persons in
the household).HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 201340
1. HEALTH STATUS
1.9. Perceived health status1.9.1. Percentage of adults reporting to be in good health, 2011 (or nearest year)
1. Results for these countries are not directly comparable with those for other countries, due to methodological differences in the survey
questionnaire resulting in an upward bias.
Source: OECD Health Statistics 2013 (EU-SILC for European countries), http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932916325
1.9.2. Perceived health status by income level, 2011 (or nearest year)
Note: Countries are ranked in descending order of perceived health status for the whole population.
1. Results for these countries are not directly comparable with those for other countries, due to methodological differences in the survey
questionnaire resulting in an upward bias.
Source: OECD Health Statistics 2013 (EU-SILC for European countries), http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932916344
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1. HEALTH STATUS1.10. Diabetes prevalence and incidenceDiabetes is a chronic disease, characterised by high levels
of glucose in the blood. It occurs either because the pan-
creas stops producing the hormone insulin (Type-1 diabe-
tes), or through a reduced ability to produce insulin (Type-2
diabetes). People with diabetes are at a greater risk of devel-
oping cardiovascular diseases such as heart attack and
stroke. They also have elevated risks for sight loss, foot and
leg amputation due to damage to nerves and blood vessels,
and renal failure requiring dialysis or transplantation.
Over 85 million people living in OECD countries are esti-
mated to have had diabetes in 2011. This represents 6.9% of
people aged 20-79 years (Figure 1.10.1). In Mexico, more
than 15% of adults have diabetes. By contrast, less than 5%
of adults suffer from diabetes in Belgium, Iceland,
Luxembourg, Norway and Sweden (IDF, 2011).
Diabetes is slightly more common among men than
women and prevalence increases substantially with age. A
Spanish study showed that around 1% of those aged less
than 45 were diagnosed with diabetes, whereas among
those aged 76 and over, the prevalence rate was over 20%
(Soriguer et al., 2012). The study also showed that around
50% of patients in the sample did not know that they had
diabetes, confirming findings from other countries that a
substantial proportion of the population have undiagnosed
diabetes (e.g. Gardete-Correia et al., 2011). The Interna-
tional Diabetes Federation estimates that around
31 million people in OECD countries have undiagnosed
diabetes.
Diabetes disproportionally affects those in lower socio-
economic groups and people from certain cultural back-
grounds. Guize et al. (2008) found that elderly people living
in lower socio-economic conditions were two to
three times more likely to have diabetes than wealthier
segments of the population. In Australia, Indigenous peo-
ple have been found to be three times more likely than
other Australians to report having diabetes (AIHW, 2011).
For many people, the onset of Type-2 diabetes can be pre-
vented (or delayed) through regular physical exercise and
maintaining a healthy weight. But in most countries, the
prevalence of obesity and physical inactivity continues to
increase (see Indicator 2.7 “Overweight and obesity among
adults”). Alongside the rise in risk factors, diabetes has
been increasing rapidly in every part of the world. Based on
current trends, the number of people with diabetes in
OECD countries is projected to reach almost 108 million by
2030 (IDF, 2011).
On average across OECD countries, over 17 new cases of
Type-1 diabetes were identified per 100 000 children aged
under 15 in 2011 (Figure 1.10.2). The incidence rate is par-
ticularly high in Nordic countries (Finland, Sweden and
Norway), with over 25 new cases detected every year per
100 000 children. In Mexico and Korea, the rate is less than
five new cases per 100 000 children aged under 15. While
Type-1 diabetes currently accounts for only 10-15% of all
diabetes cases, there is evidence that incidence rates are
rising strongly in some countries. Between 2005 and 2020,
new cases of Type-1 diabetes for those under age 5 are
expected to double and the prevalence of cases in those
younger than 15 years is expected to increase by 70% in
Europe (Patterson et al., 2009). There is no clear consensus
on why incidence is rising so fast, but a changing environ-
ment, infant and maternal diets are all plausible explana-
tions (Myers and Zimmet, 2008).
Both Type-1 and Type-2 diabetes inflict enormous health
burdens on the community. In 2011, there were almost
660 000 diabetes-related deaths in OECD countries, and the
2010 Global Burden of Disease study showed that diabetes
was the ninth leading cause of death in the world (IDF,
2011; Lozano et al., 2012). Diabetes-related health expendi-
ture was estimated to be USD 176 billion in the United
States alone, and USD 390 billion across OECD countries in
2011 (ADA, 2013; IDF, 2011). These burdens underline the
need for preventive actions and effective management of
diabetes and its complications (also see Indicator 5.1
“Avoidable hospital admissions”).
Definition and comparability
The sources and methods used by the International
Diabetes Federation for publishing national preva-
lence and incidence estimates of diabetes are out-
lined in their Diabetes Atlas, 5th edition (IDF, 2011).
Country data were derived from studies published
between 1980 and April 2011, and were only included
if they met several criteria for reliability. Prevalence
rates were adjusted to the age-standardised rates
using the world population, based on the distribution
provided by the World Health Organization. See
Guariguata et al. (2011) for more details on the meth-
odology used.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 201342
1. HEALTH STATUS
1.10. Diabetes prevalence and incidence1.10.1. Prevalence estimates of diabetes, adults aged 20-79 years, 2011
Note: The data cover both Type-1 and Type-2 diabetes. Data are age-standardised to theWorld Standard Population.
Source: International Diabetes Federation (2011).
1 2 http://dx.doi.org/10.1787/888932916363
1.10.2. Incidence estimates of Type-1 diabetes, children aged 0-14 years, 2011
Source: International Diabetes Federation (2011).
1 2 http://dx.doi.org/10.1787/888932916382
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HEALTH AT A GLANCE 2013: OECD INDIC2. NON-MEDICAL DETERMINANTS
OF HEALTH
2.1. Smoking and alcohol consumption among children
2.2. Overweight and obesity among children
2.3. Fruit and vegetable consumption among children
2.4. Physical activity among children
2.5. Tobacco consumption among adults
2.6. Alcohol consumption among adults
2.7. Overweight and obesity among adults
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2. NON-MEDICAL DETERMINANTS OF HEALTH2.1. Smoking and alcohol consumption among childrenRegular smoking and excessive drinking in adolescence
have both immediate and long-term health consequences.
Children who establish smoking habits in early adoles-
cence increase their risk of cardiovascular diseases, respi-
ratory illnesses and cancer. They are also more likely to
experiment with alcohol and other drugs. Alcohol misuse
is itself associated with a range of social, physical andmen-
tal health problems, including depressive and anxiety dis-
orders, obesity and accidental injury (Currie et al., 2012).
Results from the Health Behaviour in School-aged Children
(HBSC) surveys, a series of collaborative cross-national
studies conducted in a number of countries worldwide,
allow for monitoring of smoking and drinking behaviours
among adolescents.
Fifteen-year-old children in Austria, the Czech Republic,
and Hungary smoke the most, with more than 25% report-
ing that they smoke at least once a week (Figure 2.1.1). In
contrast, less than 10% of 15-year-olds smoke weekly in
Canada, Iceland, Norway, and the United States. On aver-
age, the same proportion of boys and girls (16%) smoke at
least once a week. However, there are gender disparities in
some countries. Smoking is much more prevalent among
boys in Estonia and Greece, while amuch higher proportion
of girls report smoking at least once a week in the Czech
Republic and Spain.
Drunkenness is reported to have been experienced at least
twice bymore than 40% of 15-year-olds in the Czech Republic,
Denmark, Estonia, Finland, Hungary, Slovenia and the
United Kingdom (Figure 2.1.2). Much lower rates (less than
20%) are reported in Iceland, Italy, Luxembourg, the
Netherlands, and the United States. Across all surveyed
OECD countries, boys are more likely than girls to report
repeated drunkenness (32% vs. 28%). France, Hungary, and
Slovenia have the biggest differences, with rates of alcohol
abuse among boys at least 9% points higher than those of
girls. In four countries, Finland, Spain, Sweden and the
United Kingdom, more girls than boys report repeated
drunkenness (around 5-7% points).
Risk-taking behaviours among adolescents have fallen in
many countries, with regular smoking for both boys and
girls and drunkenness rates for boys showing some decline
from the levels of the late 1990s on average (Figures 2.1.3
and 2.1.4). Levels of smoking for both sexes are at their low-
est for a decade, with, on average, fewer than one in five
children of either sex smoking regularly. However, increas-
ing rates of smoking and/or drunkenness among adoles-
cents in the Czech Republic, Estonia, Hungary, Poland, the
Slovak Republic and Spain are cause for concern.
Definition and comparability
Estimates for smoking refer to the proportion of 15-
year-old children who self-report smoking at least
once a week. Estimates for drunkenness record the
proportions of 15-year-old children saying they have
been drunk twice or more in their lives.
The Health Behaviour in School-aged Children (HBSC)
surveys were undertaken every four years between
1993-94 and 2009-10 and include up to 26 OECD coun-
tries and the Russian Federation. Data are drawn from
school-based samples of 1 500 in each age group (11-,
13- and 15-year-olds) in most countries. Turkey was
included in the 2009-10 HBSC survey, but children
were not asked about their alcohol drinking and
smoking.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 201346
2. NON-MEDICAL DETERMINANTS OF HEALTH
2.1. Smoking and alcohol consumption among children2.1.1. Smoking among 15-year-olds, 2009-10
Source: Currie et al. (2012).
1 2 http://dx.doi.org/10.1787/888932916401
2.1.3. Trends in regular smoking among 15-year-olds,
19 OECD countries
Source: Currie et al. (2000); Currie et al. (2004); Currie et al. (2008); Currie
et al. (2012); WHO (1996).
 2 http://dx.doi.org/10.1787/888932916439
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2.1.2. Drunkenness among 15-year-olds, 2009-10
Source: Currie et al. (2012).
1 2 http://dx.doi.org/10.1787/888932916420
2.1.4. Trends in repeated drunkenness among
15-year-olds, 19 OECD countries
Source: Currie et al. (2000); Currie et al. (2004); Currie et al. (2008); Currie
et al. (2012); WHO (1996).
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2. NON-MEDICAL DETERMINANTS OF HEALTH2.2. Overweight and obesity among childrenChildren who are overweight or obese are at greater risk of
poor health in adolescence, as well as in adulthood. Among
young people, orthopaedic problems and psychosocial
problems such as low self-image, depression and impaired
quality of life can result from being overweight. Excess
weight problems in childhood are associated with an
increased risk of being an obese adult, at which point car-
diovascular disease, diabetes, certain forms of cancer,
osteoarthritis, a reduced quality of life and premature
death become health concerns (Lobstein, 2010; Currie et al.,
2012).
Obesity and overweight rates rely on individual height and
weight data which can either be measured by examination
or self-reported. The latter type of data is collected consis-
tently among 15-year-olds through the Health Behaviour in
School-aged Children (HBSC) surveys every four years in a
number of countries (Currie et al., 2004, 2008, 2012). How-
ever, self-reported data tend to under-estimate obesity and
overweight.
Overweight (including obesity) rates based on measured
height and weight are about 23% for boys and 21% for girls,
on average, in OECD countries, although rates are mea-
sured in different age groups in different countries
(Figure 2.2.1, left panel). Boys tend to carry excess weight
more often than girls, with the largest gender differences
observed in Slovenia, China and Iceland. In contrast, Turkey
and South Africa show larger overweight rates among girls.
More than 30% of boys and girls are overweight in Greece,
Italy, New Zealand and the United States, and this is also
the case for boys in Slovenia.
Self-reported overweight (including obesity) rates are about
18% for boys and 11% for girls on average in OECD countries
among the 15-year-olds (Figure 2.2.1, right panel), although
this average relates to a different set of countries compared
with the average based on measured data. Rates based on
self-reports are lower than those based on measured data,
except for overweight boys in the United States, Austria,
Sweden, Czech Republic, Norway and Turkey, due to age
differences. Consistent with measured data, overweight
rates based on self-reports are higher among boys than
girls. More than 20% of boys are defined as overweight in
Greece, Italy, Slovenia, the United States and Canada based
on self-reported data, and more than 20% of girls in the
United States. Young people who are overweight are more
likely to miss eating breakfast, are less physically active,
and spend more time watching television (Currie et al.,
2012).
Rates of excess weight based on self-reports have increased
slightly over the past decade in most OECD countries
(Figure 2.2.2). Average of overweight rates (including obe-
sity) across OECD countries increased between 2001-02 and
2009-10 from 13% to 15% in 15-year-olds. The largest
increases during this eight-year period were in the Czech
Republic, Estonia, Poland and Slovenia, all greater than 5%.
Significant reductions in the proportion of overweight or
obese children at age 15 were only observed in Denmark
and the United Kingdom between 2001-02 and 2009-10,
although non-response rates to questions about self-
reported height and weight demand cautious in interpreta-
tion.
Childhood is an important period for forming healthy
behaviours, and the increased focus on obesity at both a
national and international level has stimulated the imple-
mentation of many community-based initiatives in OECD
countries in recent years. Studies show that locally
focussed interventions, targeting children up to 12 years of
age can be effective in changing behaviours. Schools pro-
vide opportunities to ensure that children understand the
importance of good nutrition and physical activity, and can
benefit from both. Teachers and health professionals are
often involved as providers of health and nutrition educa-
tion, and the most frequent community-based initiatives
target professional training, the social or physical environ-
ment, and actions for parents (Bemelmans et al., 2011).
Definition and comparability
Estimates of overweight and obesity are based on
body mass index (BMI) calculations using either mea-
sured or child self-reported height and weight. Over-
weight and obese children are those whose BMI is
above a set of age- and sex-specific cut-off points
(Cole et al., 2000). Data presented here use the Inter-
national Obesity Task Force (IOTF) BMI cut-off points.
Measured data are gathered by the International
Association for the Study of Obesity (IASO) from dif-
ferent national studies. The estimates are based on
national surveys of measured height and weight
among children at various ages. Caution is therefore
needed in comparing rates across countries. Defini-
tions of overweight and obesity among children may
sometimes vary among countries, although whenever
possible the IOTF BMI cut-off points are used.
Self-reported data are from the Health Behaviour in
School-aged Children (HBSC) surveys undertaken
between 2001-02 and 2009-10. Data are drawn from
school-based samples of 1 500 in each age group (11-,
13-and 15-year-olds) in most countries. Self-reported
height and weight are subject to under-reporting,
missing data and error, and require cautious interpre-
tation.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 201348
2. NON-MEDICAL DETERMINANTS OF HEALTH
2.2. Overweight and obesity among children2.2.1. Overweight (including obesity) among children, 2010 (or latest year)
Note: Measured data for United Kingdom refer to England.
Source: International Association for the Study of Obesity, 2013; Bös et al. (2004) for Luxembourg; and KNHANES for Korea (measured data). Currie et al.
(2012) (self-reported data).
1 2 http://dx.doi.org/10.1787/888932916477
2.2.2. Change in self-reported overweight among 15-year-olds, 2001-02, 2005-06 and 2009-10
Source: Currie et al. (2004); Currie et al. (2008); Currie et al. (2012).
1 2 http://dx.doi.org/10.1787/888932916496
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2. NON-MEDICAL DETERMINANTS OF HEALTH2.3. Fruit and vegetable consumption among childrenNutrition is important for children’s development and
long-term health. Eating fruit during adolescence, for
example in place of foods high in fat, sugar and salt, can
protect against health problems such as obesity, diabetes,
and cardiovascular diseases. Moreover, eating fruit and
vegetables when young can be habit forming, promoting
healthy eating in adult life.
A number of factors influence the amount of fruit con-
sumed by adolescents, including family income, the cost of
alternatives, preparation time, whether parents eat fruit,
and the availability of fresh fruit which can be linked to the
country or local climate (Rasmussen et al., 2006). Fruit con-
sumption and vegetable consumption have a high priority
as indicators of healthy eating in most OECD countries.
Overall, boys in Canada, Denmark and Portugal, and girls in
Denmark, Norway and Canada had the highest rates of
daily fruit consumption, while consumption was relatively
low in Poland, Sweden, Estonia, and Finland, with rates of
around one in four for girls and one in five, or even less, for
boys (Figure 2.3.1). In all countries, girls were more likely
than boys to eat fruit daily. The gap between the fruit con-
sumption of boys and girls was especially large in Denmark,
where 56% of girls, but only 34% of boys reported eating
fruit each day. Norway and Germany also had large differ-
ences.
Daily vegetable eating was reported by around one in three
girls and one in four boys on average across OECD member
states in 2009-10 (Figure 2.3.2). Girls in Belgium most com-
monly ate vegetables daily (60%), followed by Denmark,
France, Canada and Switzerland (45-50%). Belgium also led
the way for boys (46%), with close to 40% in France, Canada
and Ireland. Eating vegetables daily was less common in
Austria, Estonia and Spain, as well as in Hungary (girls),
and Finland (boys).
Average reported rates of daily vegetable consumption
across OECD countries showed some increase between
2001-02 and 2009-10, for both girls and boys (Figure 2.3.3).
The largest increases (above 10%) are observed in Denmark
and Greece (in both genders), and in Norway and Spain (in
girls only). For fruit consumption, trends show on average a
small increase over the past decade among boys and girls.
Rates have grown by 10% or more in Canada, Denmark,
Norway, the United Kingdom, and the United States,
whereas they have fallen in Poland and in Germany (in boys
only).
Effective and targeted strategies are required to ensure that
children are eating enough fruit and vegetables to conform
to recommended national dietary guidelines. A European
study found that schoolchildren generally hold a positive
attitude toward fruit intake, and report good availability of
fruit at home, but a lesser availability at school and during
leisure time. Improved access to fruit and vegetables, com-
bined with educational and motivational activities may
help to increase consumption (Sandvik et al., 2005).
Definition and comparability
Dietary habits are measured here in terms of the pro-
portions of children who report eating fruit and vege-
tables at least every day or more than once a day. In
addition to fruit and vegetables, healthy nutrition also
involves other types of foods.
Data are from the Health Behaviour in School-aged
Children (HBSC) surveys. They are drawn from
school-based samples of 1 500 in each age group (11-,
13- and 15-year-olds) in most countries.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 201350
2. NON-MEDICAL DETERMINANTS OF HEALTH
2.3. Fruit and vegetable consumption among children2.3.1. Daily fruit eating among 15-year-olds, 2009-10
Source: Currie, C. et al. (2012).
1 2 http://dx.doi.org/10.1787/888932916515
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2.3.2. Daily vegetable eating among 15-year-olds, 2009-10
Source: Currie, C. et al. (2012).
1 2 http://dx.doi.org/10.1787/888932916534
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2.3.3. Trends in daily fruit and vegetable eating among 15-year-olds, 27 OECD countries, 2001-02 to 2009-10
Source: Currie et al. (2004); Currie et al. (2008); Currie et al. (2012).
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2. NON-MEDICAL DETERMINANTS OF HEALTH2.4. Physical activity among childrenUndertaking physical activity in adolescence is beneficial for
health, and can set standards for adult physical activity levels,
thereby influencing health outcomes later in life. Research
suggests that physical activity has a role in child and adoles-
cent development, learning and well-being, and in the pre-
vention and treatment of a range of youth health issues
including asthma, mental health, and bone health. More
direct links to adult health are found between physical activ-
ity in adolescence and its effect on overweight and obesity
and related diseases, breast cancer rates and bone health in
later life. The health effects of adolescent physical activity
are sometimes dependent on the activity type, e.g. water
physical activities in adolescence are effective in the treat-
ment of asthma, and exercise is recommended in the treat-
ment of cystic fibrosis (Hallal et al., 2006; Currie et al., 2012).
A large study recommends that children participate in at least
60 minutes of moderate-to-vigorous physical activity daily,
although evidence suggests that many children do not meet
these guidelines (Strong et al., 2005; Borraccino et al., 2009;
Hallal et al., 2012). Some of the factors influencing the levels
of physical activity undertaken by adolescents include the
availability of space and equipment, children’s present health
conditions, their school curricula and other competing
pastimes.
In OECD countries, fewer than one in four children report
that they undertake moderate-to-vigorous exercise regu-
larly, according to results from the 2009-10 HBSC survey
(Figure 2.4.1). At age 11, Austria, Ireland, Spain, and Finland
stand out as strong performers with over 30% of children
reporting exercising for at least 60 minutes per day over the
past week. At age 15, children in the United States are the
most active, followed by Ireland, Czech Republic, the Slovak
Republic and Canada. Children in Denmark, France, Italy,
and Switzerland were least likely to report exercising regu-
larly. Italy ranks at the bottom end of the spectrum for both
boys and girls, and at both ages. A consistently higher pro-
portion of boys than girls reported undertaking physical
activity, whether moderate or vigorous, across all countries
and all age groups (Figure 2.4.1).
It is of concern that physical activity tends to fall between
ages 11 to 15 in almost all OECD countries, with boys in
Italy and in the United States the only exceptions. In
Austria, Finland, Norway and Germany, the rate of boys
exercising at recommended levels is reduced by half
between age 11 and age 15. This is also the case for girls in
many countries. In Austria, Ireland, Spain and Finland,
rates of physical activity among girls fall by over 60%.
The change in activity levels between age 11 and age 15
may reflect a move to different types of activity, since free
play is more common among younger children, and struc-
tured activities at school or in sports clubs become more
common later. Boys tend to be more physically active than
girls in all countries, also suggesting that the opportunities
to undertake physical activity may be gender-biased (Currie
et al., 2012).
On average across OECD countries, daily moderate-to-
vigorous physical activity fell slightly for both boys and
girls, and in all age groups between 2005-06 and 2009-10 as
shown in Figure 2.4.2.
Definition and comparability
Data for physical activity consider the regularity of
moderate-to-vigorous physical activity as reported
by 11-, 13- and 15-year-olds in 2005-06 and 2009-10.
Moderate-to-vigorous physical activity refers to exer-
cise undertaken for at least an hour each day which
increases the heart rate, and leaves the child out of
breath sometimes.
Data for OECD countries are from the Health Behaviour
in School-aged Children (HBSC) surveys. They are
drawn from school-based samples of 1 500 in each
age group in most countries.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 201352
2. NON-MEDICAL DETERMINANTS OF HEALTH
2.4. Physical activity among children2.4.1. Daily moderate-to-vigorous physical activity, 11- and 15-year-olds, 2009-10
Source: Currie et al. (2012).
1 2 http://dx.doi.org/10.1787/888932916572
2.4.2. Trends in daily moderate-to-vigorous physical activity, 27 OECD countries, 2005-06 to 2009-10
Source: Currie et al. (2008); Currie et al. (2012).
1 2 http://dx.doi.org/10.1787/888932916591
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2. NON-MEDICAL DETERMINANTS OF HEALTH2.5. Tobacco consumption among adultsTobacco kills nearly 6 million people each year, of whom
more than 5 million are from direct tobacco use and more
than 600 000 are non-smokers exposed to second-hand
smoke (WHO, 2013). It is a major risk factor for at least two
of the leading causes of premature mortality – circulatory
disease and cancer, increasing the risk of heart attack,
stroke, lung cancer, cancers of the larynx and mouth, and
pancreatic cancer. Smoking also causes peripheral vascular
disease and hypertension. In addition, it is an important
contributing factor for respiratory diseases such as chronic
obstructive pulmonary disease (COPD). Smoking in preg-
nancy can lead to low birth weight and illness among
infants. It remains the largest avoidable risk factor for
health in OECD countries.
The proportion of daily smokers in the adult population
varies greatly, even between neighboring countries
(Figure 2.5.1). Fifteen of 34 OECD countries had less than
20% of the adult population smoking daily in 2011. Rates
were lowest in Sweden, Iceland and the United States (less
than 15%). Rates were also less than 15% in India, South
Africa, and Brazil. Although large disparities remain, smok-
ing rates across most OECD countries have shown a
marked decline. On average, smoking rates have decreased
by about one fifth over the past ten years, with a steeper
decline in men than in women. Large reductions occurred
since 2000 in Norway (32% to 17%), Iceland (22% to 14%),
Netherlands (32% to 21%), Denmark (31% to 20%) and New
Zealand (25% to 17%). Greece maintains the highest level of
daily smoking among OECD countries, at around 32% of the
adult population, along with Chile and Ireland, with
around 30%, although the latest figure for Ireland dates
from 2007. Smoking rates were even higher in the Russian
Federation.
In the post-war period, most OECD countries tended to fol-
low a pattern marked by very high smoking rates among
men (50% or more) through to the 1960s and 1970s, while
the 1980s and the 1990s were characterised by a marked
downturn in tobacco consumption. Much of this decline
can be attributed to policies aimed at reducing tobacco
consumption through public awareness campaigns, adver-
tising bans and increased taxation, in response to rising
rates of tobacco-related diseases. In addition to govern-
ment policies, actions by anti-smoking interest groups
were very effective in reducing smoking rates by changing
beliefs about the health effects of smoking, particularly in
North America (Cutler and Glaeser, 2006).
Smoking prevalence is higher among men compared to
women in all OECD countries except Norway, although
male and female rates in Denmark, Iceland and the United
Kingdom are similar (Figure 2.5.2). Female smoking rates
continue to decline in most OECD countries, and in a num-
ber of cases (Ireland, Turkey, and New Zealand) at an even
faster pace than male rates. However, in three countries,
female smoking rates have been increasing over the last
ten years (Czech Republic, Portugal and Korea), but even in
these countries women are still less likely to smoke than
men. In 2011, the gender gap in smoking rates was particu-
larly large in Korea, Japan, Mexico, and Turkey, as well as in
the Russian Federation, India, Indonesia and China
(Figure 2.5.2).
Several studies provide strong evidence of socio-economic
differences in smoking and mortality (Mackenbach et al.,
2008). People in less affluent social groups have a greater
prevalence and intensity of smoking, a higher all-cause
mortality rate and lower rates of cancer survival (Woods et
al., 2006). The influence of smoking as a determinant of
overall health inequalities is such that, if the entire popula-
tion was non-smoking, mortality differences between
social groups would be halved (Jha et al., 2006).
Definition and comparability
The proportion of daily smokers is defined as the per-
centage of the population aged 15 years and over who
report smoking every day.
International comparability is limited due to the lack
of standardisation in the measurement of smoking
habits in health interview surveys across OECD coun-
tries. Variations remain in the age groups surveyed,
the wording of questions, response categories and
survey methodologies (e.g. in a number of countries,
respondents are asked if they smoke regularly, rather
than daily).HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 201354
2. NON-MEDICAL DETERMINANTS OF HEALTH
2.5. Tobacco consumption among adults2.5.1. Adult population smoking daily, 2011 and change between 2000 and 2011 (or nearest year)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en; national sources for non-OECD countries.
1 2 http://dx.doi.org/10.1787/888932916610
2.5.2. Gender gap in adults smoking daily, 2011 (or nearest year)
Note: Countries are ranked in increasing order of smoking rates for the whole population.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en; national sources for non-OECD countries.
1 2 http://dx.doi.org/10.1787/888932916629
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2. NON-MEDICAL DETERMINANTS OF HEALTH2.6. Alcohol consumption among adultsThe health burden related to harmful alcohol consump-
tion, both in terms of morbidity and mortality, is consider-
able in most parts of the world (Rehm et al., 2009; WHO,
2011d). Alcohol use is associated with numerous harmful
health and social consequences, including an increased
risk of a range of cancers, stroke, and liver cirrhosis, among
others. Foetal exposure to alcohol increases the risk of birth
defects and intellectual impairment. Alcohol also contrib-
utes to death and disability through accidents and injuries,
assault, violence, homicide and suicide, and is estimated to
cause more than 2.5 million deaths worldwide per year
(WHO, 2011d). WHO estimates that 4% of the global burden
of disease is attributable to alcohol, which accounts for
about as much mortality and disability as tobacco and
hypertension (Rehm et al., 2009). In the United States,
excessive alcohol consumption is the third leading cause of
death, accounting for 80,000 deaths per year and
2.3 million potential years of life lost (CDC, 2012). Health
care costs associated with excessive drinking in the United
States are estimated at USD 25.6 billion (Bouchery et al.,
2006). In the Russian Federation, alcohol misuse was a
major contributing factor to the sharp rise in premature
mortality and decline in life expectancy during the 1990s
(OECD, 2012c).
Alcohol consumption, as measured by annual sales, stands
at 9.4 litres per adult, on average, across OECD countries,
based on the most recent data available (Figure 2.6.1). Leav-
ing aside Luxembourg – given the high volume of pur-
chases by non-residents in that country – France, Austria,
Estonia reported the highest consumption of alcohol, with
12.0 litres or more per adult per year in 2011. Low alcohol
consumption was recorded in Turkey and Israel, as well as
in Indonesia and India, where religious and cultural tradi-
tions restrict the use of alcohol in some population groups.
Although average alcohol consumption has gradually
fallen inmany OECD countries over the past two decades, it
has risen in several Northern European countries (Iceland,
Sweden, Norway and Finland) as well as in Poland and
Israel. There has been a degree of convergence in drinking
habits across the OECD, with wine consumption increasing
in many traditional beer-drinking countries and vice versa.
The traditional wine-producing countries of Italy, Greece,
Spain, Portugal and France, as well as the Slovak Republic,
Switzerland and Hungary have seen per capita consump-
tion fall by one fifth or more since 1990 (Figure 2.6.1).
Alcohol consumption in the Russian Federation, as well as
in Brazil, India, and China has risen substantially, although
in the latter two countries per capita consumption is still
low.
Variations in alcohol consumption across countries and
over time reflect not only changing drinking habits but also
the policy responses to control alcohol use. Curbs on adver-
tising, sales restrictions and taxation have all proven to be
effective measures to reduce alcohol consumption (Babor
et al., 2010).
Although adult alcohol consumption per capita gives use-
ful evidence of long-term trends, it does not identify sub-
populations at risk from harmful drinking patterns. The
consumption of large quantities of alcohol in a single ses-
sion (heavy episodic drinking, or binge drinking), is an
especially dangerous pattern of consumption (Institute of
Alcohol Studies, 2007), which is on the rise in some coun-
tries and social groups, especially among young people
(Devaux and Sassi, forthcoming).
In 2010, the World Health Organization endorsed a global
strategy to combat the harmful use of alcohol, through
direct measures such as medical services for alcohol-
related health problems, and indirect measures such as the
dissemination of information on alcohol-related harm
(WHO, 2010a).
Definition and comparability
Alcohol consumption is defined as annual sales of
pure alcohol in litres per person aged 15 years and
over. The methodology to convert alcoholic drinks to
pure alcohol may differ across countries. Official sta-
tistics do not include unrecorded alcohol consump-
tion, such as home production.
Italy reports consumption for the population 14 years
and over, Sweden for 16 years and over, and Japan
20 years and over. In some countries (e.g. Luxembourg),
national sales do not accurately reflect actual con-
sumption by residents, since purchases by non-
residents create a significant gap between sales and
consumption.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 201356
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2.6. Alcohol consumption among adults2.6.1. Alcohol consumption among adults, 2011 and change between 1990 and 2011 (or nearest year)
1. In Luxembourg, national sales do not accurately reflect actual consumption by residents, since purchases by non-residents create a significant gap.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en; WHO for non-OECD countries.
1 2 http://dx.doi.org/10.1787/888932916648
2.6.2. Trends in alcohol consumption, selected OECD countries, 1990-2011
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932916667
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2. NON-MEDICAL DETERMINANTS OF HEALTH2.7. Overweight and obesity among adultsThe rise in overweight and obesity is a major public health
concern. Obesity is a known risk factor for numerous
health problems, including hypertension, high cholesterol,
diabetes, cardiovascular diseases, respiratory problems
(asthma), musculoskeletal diseases (arthritis) and some
forms of cancer. Mortality also increases progressively once
the overweight threshold is crossed (Sassi, 2010).
Based on the latest available surveys, more than half
(52.6%) of the adult population in the OECD report that they
are overweight or obese. In countries where height and
weight were measured (as opposed to self-reported), the
proportion was even greater, at 55.6%. The prevalence of
overweight and obesity among adults exceeds 50% in no
less than 20 of 34 OECD countries. In contrast, over-
weight and obesity rates are much lower in Japan and
Korea and in some European countries (France and
Switzerland), although even in these countries rates
have been increasing.
The prevalence of obesity, which presents even greater
health risks than overweight, varies nearly tenfold in OECD
countries, from a low of 4% in Japan and Korea, to over 32%
in Mexico and the United States (Figure 2.7.1). Across OECD
countries, 18% of the adult population are obese. Average
obesity rates in men and women are similar in most coun-
tries. However, in South Africa, the Russian Federation,
Turkey, Chile, and Mexico, a greater proportion of women
are obese, while the reverse is true in Iceland and Norway.
The prevalence of obesity has increased over the past
decade in all OECD countries (Figure 2.7.2). In 2011, at least
one in five adults was obese in ten OECD countries, com-
pared to five a decade ago. Since 2000, obesity rates have
increased by a third or more in 16 countries. The rapid rise
occurred regardless of where levels stood a decade ago.
Obesity increased by almost half in both Iceland and
Norway, even though the current rate in Norway is around
half that of Iceland.
The rise in obesity has affected all population groups,
regardless of sex, age, race, income or education level, but
to varying degrees. Evidence from Australia, Austria,
Canada, England, France, Italy, Korea, Spain and the United
States shows that obesity tends to be more common in dis-
advantaged socio-economic groups, especially in women
(Sassi et al., 2009). There is also a relationship between the
number of years spent in full-time education and obesity,
with the more educated displaying lower rates. Again, the
gradient in obesity is stronger in women than in men
(Devaux et al., 2011).
A number of behavioural and environmental factors have
contributed to the global spread of overweight and obesity,
including falling real prices of food and more time spent in
sedentary activities. Overweight and obesity have risen
rapidly in children in recent decades, reaching double-
figure rates in most OECD countries (see Indicator 2.2
“Overweight and obesity among children”).
Because obesity is associated with higher risks of chronic
illnesses, it is linked to significant additional health care
costs. There is a time lag between the onset of obesity and
related health problems, suggesting that the rise in obesity
over the past decade will mean higher health care costs in
the future. A 2007 study estimated that total costs linked
with overweight and obesity in England in 2015 could
increase by as much as 70% relative to 2007 and could be
2.4 times higher in 2025 (Foresight, 2007).
Definition and comparability
Overweight and obesity are defined as excessive
weight presenting health risks because of the high
proportion of body fat. The most frequently used
measure is based on the body mass index (BMI),
which is a single number that evaluates an individ-
ual’s weight in relation to height (weight/height2,
with weight in kilograms and height in metres). Based
on the WHO classification (WHO, 2000), adults with a
BMI from 25 to 30 are defined as overweight, and
those with a BMI of 30 or over as obese. This classifi-
cation may not be suitable for all ethnic groups, who
may have equivalent levels of risk at lower or higher
BMI. The thresholds for adults are not suitable to
measure overweight and obesity among children.
For most countries, overweight and obesity rates are
self-reported through estimates of height and weight
from population-based health interview surveys.
However, around one-third of OECD countries derive
their estimates from health examinations. These dif-
ferences limit data comparability. Estimates from
health examinations are generally higher, and more
reliable than estimates from health interviews. Note
that the OECD average is based on both types of esti-
mates (self-reported andmeasured) and, thus, may be
underestimated.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 201358
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2.7. Overweight and obesity among adults2.7.1. Obesity among adults, 2011 (or nearest year)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en; national sources for non-OECD countries.
1 2 http://dx.doi.org/10.1787/888932916686
2.7.2. Increasing obesity among adults in OECD countries, 2000 and 2011 (or nearest year)
1. Data are based on measurements rather than self-reported height and weight.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932916705
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2. NON-MEDICAL DETERMINANTS OF HEALTH2.8. Fruit and vegetable consumption among adultsNutrition is an important determinant of health. Inade-
quate consumption of fruit and vegetables is one factor
that can play a role in increased morbidity. Proper nutrition
assists in preventing a number of chronic conditions,
including cardiovascular disease, hypertension, Type-2 dia-
betes, stroke, certain cancers, musculoskeletal disorders
and a range of mental health conditions.
In response to a health survey question asking “How often
do you eat fruit?”, the percentage of adults consuming fruit
daily varied from 20% in men in Finland, to more than 90%
in Australia (Figure 2.8.1). Across the 24 countries providing
data, an average 57% of men and 69% of women reported to
eat fruit daily. Women reported eating fruit more often
than men in all countries, with the largest gender differ-
ences in Denmark, the Slovak Republic, Germany, and Ice-
land (20 percentage points or more). In Australia, Greece,
Turkey and Mexico, gender differences were much smaller,
under 5%.
Persons aged 65 and over were more likely to eat fruit than
those in younger age group, with the lowest consumption
in people aged 15-24 years (see also Indicator 2.3, “Fruit and
vegetable consumption among children”). Fruit consump-
tion also varies by socio-economic status, generally being
highest among persons with higher educational levels
(Figure 2.8.3). However, this was not the case in Spain and
Greece, where less educated persons reported eating fruit
more often.
Daily vegetable consumption ranged from around 30% in
men in Germany to nearly 100% in Korea, with Australia
and New Zealand at about the same levels, but counting
potatoes as vegetables (Figure 2.8.2). The average across
28 OECD countries was 64% for men and 73% for women.
Again, more women than men reported eating vegetables
daily in all countries, except in Korea and Australia where
rates were similar. In Norway, Denmark, Finland and
Germany, gender differences exceeded 15%.
Patterns of vegetable consumption across age groups and
by level of education are similar to those observed for fruit.
Older persons were more likely to eat vegetables daily.
Highly educated persons ate vegetables more often,
although the difference between educational groups was
small in Belgium, Italy, Greece, Slovenia and the Slovak
Republic (Figure 2.8.4).
The availability of fruit and vegetables is the most impor-
tant determinant of consumption. Despite large variations
between countries, vegetable, and especially fruit, avail-
ability is higher in Southern European countries, with cere-
als and potatoes more available in central and eastern
European countries. Fruit and vegetable availability also
tends to be higher in families where household heads have
a higher level of education (Elmadfa, 2009).
The promotion of fruit and vegetable consumption, espe-
cially in schools and at the workplace, features in the
EU platform for action on diet, physical activity and health
(European Commission, 2011a).
Definition and comparability
Estimates of daily fruit and vegetable consumption
are derived from national and European Health Inter-
view Survey questions. Typically, respondents were
asked “How often do you eat fruit (excluding juice)?”
and “How often do you eat vegetables or salad
(excluding juice and potatoes)?”
Data for Greece and Switzerland include juices as a
portion of fruit, and juices and soups as a portion of
vegetable. Data for Australia, Greece, New Zealand,
and the United Kingdom include potatoes as vegeta-
bles. Data rely on self-reporting, and are subject to
errors in recall. The same surveys also ask for infor-
mation on age, sex and educational level. Data are not
age standardised, with aggregate country estimates
representing crude rates among respondents aged
15 years and over in all countries, except Germany
and Australia which is 18 years and over.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 201360
2. NON-MEDICAL DETERMINANTS OF HEALTH
2.8. Fruit and vegetable consumption among adults2.8.1. Daily fruit eating among adults, 2011
(or nearest year)
1. Include juices.
1 2 http://dx.doi.org/10.1787/888932916724
2.8.3. Daily fruit eating among adults, by educational
level, European countries, 2008
(or nearest year)
Source: Eurostat Statistics Database 2013 (EHIS collection round 2008).
1 2 http://dx.doi.org/10.1787/888932916762
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2.8.2. Daily vegetable eating among adults, 2011
(or nearest year)
1. Include potatoes.
2. Include juices and soups.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932916743
2.8.4. Daily vegetable eating among adults,
by educational level, European countries, 2008
(or nearest year)
Source: Eurostat Statistics Database 2013 (EHIS collection round 2008).
1 2 http://dx.doi.org/10.1787/888932916781
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3.1. Doctors (overall number)
3.2. Doctors by age, sex and category
3.3. Gynaecologists and obstetricians, and midwives
3.4. Psychiatrists and mental health nurses
3.5. Medical graduates
3.6. Remuneration of doctors (general practitioners and specialists)
3.7. Nurses
3.8. Nursing graduates
3.9. Remuneration of nurses
The statistical data for Israel are supplied by and under the responsibility of the relevant
Israeli authorities. The use of such data by the OECD is without prejudice to the status of the
Golan Heights, East Jerusalem and Israeli settlements in the West Bank under the terms of
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3. HEALTH WORKFORCE3.1. Doctors (overall number)The number of doctors per capita varies widely across
OECD and emerging countries. In 2011, Greece had by far
the highest number of doctors per capita (6.1 per
1 000 population), followed by the Russian Federation and
Austria. Chile, Turkey and Korea had the lowest number of
doctors per capita among OECD countries, with around
two doctors per 1 000 population. This compares with an
OECD average of just over three doctors per 1 000 population.
The number of doctors per capita is much lower in some
emerging countries, with less than one doctor per
1 000 population in Indonesia, India and South Africa
(Figure 3.1.1).
Between 2000 and 2011, the number of physicians has
grown in most OECD countries, both in absolute number
and on a per capita basis. The growth rate was particularly
rapid in countries which started with lower levels in 2000
(Turkey, Korea and Mexico), as well as in Australia, the
United Kingdom and Greece. In Australia and the United
Kingdom, the increasing number of doctors has been
driven mainly by a strong rise in graduation rates from
domest ic medical educat ion programmes (see
Indicator 3.5). In Greece, the number of doctors per capita
increased strongly between 2000 and 2008, but has stabi-
lised since then. On the other hand, there was almost no
growth in the number of physicians per capita in Estonia
and France between 2000 and 2011, and there was a decline
in Israel.
The absolute number of doctors has continued to grow in
most OECD countries during the 2008-09 recession and
afterwards, although it has slowed down in some countries
that have been hard hit by the recession such as Greece. In
Portugal, the absolute number of doctors licensed to prac-
tice increased by 12% between 2008 and 2011, although this
does not mean that the number of doctors engaged in reg-
ular practice has grown at the same pace. In the United
Kingdom, there were 15% more employed doctors in 2012
compared with 2008 (Figure 3.1.2).
In France, there has been a slight increase in the absolute
number of doctors since 2008, which has grown at the same
pace as the population size. The increase over the past few
years has been driven mainly by a large number of doctors
beyond age 65 remaining in activity (DREES, 2013).
Projecting the future supply and demand of doctors is diffi-
cult, because of high levels of uncertainties concerning
their working hours and retirement patterns on the supply
side, and changing health needs of ageing populations and
future trends in economic growth and health expenditure
growth on the demand side (Ono et al., 2013). In Australia,
the baseline (or comparison) scenario in a recent projection
exercise estimated a possible small shortage of physicians
by 2025. The projection explored different scenarios that
may either mitigate or exacerbate these baseline results. If
the demand for doctor services is growing at a slightly
slower pace than projected, the projected shortage would
disappear. However, if there is a sharp reduction in the
number of immigrant doctors or if a maximum limit is set
to the number of working hours of doctors per week, then a
growing number of medical graduates would be required to
close the projected gap (HealthWorkforce Australia, 2012).
In the United Kingdom, a recent projection exercise identi-
fied a potential surplus of specialist doctors (consultants),
based on a set of assumptions about future health expendi-
ture, as well as developments concerning pay rates and
inflation. While the supply of GPs is projected to increase
by 29% between 2010-11 and 2039-40, the supply of hospital
doctors is projected to increase by 64% (based on current
levels of student intakes and graduation rates), exceeding
by a wide margin the additional staff that the NHS may be
able to recruit over that period. One of the conclusions from
this projection exercise was that it may be advisable
to reduce slightly medical intakes and to reduce the train-
ing of hospital doctors more specifically (CfWI, 2012).
Definition and comparability
The data for most countries refer to practising medi-
cal doctors, defined as the number of doctors who are
providing care directly to patients. In many countries,
the numbers include interns and residents (doctors in
training). The numbers are based on head counts. The
data for Ireland are based on estimations. Several
countries also include doctors who are active in the
health sector even though they may not provide
direct care to patients. Portugal reports the number of
physicians entitled to practice (resulting in a large
over-estimation of the number of practising doctors).
Data for Spain (up to 2010) include dentists, while
data for Belgium include stomatologists (also result-
ing in some over-estimation).
Data for India are also likely over-estimated as they
are based on medical registers which are not updated
to account for migration, retirement or death, nor do
they take into account doctors registered in multiple
states.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 201364
3. HEALTH WORKFORCE
3.1. Doctors (overall number)3.1.1. Practising doctors per 1 000 population, 2000 and 2011 (or nearest year)
1. Data include not only doctors providing direct care to patients, but also those working in the health sector as managers, educators, researchers, etc.
(adding another 5-10% of doctors).
2. Data refer to all doctors licensed to practice (resulting in a large over-estimation of the number of practising doctors in Portugal).
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932916800
3.1.2. Evolution in the number of doctors, selected OECD countries, 2000 to 2012 (or nearest year)
1. Data refer to all doctors who are licensed to practice.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932916819
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3. HEALTH WORKFORCE3.2. Doctors by age, sex and categoryBeyond the overall number of doctors, the age and gender
composition of themedical workforce and themix between
different categories of doctors also have important implica-
tions on the current and future supply of medical services.
The ageing of doctors in OECD countries has, for many
years, raised concerns that there may not be sufficient new
recruits to replace them, although there is evidence in sev-
eral countries that the retirement of doctors often only
occurs gradually and that their retirement age is increasing
(Pong, 2011). The rising share of female doctors (the “femi-
nisation” of medical professions) affects the overall supply
of services, as women tend to work fewer hours than men,
although it appears that working time preferences are
becoming more similar among new generations of men
and women doctors (Maiorova, 2007). The growing imbal-
ance in favour of greater specialism over generalist medi-
cine raises concerns in many countries about ensuring
adequate access to primary care for all the population.
In 2011, on average across OECD countries, nearly one-third
of all doctors were over 55 years of age, up from one-in-five
in 2000 (Figure 3.2.1). These doctors might be expected to
retire over the next ten years although a significant num-
ber of doctors continue to practice after 65 years. In Israel,
almost half (49%) of all doctors were over 55 years of age in
2011, but this may be due partly to the fact that these num-
bers relate to all doctors licensed to practice. This propor-
tion reached over 40% in Belgium, France and Italy. By
contrast, less than 15% of doctors in the United Kingdom
and Korea were aged over 55, due to large numbers of new
graduates entering medical practice over the past decade
(Indicator 3.5).
In 2011, 44% of doctors on average across OECD countries
were women, up from 38% in 2000 (and 29% in 1990)
(Figure 3.2.2). More than half of doctors now are women in
nine countries (Estonia, Slovenia, Poland, the Slovak
Republic, Finland, Hungary, Czech Republic, Portugal and
Spain). By contrast, only one in five doctors in Japan and
Korea were women in 2011. Since 2000, the share of female
physicians increased in all OECD countries for which data
are available, with particularly large increases in the
Netherlands and Spain.
The balance in the physician workforce between general-
ists and specialists has changed over the past few decades,
with the number of specialists increasing much more rap-
idly. Although health service research emphasises the
importance and cost-effectiveness of generalist primary
care (Starfield et al., 2005), on average across OECD coun-
tries, generalists made up only 30% of all physicians. There
were more than two specialists for every generalist in 2011
(Figure 3.2.3). Specialists greatly outnumber generalists in
central and eastern European countries and in Greece.
However, some countries have maintained a more equal
balance between specialists and generalists, such as
Australia, Canada and France. In Ireland, most generalists
are not really general practitioners, but rather non-specialist
doctors working in hospitals or other settings. In some
countries such as the United States, general internal medi-
cine doctors are categorised as specialists although their
practice can be very similar to that of general practitioners,
resulting in some underestimation of the capacity of these
countries to provide generalist care.
In many OECD countries, specialists earn more and have
seen their earnings grow faster than general practitioners
(see Indicator 3.6). This creates a financial incentive for
doctors to specialise, although other factors such as work-
ing conditions and professional prestige also influence
choices. In response to concerns about shortages of general
practitioners, many countries have taken steps to improve
the number of training places and attractiveness of general
medicine. For example, in France, about 50% of all graduate
medical training places are reserved for general medicine
(DREES, 2013). In the Netherlands, the number of graduate
training places in different areas of medical training is reg-
ularly revised to take into account expected changes in
staffing requirements (ACMMP, 2010).
Definition and comparability
The definition of doctors is provided under
Indicator 3.1. In some countries, the data are based on
all doctors licensed to practice, not only those practis-
ing (e.g., Ireland and Portugal).
Not all countries are able to report all their physicians
in the two broad categories of specialists and general-
ists. This may be due to the fact that specialty-
specific data are not available for doctors in training
or for those working in private practice.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 201366
3. HEALTH WORKFORCE
3.2. Doctors by age, sex and category3.2.1. Share of doctors aged 55 years and over, 2000 and 2011 (or nearest year)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en. 1 2 http://dx.doi.org/10.1787/888932916838
3.2.2. Share of female doctors, 2000 and 2011 (or nearest year)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en. 1 2 http://dx.doi.org/10.1787/888932916857
3.2.3. Generalists and specialists as a share of all doctors, 2011 (or nearest year)
1. Generalists include general practitioners/family doctors and other generalist (non-specialist) medical practitioners.
2. Specialists include paediatricians, obstetricians/gynaecologists, psychiatrists, medical, surgical and other specialists.
3. In Ireland, most generalists are not GPs (“family doctors”), but rather non-specialist doctors working in hospitals or other settings.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932916876
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3. HEALTH WORKFORCE3.3. Gynaecologists and obstetricians, and midwivesGynaecologists are concerned with the functions and dis-
eases affecting the female reproductive system, while
obstetricians specialise in pregnancy and childbirth. A doc-
tor will often specialise in both these areas, and the data
reported in this section does not distinguish between the
two. Midwives provide care and advice to women during
pregnancy, labour and childbirth and the post-natal period.
They deliver babies working independently or in collabora-
tion with doctors and nurses.
In countries with a medicalised approach to pregnancy,
obstetricians provide the majority of care. Where a less
medicalised approach exists, trained midwives are the lead
professional, often working in collaboration with general
practitioners, although obstetricians may be called upon if
complications arise. Regardless of the different mix of pro-
viders across countries, the progress achieved over the past
few decades in the provision of pre-natal advice and preg-
nancy surveillance, together with progress in obstetrics to
deal with complicated births, has resulted in major reduc-
tions in perinatal mortality in all OECD countries.
In 2011, the number of gynaecologists and obstetricians per
100 000 women was the highest in the Czech Republic and
Greece, followed by Italy and the Slovak Republic
(Figure 3.3.1). These are all countries where obstetricians
are given a primary role in providing pre-natal and child-
birth care. The number of gynaecologists and obstetricians
per 100 000 women was the lowest in New Zealand,
Canada, Ireland, Chile and the Netherlands.
Since 2000, the number of gynaecologists and obstetricians
per 100 000 women has increased in most countries,
although the growth rate varied (Figure 3.3.1). It was highest
in Mexico, Australia, Switzerland and the United Kingdom.
On the other hand, the number of gynaecologists and
obstetricians per 100 000 women declined slightly in Japan
and the United States. In the United States, this was
because the growth in the population number exceeded the
growth in the number of gynaecologists and obstetricians.
The number of midwives per 100 000 women was highest
in Iceland, Sweden, Turkey and Australia in 2011
(Figure 3.3.2). It was the lowest in Korea, Canada and
Slovenia.While the number of midwives has increased sig-
nificantly in Canada and Slovenia over the past decade, it
has fallen in Korea. This decline has coincided with a con-
tinued reduction in fertility rates in Korea. The number of
midwives per capita also decreased slightly in Estonia,
Hungary and Israel between 2000 and 2011. In Hungary,
most of the reduction occurred between 2006 and 2007, as
the number of beds in maternity wards was cut by more
than one-third in the context of a health reform. In the
Netherlands, the number of midwives has increased faster
than the number of gynaecologists and obstetricians, and
the number of births in hospitals attended by midwives
rose from 8% in 1998 to 26% in 2007 (Wiegers and
Hukkelhoven, 2010).
The relative mix of providers has both direct and indirect
implications for the costs of pre-natal and natal services.
Services involving midwives are likely to be cheaper. This
reflects in part the lower training time and hence a lower
compensating pay for midwives in comparison to gynaeco-
logists and obstetricians. In addition, obstetricians may be
inclined to provide more medicalised services. A study of
nine European countries found that the cost of delivery is
lower in those countries and hospitals that employ more
midwives and nurses than obstetricians (Bellanger and Or,
2008).
There is little evidence that systems that rely more on mid-
wives are less effective. A review of a number of studies
finds that midwife-led models of care resulted in fewer
complications (Hatem et al., 2008). Another review found
that midwives are equally effective in providing pre-natal
care and advice in the case of normal pregnancies (Di Mario
et al., 2005), although support from obstetricians is
required for complications.
Definition and comparability
The number of gynaecologists and obstetricians com-
bines these two specialities.
The figures for gynaecologists and obstetricians, and
for midwives, are presented as head counts, not tak-
ing into account full-time or part-time status (except
in Ireland where the data on midwives are based on
full-time equivalents). In Spain, the number of gynae-
cologists and obstetricians only includes those work-
ing in hospital.
The number of midwives in Canada may be under-
estimated, as they may undercount the number of
midwives in provinces/territories where there is no
regulation requiring licensure as a condition of prac-
tice. In Austria, the number of midwives only includes
those employed in hospital (resulting in an under-
estimation of 40 to 50%).HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 201368
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3.3. Gynaecologists and obstetricians, and midwives3.3.1. Gynaecologists and obstetricians per 100 000 women, 2011 and change between 2000 and 2011
1. In Spain, the number of gynaecologists and obstetricians only includes those working in hospital.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932916895
3.3.2. Midwives per 100 000 women, 2011 and change between 2000 and 2011
1. In Austria, the number of midwives only includes those working in hospital.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932916914
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3. HEALTH WORKFORCE3.4. Psychiatrists and mental health nursesAt any point in time, about 10% of the adult population will
report having some type of mental or behavioural disorder
(WHO, 2001). People with mental health problems may
receive help from a variety of professionals, including gen-
eral practitioners, psychiatrists, psychologists, psychother-
apists, social workers, specialist nurses and others. This
section focuses on two categories of mental health service
providers, psychiatrists and mental health nurses, as the
availability of comparable data for other providers is more
limited. Psychiatrists are responsible for diagnosing and
treating a variety of serious mental health problems,
including depression, learning disabilities, alcoholism and
drug addiction, eating disorders, and personality disorders
such as schizophrenia. A mental health nurse has usually
completed a formal training in nursing at a university level
and work in mental health care services (WHO, 2011e).
In 2011, there were 15.6 psychiatrists per 100 000 population
on average across OECD countries (Figure 3.4.1). The number
was by far the highest in Switzerland, with 45 psychiatrists
per 100 000 population. Following Switzerland were Iceland,
France and Sweden, with 22 psychiatrists per 100 000 pop-
ulation. In most OECD countries, the number was between
10 and 20 per 100 000 population. There were fewer than
ten psychiatrists per 100 000 population in Mexico, Turkey,
Chile, Korea and Poland.
The number of psychiatrists per capita has increased since
2000 in most OECD countries for which data are available
(Figure 3.4.1). The rise has been particularly rapid in
Switzerland, Austria, Poland, the Netherlands and the
United Kingdom. There was a slight decrease in the num-
ber of psychiatrists per capita in the United States, as the
increase in the number of psychiatrists did not fully keep
up with the increase in the population.
As is the case for many other medical specialties, psychia-
trists may be unevenly distributed across regions within
each country. For example, in Australia, the number of psy-
chiatrists per capita was two times greater in certain states
and territories compared with others in 2009 (AIHW, 2012b).
The role of psychiatrists varies across countries. For exam-
ple, in Spain, psychiatrists work in close co-operation with
general practitioners (GPs). Hence, although the number of
psychiatrists is relatively low, consultation rates of psychi-
atrists by people with mental disorders are higher than in
many other countries that have more psychiatrists,
because of higher referral rates from their GPs (Kovess-
Masfety, 2007).
In many countries, mental health nurses play an important
and increasing role in the delivery of mental health services
in hospital or outside hospital. In 2011, the Netherlands,
Ireland and Japan had the highest rates (with over
100 mental health nurses per 100 000 population), and
Turkey, Mexico and Hungary the lowest rates (under ten per
100 000 population). The number of mental health nurses
is also relatively low in Portugal and Korea, with between
ten and 15 nurses per 100 000 population. The OECD aver-
age was 50 mental health nurses per 100 000 population
(Figure 3.4.2).
Some countries such as Australia have introduced new pro-
grammes to improve access to mental health care by
extending the role of mental health nurses in primary care.
Under the Mental Health Nurse Incentive Program
launched in 2007, mental health nurses in Australia work
with general practitioners, psychiatrists and other mental
health professionals to treat people suffering from differ-
ent mental health conditions. A recent evaluation of this
programme found that mental health nurses have the
potential to make a significant contribution to enhance
access and quality of mental care through flexible and
innovative approaches (Happell et al., 2010).
Definition and comparability
Psychiatrists are medical doctors who specialise in
the prevention, diagnosis and treatment of mental
illness. They have post-graduate training in psychia-
try, and may also have additional training in a psychi-
atric specialty, such as neuropsychiatry or child
psychiatry. Psychiatrists can prescribe medication,
which psychologists cannot do in most countries.
The figures normally include psychiatrists, neuropsy-
chiatrists and child psychiatrists. Psychologists are
excluded. The numbers are presented as head counts,
regardless of whether psychiatrists work full time or
part time. In Spain, the number of psychiatrists only
includes those working in hospital.
A mental health nurse is usually defined as a nurse
who has completed a formal training in nursing at a
university level and work in mental health care
services in hospital, in primary care or other settings
(WHO, 2011e).HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 201370
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3.4. Psychiatrists and mental health nurses3.4.1. Psychiatrists per 100 000 population, 2011 and change between 2000 and 2011
1. In Spain, the number of psychiatrists only includes those working in hospital.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932916933
3.4.2. Mental health nurses per 100 000 population, 2011 (or nearest year)
Source: OECD Mental Health Questionnaire 2012, WHO Mental Health Atlas 2011.
1 2 http://dx.doi.org/10.1787/888932916952
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3. HEALTH WORKFORCE3.5. Medical graduatesMaintaining or increasing the number of doctors requires
either investment in training new doctors or recruiting
trained physicians from abroad. As it takes about ten years
to train a doctor, any current shortages can be met only by
recruiting qualified doctors from abroad, unless there are
unemployed doctors at home. Conversely, any surpluses or
sudden fall in demand may mean that new graduates
struggle to find vacant posts at home.
Virtually all OECD countries exercise some form of control
over medical school intakes, often by limiting the number
of available training places, for example in the form of a
numerus clausus. Such control is motivated by different fac-
tors including: 1) confining medical entry to the most able
applicants; 2) the desire to control the total number of doc-
tors for cost-containment reasons (because greater supply
induces greater demand); and 3) the cost of training itself
(in all countries, including the United States, a significant
part of medical education costs are publicly funded, so
expansion of the number of medical students involves
significant public expenditure).
Austria, Denmark and Ireland had the highest number of
medical graduates per 100 000 population in 2011. Gradua-
tion rates were the lowest in Israel, Japan and France. The
average across OECD countries was slightly more than
ten new medical graduates per 100 000 population
(Figure 3.5.1). Measured in proportion to the stock of physi-
cians (i.e., a measure of the replacement rate), the number
of new medical graduates in 2011 was highest in Mexico,
Ireland, the Netherlands, and Denmark, and the lowest in
Israel and France. The average across OECD countries was
34 medical graduates per 1 000 currently employed doctors
(Figure 3.5.2). The persistently low number of medical grad-
uates in Israel and France over the past two decades has led
to a gradual ageing of the physician workforce, with these
two countries having amongst the highest share of doctors
above age 55 (Indicator 3.2).
In several countries (e.g., Australia, Canada, Denmark, the
Netherlands and the United Kingdom), the number of med-
ical graduates has risen strongly since 2000, reflecting past
decisions to expand training capacities (Figure 3.5.3). In
Australia, the number of medical graduates has increased
by 2½ times between 1990 and 2010, with most of the
growth occurring since 2000. In the United Kingdom, the
number of medical graduates doubled between 1990 and
2011, with most of the growth also taking place in the past
ten years. These increases reflect a deliberate policy in
Australia and the United Kingdom to reduce their reliance
on foreign-trained doctors to meet their own needs. In
Canada also, following a reduction in the number of medi-
cal graduates in the 1990s, there has been a strong rise of
over 50% over the past decade.
In the Netherlands, the number of medical graduates
increased steadily over the past decade, following fluctua-
tions in the 1990s. Since 1999, the DutchMedical Manpower
Planning Committee (ACMMP) makes recommendations
every two to three years to the different stakeholders and
the government concerning the numerus clausus (the quan-
titative limits to enrolments in medical education and
training programmes). The recommendations from this
Planning Committee have generally been accepted and
have led to this steady growth over the past few years
(ACMMP, 2010).
In the United States, the increase in the number of medical
graduates over the past two decades has been more mod-
est than in several other countries, although it has acceler-
ated slightly in recent years (+6% between 1990 and 2000,
and +14% between 2000 and 2011).
By contrast, in Japan, the number of medical graduates was
slightly lower in 2011 compared with 1990, following reduc-
tions in the 1990s which were only partly offset by small
increases since 2000. In Italy, there was a marked decline in
the number of medical graduates in the first half of the
1990s (pursuing a trend that had begun in the mid-1980s),
after which the number stabilised. The reduction in medi-
cal graduate numbers over the past two decades in Italy
has led to a growing proportion of doctors aged 55 and over,
as in France and Israel (Indicator 3.2). Even with an increase
in the number of medical school admissions in recent years
in these three countries, the number of doctors who may
be leaving the profession is likely to exceed the number of
new entrants in the coming years.
Definition and comparability
Medical graduates are defined as the number of stu-
dents who have graduated from medical schools or
similar institutions in a given year. Dental, public
health and epidemiology graduates are excluded.
The data for Austria and the United Kingdom exclude
foreign graduates, while other countries include them
(in the Czech Republic, foreign graduates account for
about 30% of all medical graduates). In Denmark, the
data refer to the number of new doctors receiving an
authorisation to practice.
In Luxembourg, the university does not provide med-
ical training, so all doctors are foreign-trained, mostly
in Belgium, France and Germany.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 201372
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3.5. Medical graduates3.5.1. Medical graduates per 100 000 population, 2011
(or nearest year)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932916971
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3. HEALTH WORKFORCE3.6. Remuneration of doctors (general practitioners and specialists)The remuneration of doctors is to a certain extent related
to the overall level of economic development of a given
country, but there are nevertheless significant variations in
their remuneration compared with the average wage in
each country. The structure of remuneration for different
categories of doctors also has an impact on the relative
financial attractiveness of different medical specialties. In
many countries, governments influence the level and
structure of physician remuneration directly as a key
employer of physicians or as a purchaser of services, or
through regulating their fees.
OECD data on physician remuneration distinguishes
between salaried and self-employed physicians, although
in some countries this distinction is increasingly blurred,
as some salaried physicians are allowed to have a separate
private practice and some self-employed doctors may
receive part of their remuneration through salaries. A dis-
tinction is also made between general practitioners and
all other medical specialists combined, though there may
be wide differences in the income of different medical
specialties.
As expected for highly skilled professionals, the remunera-
tion of doctors (both generalists and specialists) is much
higher than that of the average worker in all OECD coun-
tries (Figure 3.6.1). Self-employed general practitioners in
Australia earned 1.7 times the average wage in 2011,
whereas in Ireland, Canada and the Netherlands (2010),
self-employed GPs earned three times the average wage. In
the United Kingdom, self-employed GPs earned 3.4 times
the average wage in 2011. The income of self-employed GPs
in the United Kingdom rose strongly following the imple-
mentation of a new contract for generalists in 2004 that
was designed to increase their income as well as quality of
primary care (Fujisawa and Lafortune, 2008).
The income of specialists varied from 1.6 times the average
wage for salaried specialists in Hungary and Poland to over
five times for self-employed specialists in Belgium and the
Netherlands.
In all countries except Denmark, Poland and the United
Kingdom, GPs earn less than the average for medical spe-
cialists. In Canada, self-employed specialists earned
4.7 times the average wage in 2010, compared with
three times for GPs. In France, self-employed specialists
earned 3.6 times the average wage, compared with
2.1 times for GPs (the income of both specialists and GPs is
underestimated in France – see box on “Definition and
comparability”). The income gap between GPs and special-
ists is particularly large in Belgium, although it has nar-
rowed slightly in recent years.
In many OECD countries, the income gap between general
practitioners and specialists has widened over the past
decade, reducing the financial attractiveness of general
practice. The remuneration of specialists has risen faster
than that of general practitioners in countries such as
Canada, Finland, France and Hungary. On the other hand,
in Austria and Belgium, the gap has narrowed slightly, as
the income of GPs grew faster than that of specialists
(Figure 3.6.2).
Definition and comparability
The remuneration of doctors refers to average gross
annual income, including social security contribu-
tions and income taxes payable by the employee. It
should normally include all extra formal payments,
such as bonuses and payments for night shifts, on-
call and overtime, and exclude practice expenses for
self-employed doctors.
A number of data limitations contribute to an under-
estimation of remuneration levels in some countries:
1) payments for overtime work, bonuses, other sup-
plementary income or social security contributions
are excluded in some countries (Austria for GPs,
Ireland and New Zealand for salaried specialists,
France, Italy and the Slovak Republic); 2) incomes
from private practices for salaried doctors are not
included in some countries (e.g. Czech Republic,
Hungary, Slovenia, Spain, Iceland and Ireland);
3) informal payments, which may be common in cer-
tain countries (e.g. Greece and Hungary), are not
included; 4) data relate only to public sector employees
who tend to earn less than those working in the pri-
vate sector in Chile, Denmark, Hungary, Norway and
the Slovak Republic; 5) data relate to net income
rather than gross income in France; and 6) physicians
in training are included in Australia, the Czech
Republic, Germany and the United Kingdom for
specialists.
The data for some countries (Australia, Austria, Belgium,
the Netherlands and the United Kingdom for GPs)
include part-time workers, while in other countries
the data refer only to doctors working full time.
In Belgium, the data for self-employed doctors include
practice expenses, resulting in an over-estimation.
The income of doctors is compared to the average
wage of full-time employees in all sectors in the coun-
try. The source for the average wage of workers in the
economy is the OECD Labour Force Statistics Database.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 201374
3. HEALTH WORKFORCE
3.6. Remuneration of doctors (general practitioners and specialists)3.6.1. Remuneration of doctors, ratio to average wage, 2011 (or nearest year)
1. Physicians in training included (resulting in an underestimation).
2. Practice expenses included (resulting in an over-estimation).
3. Remuneration of self-employed physicians is net income, rather than gross income (resulting in an underestimation).
4. Public sector employees only (resulting in an underestimation).
5. Specialists in training included (resulting in an underestimation).
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932917028
3.6.2. Growth in the remuneration of GPs and specialists, 2005-11 (or nearest year)
1. The growth rate for the Netherlands is for self-employed GPs and specialists.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en. 1 2 http://dx.doi.org/10.1787/888932917047
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3. HEALTH WORKFORCE3.7. NursesNurses greatly outnumber physicians in most OECD coun-
tries. Nurses play a critical role in providing health care not
only in traditional settings such as hospitals and long-term
care institutions but increasingly in primary care (espe-
cially in offering care to the chronically ill) and in home
care settings.
However, there are concerns in many countries about
shortages of nurses, and these concerns may well intensify
in the future as the demand for nurses continues to
increase and the ageing of the “baby-boom” generation pre-
cipitates a wave of retirements among nurses. These con-
cerns have prompted actions in many countries to increase
the training of new nurses combined with efforts to
increase the retention of nurses in the profession, even as
the economic crisis has squeezed health budgets.
On average across OECD countries, there were 8.8 nurses
per 1 000 population in 2011 (Figure 3.7.1). The number of
nurses per capita was highest in Switzerland, Denmark,
Belgium and Iceland, with more than 14 nurses per
1 000 population (although the number in Belgium is over-
estimated because it refers to all nurses who are licensed to
practice). The number of nurses per capita in OECD coun-
tries was lowest in Turkey, Mexico and Greece. The number
of nurses per capita was also low compared with the OECD
average in key emerging countries, such as Indonesia,
India, South Africa, Brazil and China where there were
fewer than two nurses per 1 000 population in 2011,
although numbers have been growing quite rapidly in some
of these countries in recent years (Figure 3.7.1).
The number of nurses per capita increased in almost all
OECD countries over the past decade. Portugal, Korea,
Turkey and Spain saw the largest increase since 2000,
although the number of nurses per capita in these four
countries remains well below the OECD average. The num-
ber of nurses per capita declined between 2000 and 2011 in
Israel, as the size of the population grew more rapidly than
the number of nurses. It also declined in the Slovak Republic
(in both absolute numbers and on a per capita basis),
although the recent increase in the number of admissions
and graduates from nursing education programmes may
lead to an increase in the coming years.
In 2011, the nurse-to-doctor ratio ranged from 4.5 nurses
per doctor in Japan to half a nurse per doctor in Greece and
one nurse per doctor in Turkey (Figure 3.7.2). The number
of nurses per doctor was also relatively low in Mexico,
Spain, Israel and Portugal, with 1.5 nurses per doctor or
less. The average across OECD countries was just below
three nurses per doctor, with most countries reporting
between two to four nurses per doctor.
In response to shortages of doctors and to ensure proper
access to care, some countries have developed more
advanced roles for nurses. Evaluations of nurse practitio-
ners from the United States, Canada, and the United
Kingdom show that advanced practice nurses can improve
access to services and reduce waiting times, while deliver-
ing the same quality of care as doctors for a range of
patients, including those with minor illnesses and those
requiring routine follow-up. Most evaluations find a high
patient satisfaction rate, while the impact on cost is either
cost-reducing or cost-neutral. The implementation of new
advanced practice nursing roles may require changes to
legislation and regulation to remove any barrier to exten-
sions in their scope of practice (Delamaire and Lafortune,
2010).
Definition and comparability
The number of nurses includes those employed in
public and private settings providing services directly
to patients (“practising”) and in some cases also those
working as managers, educators or researchers. Bel-
gium reports all nurses licensed to practice (resulting
in a large over-estimation).
In those countries where there are different levels of
nurses, the data include both “professional nurses”
who have a higher level of education and perform
higher level tasks and “associate professional nurses”
who have a lower level of education but are nonethe-
less recognised and registered as nurses. Midwives, as
well as nursing aids who are not recognised as nurses,
should normally be excluded. However, about half of
OECD countries include midwives because they are
considered as specialist nurses.
Austria reports only nurses working in hospitals,
resulting in an under-estimation. Data for Germany
does not include about 277 500 nurses (representing
an additional 30% of nurses) who have three years of
education and are providing services for the elderly.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 201376
3. HEALTH WORKFORCE
3.7. Nurses3.7.1. Practising nurses per 1 000 population, 2011 and change between 2000 and 2011
1. Data include not only nurses providing direct care to patients, but also those working in the health sector as managers, educators, researchers, etc.
2. Data refer to all nurses who are licensed to practice.
3. Austria reports only nurses employed in hospital.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932917066
3.7.2. Ratio of nurses to physicians, 2011 (or nearest year)
Note: For those countries which have not provided data for practising nurses and/or practising physicians, the numbers relate to the same concept
(“professionally active” or “licensed to practice”) for both nurses and physicians, for the sake of consistency.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932917085
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3. HEALTH WORKFORCE3.8. Nursing graduatesMany OECD countries have taken steps in recent years to
expand the number of students in nursing education pro-
grammes in response to concerns about current or antici-
pated shortages of nurses. Increasing investment in
nursing education is particularly important as the nursing
workforce is ageing in many countries and the baby-boom
generation of nurses approaches retirement.
In 2011, there were 43 newly graduated nurses per
100 000 population on average across OECD countries
(Figure 3.8.1). The number was highest in Korea, Slovenia,
Denmark and Switzerland, and lowest in Mexico, Israel, the
Czech Republic, Turkey, Italy and Luxembourg, with less
than half the OECD average. Nurse graduation rates have
traditionally been low in Mexico, Turkey and Israel, three
countries which report a relatively low number of nurses
per capita (see Indicator 3.7). In Luxembourg, nurse gradu-
ation rates are also low, but many nurses are foreign-
trained.
The institutional arrangements for nursing education dif-
fer across OECD countries. In some countries, the number
of students admitted in nursing programmes is not limited.
This is the case in Belgium, Chile, the Czech Republic, the
Netherlands, New Zealand and the United States, although
in this latter case state decisions on public funding for
nursing education have a direct impact on the capacity of
nursing schools to admit students. In most countries, how-
ever, entry into nursing programmes is regulated (OECD,
2008a).
The expansion of nursing education in some countries is
also visible in the number of graduates per 1 000 currently
employed nurses (Figure 3.8.2). There were 54 nursing grad-
uates per 1 000 employed nurses on average in OECD coun-
tries in 2011. The number of new graduates per practising
nurse was by far the highest in Korea, with more than
200 nursing graduates per 1 000 currently employed nurses
in 2011. This should help to rapidly increase the supply of
nurses in Korea, and move it closer to the OECD average. In
Luxembourg, the Czech Republic, Israel and Germany, there
were fewer than 25 nursing graduates per 1 000 employed
nurses.
The number of nursing graduates has increased in many
OECD countries over the last decade (Figure 3.8.3). This has
been the case in Italy, where concerns about shortages of
nurses have led to a large increase in university-level nurs-
ing education programmes starting around 2000, with the
number of newly graduated nurses more than tripling
between 2000 and 2007. This contrasts with a zero growth
in the number of medical graduates during the last decade
in Ita ly, fo l lowing a sharp decl ine in the 1990s
(Indicator 3.5). In Portugal also, there has been a strong
growth in the number of nursing graduates between 2003
and 2007, but the number has stabilised since then. In
France, the number of nursing graduates increased at a
fairly steady pace between 2000 and 2011, with the number
rising by two-thirds during this period. In Switzerland, the
number increased by 50% between 2000 and 2011.
Definition and comparability
Nursing graduates refer to the number of students
who have obtained a recognised qualification
required to become a licensed or registered nurse.
They include graduates from both higher level and
lower level nursing programmes.They exclude gradu-
ates from Masters or PhD degrees in nursing to avoid
double-counting nurses acquiring further qualifica-
tions.
The numbers reported by Sweden do not include
graduates from lower level nursing programmes, nor
are graduates from three-year education programmes
focusing on elderly care included in Germany, result-
ing in an under-estimation in graduation rates per
capita. However, the calculation of graduation rates
per practising nurses includes the same categories of
nurses in the numerator and the denominator to
avoid any under-estimation.
The United Kingdom data are estimates based on the
number of nurses newly registered with the Nursing
and Midwifery Council. In Denmark, the data refer to
the number of new nurses receiving an authorisation
to practice.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 201378
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3.8. Nursing graduates3.8.1. Nursing graduates per 100 000 population, 2011
(or nearest year)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932917104
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3.8.3. Evolution in the number of nursing graduates, selected OECD countries, 2000 to 2011 (or nearest year)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932917142
0
3 000
6 000
9 000
12 000
15 000
18 000
21 000
24 000
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
France Italy
Number of graduates
Portugal SwitzerlandHEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013 79
3. HEALTH WORKFORCE3.9. Remuneration of nursesThe remuneration level of nurses is one of the factors
affecting job satisfaction and the attractiveness of the pro-
fession. It also has a direct impact on costs, as wages repre-
sent one of the main spending items in health systems.
The data presented in this section generally focus on the
remuneration of nurses working in hospitals, although the
data coverage differs for some countries (see the box below
on “Definition and comparability”).
The data are presented in two ways. First, it is compared
with the average wage of all workers in each country, pro-
viding some indication of the relative financial attractive-
ness of nursing compared to other occupations. Second,
the remuneration level in each country is converted into a
common currency, the US dollar, and adjusted for purchas-
ing power parity, to provide an indication of the relative
economic well-being of nurses compared with their coun-
terparts in other countries.
In most countries, the remuneration of hospital nurses was
at least slightly above the average wage of all workers in
2011. In Luxembourg and Israel, the income of nurses was
40% greater than the average wage. In the United States, it
was 30% greater than the average wage while in Greece,
Spain, Australia and Germany it was 20% higher. However,
in other countries, the salary of hospital nurses is roughly
equal to the average wage in the economy. In the Slovak
Republic and Hungary, it is 20% lower.
When converted to a common currency, the remuneration
of nurses was more than four times higher in Luxembourg
than in Hungary, the Slovak Republic and Estonia. Nurses
in the United States also had relatively high earnings com-
pared with their counterparts in other countries. This
partly explains the ability of the United States to attract
many nurses from other countries (Aiken and Cheung,
2008).
Prior to the economic crisis, concerns about the competi-
tiveness of nurses’ pay, pay equity, and shortages or uneven
geographic distribution of nurses motivated pay interven-
tions in some countries. Between 2005 and 2008, a number
of countries including the Slovak Republic, the Czech
Republic, Hungary, Italy and Iceland implemented pay
increases for certain categories of nurses. These pay
increases led to increased numbers of applicants in nursing
education in some of these countries (Buchan and Black,
2011). Following the economic crisis, some European coun-
tries have cut down, at least temporarily, the wages of
nurses in response to acute budgetary pressures. In Greece,
the annual remuneration of nurses was reduced on average
by 6% per year in nominal terms between 2009 and 2011. In
Iceland, the remuneration of nurses was also reduced in
2009 and 2010 (Friðfinnsdóttir and Jónsson, 2010), before
returning to their 2008 level in 2011.
Definition and comparability
The remuneration of nurses refers to average gross
annual income, including social security contribu-
tions and income taxes payable by the employee. It
should normally include all extra formal payments,
such as bonuses and payments for night shifts and
overtime. In most countries, the data relate specifi-
cally to nurses working in hospitals, although in
Canada the data also cover nurses working in other
settings. In some federal states, such as Australia,
Canada and the United States, the level and structure
of nurse remuneration is determined at the sub-
national level, which may contribute to variations
across jurisdictions.
Data refer only to registered (“professional”) nurses in
Australia, Canada and the United States, resulting in
an overestimation compared to other countries
where lower-level nurses (“associate professional”)
are also included.
Data for New Zealand relate to nurses employed by
publically funded district health boards.
The data relate to nurses working full time, with the
exception of Belgium where part-time nurses are also
included (resulting in an under-estimation). The data
for some countries do not include additional income
such as overtime payments and bonuses (e.g., Italy
and Slovenia). Informal payments, which in some
countries represent a significant part of total income,
are not reported.
The income of nurses is compared to the average
wage of full-time employees in all sectors in the coun-
try. The source for the average wage of workers in the
economy is the OECD Labour Force Statistics Database.
In Figure 3.9.3, the growth rate in remuneration levels
of nurses covers only the two-year period from 2008
to 2010 in some countries, either because more recent
data were not available (Australia, Belgium, Canada,
Netherlands) or because there was a break in the time
series due to changing sources andmethods (Ireland).HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 201380
3. HEALTH WORKFORCE
3.9. Remuneration of nurses3.9.1. Remuneration of hospital nurses, ratio to average
wage, 2011 (or nearest year)
1. Data refer to registered (“professional”) nurses in the United States,
Australia and Canada (resulting in an over-estimation).
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932917161
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3.9.2. Remuneration of hospital nurses, USD PPP, 2011
(or nearest year)
1. Data refer to registered (“professional”) nurses in the United States,
Australia and Canada (resulting in an over-estimation).
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932917180
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4. HEALTH CARE ACTIVITIES4.1. Consultations with doctorsConsultations with doctors can take place in doctors’
offices or clinics, in hospital outpatient departments or, in
some cases, in patients’ own homes. In many European
countries (e.g. Denmark, Italy, Netherlands, Norway, Portugal,
the Slovak Republic, Spain and United Kingdom), patients
are required or given incentives to consult a general
practitioner (GP) about any new episode of illness. The GP
may then refer them to a specialist, if indicated. In other
countries (e.g. Austria, Czech Republic, Iceland, Japan and
Korea), in practice patients may approach specialists
directly.
In 2011, the number of doctor consultations per person
ranged from over 13 in Korea and Japan, and 11 and over in
Hungary, the Czech Republic and the Slovak Republic,
to three or fewer in Mexico, Sweden, as well as in South
Africa and Brazil (Figure 4.1.1). The OECD average was
between six and seven consultations per person per year.
Cultural factors play a role in explaining some of the varia-
tions across countries, but certain characteristics of health
systems also play a role. Countries which pay their doctors
mainly by fee-for-service tend to have above-average con-
sultation rates (e.g. Japan and Korea), while countries with
mostly salaried doctors tend to have below-average rates
(e.g. Mexico and Sweden). However, there are examples of
countries, such as Switzerland and the United States,
where doctors are paid mainly by fee-for-service and where
consultation rates are below average, suggesting that other
factors also play a role.
In Sweden, the low number of doctor consultations may be
explained partly by the fact that nurses play an important
role in primary care (Bourgueil et al., 2006). Similarly, in
Finland, nurses and other health professionals play an
important role in providing primary care to patients in
health centres, lessening the need for consultations with
doctors (Delamaire and Lafortune, 2010).
The average number of doctor consultations per person has
increased in many OECD countries since 2000. There was a
particularly strong rise in Korea, which can be at least
partly explained by the rapid increase in the number of
physicians during that period (see Indicator 3.1 “Medical
doctors”). In some other countries, the number of consulta-
tions with doctors fell during that period. This was notably
the case in the Slovak Republic, where the number of doc-
tor consultations fell from about 13 to 11 over the past
decade, coinciding with a reduction in the number of doc-
tors per capita.
The same information can be used to estimate annual
numbers of consultations per doctor in OECD countries.
This should not be taken as a measure of doctors’ produc-
tivity, since consultations can vary in length and effective-
ness, and because it excludes the work doctors do on
hospital inpatients, administration and research. There are
other comparability limitations reported in the box below
on “Definition and comparability”. Keeping these reserva-
tions in mind, the estimated number of consultations per
doctor is highest in Korea and Japan, followed by Turkey
and Hungary (Figure 4.1.2).
There are significant differences among population groups
within each country in doctor consultations. Chapter 6 on
“Access to care” provides additional information on dispar-
ities in doctor consultations by income group in a number
of countries (Indicator 6.4 “Inequalities in doctor consulta-
tions”).
Definition and comparability
Consultations with doctors refer to the number of
contacts with physicians (both generalists and spe-
cialists). There are variations across countries in the
coverage of different types of consultations, notably
in outpatient departments of hospitals.
The data come mainly from administrative sources,
although in some countries (Ireland, Israel, Italy,
Netherlands, New Zealand, Spain, Switzerland, and
the United Kingdom) the data come from health
interview surveys. Estimates from administrative
sources tend to be higher than those from surveys
because of problems with recall and non-response
rates.
In Hungary, the figures include consultations for diag-
nostic exams, such as CT and MRI scans (resulting in
an over-estimation). The figures for the Netherlands
exclude contacts for maternal and child care. The
data for Portugal exclude visits to private practitio-
ners, while those for the United Kingdom exclude
consultations with specialists outside hospital outpa-
tient departments (resulting in an under-estimation).
In Germany, the data include only the number of
cases of physicians’ treatment according to reim-
bursement regulations under the Social Health Insur-
ance Scheme (a case only counts the first contact over
a three-month period, even if the patient consults a
doctor more often, leading to an under-estimation of
consultations with doctors). Telephone contacts are
included in some countries (e.g. Ireland, Spain and
the United Kingdom). In Turkey, a majority of consul-
tations with doctors occur in outpatient departments
in hospitals.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 201384
4. HEALTH CARE ACTIVITIES
4.1. Consultations with doctors4.1.1. Number of doctor consultations per capita, 2011 (or nearest year)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932917218
4.1.2. Estimated number of consultations per doctor, 2011 (or nearest year)
1. In Chile, data for the denominator include all doctors licensed to practice.
2. In Portugal, the number of doctors only includes those working in the public sector to be consistent with the data coverage on consultations.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932917237
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4. HEALTH CARE ACTIVITIES4.2. Medical technologiesNew medical technologies are improving diagnosis and
treatment, but they are also increasing health spending.
This section presents data on the availability and use of
two diagnostic technologies: computed tomography (CT)
scanners and magnetic resonance imaging (MRI) units.
CT scanners and MRI units help physicians diagnose a
range of conditions by producing images of internal organs
and structures of the body. Unlike conventional radiogra-
phy and CT scanning, MRI exams do not expose patients to
ionising radiation.
The availability of CT scanners and MRI units has increased
rapidly in most OECD countries over the past two decades.
Japan has, by far, the highest number of MRI and CT scanners
per capita, followed by the United States for MRI units and by
Australia for CT scanners (Figures 4.2.1 and 4.2.2). Greece,
Iceland, Italy and Korea also had significantly more MRI
and CT scanners per capita than the OECD average. The
number of MRI units and CT scanners per population was
the lowest in Mexico, Hungary and Israel.
There is no general guideline or benchmark regarding the
ideal number of CT scanners or MRI units per population.
However, if there are too few units, this may lead to access
problems in terms of geographic proximity or waiting
times. If there are too many, this may result in an overuse
of these costly diagnostic procedures, with little if any bene-
fits for patients.
Data on the use of these diagnostic scanners are available
for a smaller group of countries, excluding Japan. Based on
this more limited country coverage, the number of MRI
exams per capita is highest in the United States and
Greece, followed by Turkey and Germany (Figure 4.2.3). In
the United States, the (absolute) number of MRI exams has
doubled between 2000 and 2011. In Turkey, it has grown
even more rapidly, doubling over a three-year period only
(from 2008 to 2011). The number of CT exams is highest in
Greece and the United States (Figure 4.2.4).
In Greece, most CT and MRI scanners are installed in pri-
vately-owned diagnostic centres, and only a minority are
found in public hospitals. While there are no guidelines
regarding the use of CT and MRI scanners in Greece (Paris
et al., 2010), since late 2010, a ministerial decree has estab-
lished certain criteria concerning the purchase of imaging
equipment in the private sector (Official Gazette, No. 1918/10,
December 2010). One of themain criteria is based on amin-
imum threshold of population density (30 000 population
per CT scanner and 40 000 per MRI). These regulations do
not apply to the public sector.
In the United States, evidence suggests that there is an
overuse of CT and MRI examinations. Between 1997 and
2006, the number of scans in the United States increased
rapidly while the occurrence of illnesses remained con-
stant (Smith-Bindman et al., 2008). Furthermore, payment
incentives allow doctors to benefit from exam referrals
which also increase the likelihood of overuse. Many studies
have attempted to assess tangible medical benefits of the
substantial increase in CT and MRI examinations in the
United States, but have found no conclusive evidence of
such benefits (Baker et al., 2008).
Clinical guidelines have been developed in some OECD
countries to promote amore rational use of such diagnostic
technologies (OECD, 2010b). In the United Kingdom, since
the creation of the Diagnostic Advisory Committee by the
National Institute for Health and Clinical Excellence (NICE),
a number of guidelines have been issued on the appropri-
ate use of MRI and CT exams for different purposes (NICE,
2012). In Australia, clinicians may use Diagnostic Imaging
Pathways to guide their choice of the most appropriate
diagnostic examinations in the correct sequence for a wide
range of clinical scenarios. The objective is to increase the
number of appropriate examinations and reduce unneces-
sary examinations which may expose patients to risk with-
out benefits (Government ofWestern Australia, 2013).
Definition and comparability
For MRI units and CT scanners, the numbers of equip-
ment per million population are reported. MRI exams
and CT exams relate to the number of exams per
1 000 population. In most countries, the data cover
equipment installed both in hospitals and the ambu-
latory sector.
However, there is only partial coverage for some
countries. CT scanners and MRI units outside hospi-
tals are not included in some countries (Belgium,
Germany and Portugal). For the United Kingdom, the
data only include equipment in the public sector. For
Australia and Hungary, the number of MRI units and
CT scanners includes only those eligible for public
reimbursement (in 1999 in Australia, 60% of total MRI
units were eligible for reimbursement under Medicare,
the universal public health system). Also for Australia,
MRI and CT exams only include those for private
patients in or out of hospitals. MRI and CT exams for
Denmark and Ireland only cover public hospitals, while
Korea, the Netherlands and New Zealand only include
publicly financed exams.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 201386
4. HEALTH CARE ACTIVITIES
4.2. Medical technologies4.2.1. MRI units, 2011 (or nearest year)
1. Equipement outside hospital not included.
2. Only equipment eligible for public reimbursement.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932917256
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4. HEALTH CARE ACTIVITIES4.3. Hospital bedsThe number of hospital beds provides a measure of the
resources available for delivering services to inpatients in
hospitals. This section presents data on the total number of
hospital beds, including those allocated for curative (acute),
psychiatric, long-term and other types of care. It also
includes an indicator of bed occupancy rates focussing on
curative care beds.
Among OECD countries, the number of hospital beds per
capita is highest in Japan and Korea, with over nine beds
per 1 000 population in 2011 (Figure 4.3.1). Both Japan and
Korea have “social admissions”, that is, a significant part of
hospital beds are devoted to long-term care. The number of
hospital beds is also well above the OECD average in the
Russian Federation, Germany and Austria. On the other
hand, large emerging countries in Asia (India and Indonesia)
have relatively few hospital beds compared with the OECD
average. This is also the case for OECD and emerging coun-
tries in Latin America (Mexico, Chile and Brazil).
The number of hospital beds per capita has decreased at
least slightly over the past decade in most OECD countries,
falling from 5.6 per 1 000 population in 2000 to 5.0 in 2011.
This reduction has been driven partly by progress in medi-
cal technology which has enabled a move to day surgery
and a reduced need for hospitalisation. The reduction in
hospital beds has been accompanied in many countries by
a reduction in hospital discharges and the average length
of stay (see Indicators 4.4. “Hospital discharges” and 4.5
“Average length of stay in hospitals”). Only in Korea, Turkey
and to a lesser extent in Greece has the number of hospital
beds per capita grown over the past decade.
More than two-thirds of hospital beds (70%) are allocated
for curative care on average across OECD countries. The
rest of the beds are allocated for psychiatric care (14%),
long-term care (12%) and other types of care (4%). In some
countries, the share of beds allocated for psychiatric care
and long-term care is much greater than the average. In
Finland, 30% of hospital beds are allocated for long-term
care, because local governments (municipalities) use beds
in health care centres (which are defined as hospitals) for
at least some of the needed institution-based long-term
care. In Belgium and the Netherlands, close to 30% of hos-
pital beds are devoted to psychiatric care (Figure 4.3.2).
In several countries, the reduction in the number of hospi-
tal beds has been accompanied by an increase in their
occupancy rates. The occupancy rate of curative (acute)
care beds stood at 78% on average across OECD countries in
2011, slightly above the 2000 level (Figure 4.3.3). Israel had
the highest rate of hospital bed occupancy at 98%, followed
by Norway and Ireland also at over 90%. This is higher than
the 85% level that is considered to be the limit of safe occu-
pancy in countries such as the United Kingdom. These
three countries with high occupancy rates have fewer cura-
tive care beds than the OECD average.
Definition and comparability
Hospital beds are defined as all beds that are regularly
maintained and staffed and are immediately avail-
able for use. They include beds in general hospitals,
mental health hospitals, and other specialty hospi-
tals. Beds in residential long-term care facilities are
excluded.
Curative care beds are accommodating patients
where the principal intent is to do one or more of the
following: manage labour (obstetric), treat non-mental
illness or injury, perform surgery, diagnostic or thera-
peutic procedures.
Psychiatric care beds are accommodating patients
with mental health problems. They include beds in
psychiatric departments of general hospitals, and all
beds in mental health hospitals.
Long-term care beds are accommodating patients
requiring long-term care due to chronic impairments
and a reduced degree of independence in activities of
daily living. They include beds in long-term care
departments of general hospitals, beds for long-term
care in specialty hospitals, and beds for palliative
care. Data on long-term care beds are not available for
several countries (Australia, Germany, Greece, Mexico,
New Zealand, Norway, Portugal, Switzerland and the
United Kingdom) and may be included with other
types of beds (e.g. with curative care beds for Australia
and the United Kingdom).
The occupancy rate for curative (acute) care beds is
calculated as the number of hospital bed-days related
to curative care divided by the number of available
curative care beds (multiplied by 365).
In the Netherlands, hospital beds include all beds that
are administratively approved rather than only those
immediately available for use, resulting in an over-
estimation (the difference between all administra-
tively approved beds and beds available for immedi-
ate use was about 10% in 2007). This also results in an
under-estimation of bed occupancy rates.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 201388
4. HEALTH CARE ACTIVITIES
4.3. Hospital beds4.3.1. Hospital beds per 1 000 population, 2000 and 2011 (or nearest year)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932917332
4.3.2. Hospital beds by function of health care, 2011 (or nearest year)
Note: Countries ranked from highest to lowest total number of hospital beds per capita.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932917351
4.3.3. Occupancy rate of curative (acute) care beds, 2000 and 2011 (or nearest year)
1. In the Netherlands, hospital beds include all beds administratively approved rather than those immediately available for use.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932917370
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4. HEALTH CARE ACTIVITIES4.4. Hospital dischargesHospital discharge rates measure the number of patients
who leave a hospital after receiving care. Together with the
average length of stay, they are important indicators of hos-
pital activities. Hospital activities are affected by a number
of factors, including the demand for hospital services, the
capacity of hospitals to treat patients, the ability of the pri-
mary care sector to prevent avoidable hospital admissions,
and the availability of post-acute care settings to provide
rehabilitative and long-term care services.
In 2011, hospital discharge rates were the highest in Austria
and Germany, followed by the Russian Federation, Hungary
and the Czech Republic (Figure 4.4.1). They were the lowest
in Mexico, Brazil, South Africa and China. In general, those
countries that have more hospital beds tend to have higher
discharge rates. For example, the number of hospital beds
per capita in Austria and Germany is more than two-times
greater than in Portugal and Spain, and discharge rates are
alsomore than two-times larger (see Indicator 4.3 “Hospital
beds”).
Across OECD countries, themain conditions leading to hos-
pitalisation in 2011 were circulatory diseases (accounting
for 12.3% of all discharges on average in OECD countries),
pregnancy and childbirth (10.2%), injuries and other exter-
nal causes (8.9%), diseases of the digestive system (8.8%),
cancers (8.4%), and respiratory diseases (8.2%).
Hungary, Austria and Germany have the highest discharge
rates for circulatory diseases, followed by Estonia and the
Czech Republic (Figure 4.4.2). The high rates in Hungary,
Estonia and the Czech Republic are associated with lots of
people having heart and other circulatory diseases (see
Indicator 1.3). This is not the case for Germany and Austria.
Austria, Germany and Hungary also have the highest dis-
charge rates for cancers (Figure 4.4.3). While the mortality
rate from cancer (a proxy indicator for the incidence of can-
cers) is the highest in Hungary, it is under the OECD average
for Austria and Germany (see Indicator 1.4). In Austria, the
high discharge rate is associated with a high rate of hospi-
tal readmissions for further investigation and treatment of
cancer patients (European Commission, 2008a).
In about one-third of OECD countries, discharge rates have
increased over the past ten years. These include countries
where discharge rates were low in 2000 (e.g. Korea, Mexico
andTurkey) and others where it was already above-average
(e.g. Germany, Slovenia and Switzerland). In a second group
of countries (e.g. Belgium, Czech Republic, Denmark,
Sweden, United Kingdom and United States), they have
remained stable, while in the third group (including
Canada, Finland, France and Italy), discharge rates fell
between 2000 and 2011.
Trends in hospital discharges reflect the interaction of sev-
eral factors. Demand for hospitalisation may grow as popu-
lations age, given that older population groups account for
a disproportionately high percentage of hospital dis-
charges. For example, in Austria and Germany, over 40% of
all hospital discharges in 2011 were for people aged 65 and
over, more than twice their share of the population. How-
ever, population ageing alone may be a less important fac-
tor in explaining trends in hospitalisation rates than
changes in medical technologies and clinical practices. The
diffusion of new medical interventions often gradually
extends to older population groups, as interventions
become safer and more effective for people at older ages
(Dormont and Huber, 2006). However, the diffusion of new
medical technologies may also involve a reduction in hos-
pitalisation if it involves a shift from procedures requiring
overnight stays in hospitals to same-day procedures. In the
group of countries where discharge rates have decreased
over the past decade, there has been a strong rise in the
number of day surgeries (see Indicator 4.9, for example, for
evidence on the rise in day surgeries for cataracts).
Definition and comparability
Hospital discharge is defined as the release of a patient
who has stayed at least one night in hospital. It
includes deaths in hospital following inpatient care.
Same-day discharges are usually excluded, with the
exceptions of Chile, the Slovak Republic, Turkey and
the United States which include some same-day sepa-
rations.
Healthy babies born in hospitals are excluded from
hospital discharge rates in several countries (e.g.
Australia, Austria, Canada, Chile, Estonia, Finland,
Greece, Ireland, Luxembourg, Mexico, Spain). These
comprise some 3-10% of all discharges. The data for
Canadaalso excludeunhealthybabies born inhospitals.
Data for some countries do not cover all hospitals. For
instance, data for Denmark, Ireland, Mexico, New
Zealand and the United Kingdom are restricted to
public or publicly-funded hospitals only. Data for
Portugal relate only to public hospitals on the main-
land (excluding the Islands of Azores and Madeira).
Data for Canada, Ireland, Luxembourg and the
Netherlands include only acute care/short-stay hos-
pitals. Data for France and Japan refer to acute care
hospitalisations.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 201390
4. HEALTH CARE ACTIVITIES
4.4. Hospital discharges4.4.1. Hospital discharges, 2011 (or nearest year)
1. Excludes discharges of healthy babies born in hospital (between 3-10% of all discharges).
2. Includes same-day separations.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932917389
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4.4.3. Hospital discharges for cancers, 2011
(or nearest year)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
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4. HEALTH CARE ACTIVITIES4.5. Average length of stay in hospitalsThe average length of stay in hospitals (ALOS) is often used
as an indicator of efficiency. All other things being equal, a
shorter stay will reduce the cost per discharge and shift
care from inpatient to less expensive post-acute settings.
However, shorter stays tend to be more service intensive
and more costly per day. Too short a length of stay could
also cause adverse effects on health outcomes, or reduce
the comfort and recovery of the patient. If this leads to a
greater readmission rate, costs per episode of illness may
fall only slightly, or even rise.
In 2011, ALOS for all causes across OECD countries was
about eight days (Figure 4.5.1). Turkey and Mexico report
the shortest stays, at less than half the OECD average, and
Japan and Korea the longest stays, at more than double the
OECD average. In most countries, ALOS for all causes has
fallen over the past decade, from an average of 9.2 days in
2000 to 8.0 days in 2011. It fell particularly quickly in some
of the countries that had relatively long stays in 2000 (e.g.
Japan, Switzerland and the United Kingdom).
Focusing on ALOS for specific diagnostic groups can
remove some of the effect of different case mix and sever-
ity. Figure 4.5.2 shows that ALOS following a normal deliv-
ery stood at three days on average in 2011, ranging from
less than two days in Mexico, Turkey, the United Kingdom,
Canada, New Zealand and Iceland, to over five days in
Hungary and the Slovak Republic.
ALOS following acute myocardial infarction was around
seven days on average in 2011. It was shortest in some of
the Nordic countries (Denmark, Norway and Sweden),
Turkey and the Slovak Republic, at fewer than five days. It
was the highest in Korea and Germany, at more than
ten days (Figure 4.5.3). Several factors can explain these
cross-country differences. Differences in the clinical need
of the patient may obviously play a role. However, clinical
need may be subsumed by many other factors. It has been
shown, for example, that physicians working in more than
one hospital adapt the ALOS associated with their practice
to match that of their peers (de Jong et al., 2006).
At the system level, factors such as practice guidelines or
payments systems are relevant. The abundant supply of
beds and the structure of hospital payments in Japan, for
example, provide hospitals with incentives to keep patients
longer (see Indicator 4.3 “Hospital beds”). A growing num-
ber of countries (France, Germany, Poland) have moved to
prospective payment methods often based on diagnosis-
related groups (DRGs) to set payments based on the esti-
mated cost of hospital care for different patient groups in
advance of service provision. These payment methods
have the advantage of encouraging providers to reduce the
cost of each episode of care (OECD, 2010b). In Switzerland,
the move from per diem payments to diagnosis-related
groups (DRG) based payments has contributed to the reduc-
tion in length of stay in those cantons that have modified
their payment system (OECD and WHO, 2011). In the
Netherlands, the introduction of a DRG-based system in
2006 is also credited with contributing to the marked
reduction in ALOS between 2000 and 2011 (Westert and
Klazinga, 2011).
Most countries are seeking to reduce ALOS whilst main-
taining or improving the quality of care. A diverse set of
policy options at clinical, service and system level are avail-
able to achieve these twin aims (Forde, forthcoming). Stra-
tegic reductions in hospital bed numbers alongside
development of community care services can be expected
to shorten ALOS, such as seen in Denmark’s quality-driven
reforms of the hospital sector (OECD, 2013d). Other options
include promoting the uptake of less invasive surgical pro-
cedures, changes in hospital payment methods, the expan-
sion of early discharge programmes which enable patients
to return to their home to receive follow-up care, and sup-
port for hospitals to improve the co-ordination of care
across diagnostic and treatment pathways (Borghans et al.,
2012).
Definition and comparability
Average length of stay refers to the average number of
days that patients spend in hospital. It is generally
measured by dividing the total number of days stayed
by all inpatients during a year by the number of
admissions or discharges. Day cases are excluded.
Compared with previous editions of Health at a Glance,
the data cover all inpatient cases (including not only
curative/acute care cases) for a greater number of
countries, with the exceptions of Canada, Japan and
the Netherlands where the data still refer to curative/
acute care only (resulting in an under-estimation).
Discharges and average length of stay of healthy
babies born in hospitals are excluded in several coun-
tries (e.g. Australia, Austria, Canada, Chile, Estonia,
Finland, Greece, Ireland, Luxembourg, Mexico, Spain),
resulting in a slight over-estimation (e.g., the inclu-
sion of healthy newborns would reduce the ALOS by
0.5 day in Canada).HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 201392
4. HEALTH CARE ACTIVITIES
4.5. Average length of stay in hospitals4.5.1. Average length of stay in hospital, 2000 and 2011 (or nearest year)
1. Data refer to average length of stay for curative (acute) care (resulting in an under-estimation).
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932917446
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4.5.2. Average length of stay for normal delivery, 2011
(or nearest year)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
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4.5.3. Average length of stay for acute myocardial
infarction (AMI), 2011 (or nearest year)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
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4. HEALTH CARE ACTIVITIES4.6. Cardiac proceduresHeart diseases are a leading cause of hospitalisation and
death in OECD countries (see Indicator 1.3). Coronary artery
bypass graft and angioplasty have revolutionised the treat-
ment of ischemic heart diseases in the past few decades. A
coronary bypass is an open-chest surgery involving the
grafting of veins and/or arteries to bypass one or multiple
obstructed arteries. A coronary angioplasty is a much less
invasive procedure involving the threading of a catheter
with a balloon attached to the tip through the arterial sys-
tem to distend the coronary artery at the point of obstruc-
tion; the placement of a stent to keep the artery open
accompanies the majority of angioplasties.
In 2011, Germany, Israel, the Netherlands, Austria, Norway
and Belgium had the highest rates of coronary angioplasty,
while the United States, Denmark, Belgium andGermany had
the highest rates of coronary bypass grafts (Figure 4.6.1).
A number of reasons can explain cross-country variations
in the rate of coronary bypass and angioplasty, including:
1) differences in the capacity to deliver and pay for these
procedures; 2) differences in clinical treatment guidelines
and practices; and 3) differences in coding and reporting
practices.
However, the large variations in the number of revasculari-
sation procedures across countries do not seem to be closely
related to the incidence of ischemic heart disease (IHD), as
measured by IHD mortality (see Figure 1.3.1). For example,
IHD mortality in Germany is slightly below the OECD aver-
age, but Germany has the highest rate of revascularisation
procedures.
National averages can hide important variations in utilisa-
tion rates within countries. For example, in Germany, the
rate of coronary bypass surgery is eight times higher in the
district with the highest utilisation rate compared with the
district with the lowest rate (Nolting et al., 2012; Kumar and
Schoenstein, 2013).
The use of angioplasty has increased rapidly over the past
20 years in most OECD countries, overtaking coronary
bypass surgery as the preferred method of revascularisa-
tion around the mid-1990s – about the same time that the
first published trials of the efficacy of coronary stenting
began to appear (Moïse et al., 2003). On average across
OECD countries, angioplasty now accounts for 78% of all
revascularisation procedures (Figure 4.6.2), and exceeds
85% in France, Spain and Israel. In many OECD countries,
the growth in angioplasty was more rapid between 2000
and 2005, compared to the 2005-11 period. In Denmark and
the United States, the share of angioplasty increased
quickly between 2000 and 2005, but has fallen slightly since
then. Part of the explanation for this slight reduction may
be due to the fact that the data reported by these two coun-
tries do not cover the growing number of angioplasties car-
ried out as day cases (without any overnight stay in
hospital). In addition, the greater use of drug-eluting stents
in the United States and other countries reduces the likeli-
hood that the same patient will need another angioplasty
(Epstein et al., 2011).
Coronary angioplasty has expanded surgical treatment
options to wider groups of patients. A UK study found that
approximately 30% of all angioplasty procedures are a
direct substitute for bypass surgery (McGuire et al., 2010).
Angioplasty is however not a perfect substitute since
bypass surgery is still the preferred method for treating
patients with multiple-vessel obstructions, diabetes and
other conditions (Taggart, 2009).
Coronary angioplasty is an expensive intervention, but it is
much less costly than a coronary bypass surgery because it
is less invasive. The estimated price of an angioplasty on
average across 24 OECD countries was about USD 7 400 in
2010, compared with 17 400 for a coronary bypass. Hence,
for patients who would otherwise have received bypass
surgery, the introduction of angioplasty has not only
improved outcomes but has also decreased costs. However,
because of the expansion of surgical interventions, overall
costs have risen.
Definition and comparability
The data for most countries cover both inpatient and
day cases, with the exception of Chile, Denmark,
Iceland, Norway, Portugal, Switzerland and the
United States, where they only include inpatient
cases (resulting in some under-estimation in the
number of coronary angioplasties; this limitation in
data coverage does not affect the number of coronary
bypasses since nearly all patients are staying at least
one night in hospital after such an operation). Some
of the variations across countries may also be due to
the use of different classification systems and differ-
ent codes for reporting these two procedures.
In Ireland, Mexico, New Zealand and the United
Kingdom, the data only include activities in publicly-
funded hospitals, resulting in an under-estimation (it
is estimated that approximately 15% of all hospital
activity in Ireland is undertaken in private hospitals).
Data for Portugal relate only to public hospitals on the
mainland. Data for Spain only partially include activ-
ities in private hospitals.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 201394
4. HEALTH CARE ACTIVITIES
4.6. Cardiac procedures4.6.1. Coronary revascularisation procedures, 2011 (or nearest year)
Note: Some of the variations across countries are due to different classification systems and recording practices.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932917503
4.6.2. Coronary angioplasty as a share of total revascularisation procedures, 2000 to 2011 (or nearest year)
Note: Revascularisation procedures include coronary bypass and angioplasty.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932917522
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4. HEALTH CARE ACTIVITIES4.7. Hip and knee replacementSignificant advances in surgical treatment have provided
effective options to reduce the pain and disability associ-
ated with certain musculoskeletal conditions. Joint
replacement surgery (hip and knee replacement) is consid-
ered the most effective intervention for severe osteoarthri-
tis, reducing pain and disability and restoring some
patients to near normal function.
Osteoarthritis is one of the ten most disabling diseases in
developed countries. Worldwide estimates are that 10% of
men and 18% of women aged over 60 years have symptom-
atic osteoarthritis, including moderate and severe forms
(WHO, 2010b). Age is the strongest predictor of the develop-
ment and progression of osteoarthritis. It is more common
in women, increasing after the age of 50 especially in the
hand and knee. Other risk factors include obesity, physical
inactivity, smoking, excess alcohol and injuries (European
Commission, 2008b). While joint replacement surgery is
mainly carried out among people aged 60 and over, it can
also be performed among people of younger ages.
In 2011, Switzerland, Germany and Austria had the highest
rates of hip replacement, while the United States had the
highest rate of knee replacement followed by Austria,
Germany and Switzerland (Figures 4.7.1 and 4.7.2). Differ-
ences in population structure may explain part of these
variations across countries, and age standardisation
reduces to some extent the cross-country variations.
Nonetheless, large differences persist and the country
ranking does not change significantly after age standardi-
sation (McPherson et al., 2013).
National averages can mask important variations in hip
and knee replacement rates within countries. In Germany,
the rate of knee replacement is 3.5 times higher in the dis-
trict with the highest rate compared with the district with
the lowest rate (Nolting et al., 2012; Kumar and Schoenstein,
2013). In the United States, regional variations in hip and
knee replacement are substantial, with the rates being four
to five times higher in some regional health care markets
compared with others in 2005-06 (Dartmouth Atlas, 2010).
In Spain also, the age-standardised rate of hip replacement
was more than four times higher in some autonomous
regions than in others in 2005, and the rate of knee replace-
ment three times higher (Allepuz et al., 2009).
The number of hip and knee replacements has increased
rapidly over the past decade in most OECD countries
(Figures 4.7.3 and 4.7.4). On average, the rate of hip replace-
ment increased by almost 30% between 2000 and 2011. The
growth rate was higher for knee replacement, nearly dou-
bling over the past decade. In the United States, both hip
replacement and knee replacement rates doubled since
2000. In Switzerland, the hip replacement rate increased by
27% between 2002 and 2011, while the knee replacement
rate nearly doubled. The growth rate for both interventions
was more modest in France.
The growing volume of hip and knee replacement is con-
tributing to health expenditure growth as these are expen-
sive interventions. In 2010, the estimated price of a hip
replacement on average across 24 OECD countries was
about USD 7 800, while the average price of a knee replace-
ment was about USD 7 600.
Definition and comparability
Hip replacement is a surgical procedure in which the
hip joint is replaced by a prosthetic implant. It is gen-
erally conducted to relieve arthritis pain or treat
severe physical joint damage following hip fracture.
Knee replacement is a surgical procedure to replace
the weight-bearing surfaces of the knee joint in order
to relieve the pain and disability of osteoarthritis. It
may also be performed for other knee diseases such
as rheumatoid arthritis.
Classification systems and registration practices vary
across countries, which may affect the comparability
of the data. Some countries only include total hip
replacement (e.g. Estonia), while most countries also
include partial replacement. In Ireland, Mexico, New
Zealand and the United Kingdom, the data only
include activities in publicly-funded hospitals (it is
estimated that approximately 15% of all hospital
activity is undertaken in private hospitals). Data for
Portugal relate only to public hospitals on the main-
land. Data for Spain only partially include activities in
private hospitals.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 201396
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4.7. Hip and knee replacement4.7.1. Hip replacement surgery, 2011 (or nearest year)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932917541
4.7.3. Trend in hip replacement surgery, selected
OECD countries, 2000 to 2011 (or nearest year)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932917579
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4.7.2. Knee replacement surgery, 2011 (or nearest year)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932917560
4.7.4. Trend in knee replacement surgery, selected
OECD countries, 2000 to 2011 (or nearest year)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932917598
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4. HEALTH CARE ACTIVITIES4.8. Caesarean sectionsRates of caesarean delivery as a percentage of all live births
have increased in all OECD countries in recent decades,
although in a few countries this trend has reversed at least
slightly in the past few years. Reasons for the increase
include reductions in the risk of caesarean delivery, mal-
practice liability concerns, scheduling convenience for both
physicians and patients, and changes in the physician-
patient relationship, among others. Nonetheless, caesar-
ean delivery continues to result in increased maternal mor-
tality, maternal and infant morbidity, and increased
complications for subsequent deliveries (Minkoff and
Chervenak, 2003; Bewley and Cockburn, 2002; Villar et al.,
2006). These concerns, combined with the greater financial
cost (the average cost associated with a caesarean section
is at least two times greater than a normal delivery in many
OECD countries; Koechlin et al., 2010), raise questions
about the appropriateness of some caesarean delivery that
may not be medically required.
In 2011, caesarean section rates were lowest in Nordic
countries (Iceland, Finland, Sweden and Norway) and the
Netherlands, with rates ranging from 15% to 17% of all live
births (Figure 4.8.1). In the Netherlands, 16% of all births
occurred at home in 2010 (a much higher proportion than
in other countries, although this proportion has come
down), while 11% occurred in a birth centre (a homelike
setting) under care of the primary midwife (Euro-Peristat,
2013). Among OECD countries, caesarean section rates
were highest in Mexico and Turkey (over 45%), followed by
Chile, Italy, Portugal and Korea (with rates ranging between
35% and 38%).
Caesarean rates have increased rapidly over the past
decade in most OECD countries, with the average rate
across countries going up from 20% in 2000 to 27% in 2011
(Figure 4.8.2). Increases in first births among older women
and the rise in multiple births resulting from assisted
reproduction have contributed to the overall rise in caesar-
ean deliveries. The growth rate since 2000 has been partic-
ularly rapid in Mexico and Turkey (which started with
already high rates in 2000, thereby widening the gap with
the OECD average) and in Slovenia, the Czech Republic and
the Slovak Republic (which started with low rates, but are
moving rapidly towards the OECD average). In many coun-
tries, however, the growth rate has slowed down since 2005.
In some countries such as Finland and Sweden (which had
low rates) and Italy and Korea (which had high rates), the
trend of rising rates has reversed and the rates have come
down at least slightly since the mid-2000s.
There can be substantial variations in caesarean rates
across regions and hospitals within the same country. In
Switzerland, where caesareans now account for one-third
of all births, caesarean rates were less than 20% in certain
regions (cantons) while they exceeded 40% in others in
2010. Within the same region (canton), there are also
important variations across hospitals. Caesarean sections
were substantially higher in private clinics (41%) than in
public hospitals (30.5%) (OFSP, 2013). In France, a 2008 study
by the French Hospital Federation also found higher caesar-
ean rates in private for-profit facilities than in public facili-
ties, even though the latter are designed to deal with more
complicated pregnancies (FHF, 2008).
While caesarean delivery is required in some circum-
stances, the benefits of caesarean versus vaginal delivery
for normal uncomplicated deliveries continue to be
debated. Professional associations of obstetricians and
gynaecologists in countries such as Canada now encourage
the promotion of normal childbirth without interventions
such as caesarean sections (Society of Obstetricians and
Gynaecologists of Canada et al., 2008).
Definition and comparability
The caesarean section rate is the number of caesar-
ean deliveries performed per 100 live births.
In Mexico, the number of caesarean sections is esti-
mated based on public hospital reports and data
obtained from National Health Surveys. Estimation is
required to correct for under-reporting of caesarean
deliveries in private facilities. The combined number
of caesarean deliveries is then divided by the total
number of live births as estimated by the National
Population Council.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 201398
4. HEALTH CARE ACTIVITIES
4.8. Caesarean sections4.8.1. Caesarean section rates, 2011 (or nearest year)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932917617
4.8.2. Increasing caesarean section rates, 2000 to 2011 (or nearest year)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932917636
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4. HEALTH CARE ACTIVITIES4.9. Cataract surgeriesIn the past few decades, the number of surgical procedures
carried out on a same-day basis, without any hospitalisa-
tion, has increased markedly in OECD countries. Advances
in medical technologies, particularly the diffusion of less
invasive surgical interventions, and better anaesthetics
have made this development possible. These innovations
have also improved patient safety and health outcomes for
patients, and have in many cases reduced the unit cost per
intervention by shortening the length of stay in hospitals.
However, the impact of the rise in same-day surgeries on
health spending depends not only on changes in their unit
cost, but also on the growth in the volume of procedures
performed. There is also a need to take into account any
additional cost related to post-acute care and community
health services following the intervention.
Cataract surgery provides a good example of a high-volume
surgery which is now carried out predominantly on a
same-day basis in most OECD countries. From a medical
point of view, a cataract surgery using modern techniques
should not normally require an hospitalisation, except in
some specific cases (e.g., general anesthesia or severe
comorbidities) (Lundtstrom et al., 2012). Day surgery now
accounts for over 90% of all cataract surgeries in a majority
of countries (Figure 4.9.1). In Estonia and Canada, nearly all
cataract surgeries are performed as day cases. However, the
use of day surgery is still relatively low in some countries,
such as Poland, the Slovak Republic and Hungary. This may
be explained by more advantageous reimbursement for
inpatient stays, national regulations, and obstacles to
changing individual practices of surgeons and anaesthe-
tists, and tradition (Castoro et al., 2007). These low rates
may also reflect limitations in data coverage of outpatient
activities in hospitals or outside hospitals.
The number of cataract surgeries performed on a same-
day basis has grown very rapidly over the past decade
in many countries, such as Portugal and Austria
(Figures 4.9.1 and 4.9.2).Whereas fewer than 10% of cataract
surgeries in Portugal were performed on a same-day basis
in 2000, this proportion has increased to 92%. In Austria,
the share of cataract surgeries performed as day cases
increased from 1% only in 2000 to 46% in 2011. The number
of cataract surgeries carried out as day cases has also risen
rapidly in France, Switzerland and Luxembourg, although it
remains below the OECD average, and there is room for fur-
ther development.
The total number of cataract surgeries has grown substan-
tially over the past decade, so that it has now become the
most frequent surgical procedure in many OECD countries.
Population ageing is one of the factors behind this rise, but
the proven success, safety and cost-effectiveness of cata-
ract surgery as a day procedure has been a more important
factor (Fedorowicz et al., 2004).
In Sweden, there is evidence that cataract surgeries are
now being performed on patients suffering from less severe
vision problems compared to ten years ago. This raises the
issue of how the needs of these patients should be priori-
tised relative to other patient groups (Swedish Association
of Local Authorities and Regions and National Board of
Health andWelfare, 2010).
Definition and comparability
Cataract surgeries consist of removing the lens of the
eye because of the presence of cataracts which are
partially or completely clouding the lens, and replac-
ing it with an artificial lens. The surgery may involve
in certain cases an overnight stay in hospital (inpa-
tient cases), but in many countries it is now per-
formed mainly as day cases (defined as a patient
admitted to the hospital and discharged the same
day) or outpatient cases in hospitals or outside hospi-
tals (without any formal admission and discharge).
However, the data for many countries do not include
such outpatient cases in hospitals or outside hospi-
tals, with the exception of the Czech Republic,
Estonia, France, Israel, Luxembourg, Slovenia and the
United Kingdom where they are included. Caution is
therefore required in making cross-country compari-
sons of available data, given the incomplete coverage
of same-day surgeries in several countries.
In Ireland, Mexico, New Zealand and the United
Kingdom, the data only include cataract surgeries
carried out in public or publicly-funded hospitals,
excluding any procedures performed in private hospi-
tals (in Ireland, it is estimated that approximately 15%
of all hospital activity is undertaken in private hospi-
tals). Data for Portugal relate only to public hospitals
on the mainland. Data for Spain only partially include
activities in private hospitals.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013100
4. HEALTH CARE ACTIVITIES
4.9. Cataract surgeries4.9.1. Share of cataract surgeries carried out as day cases, 2000 and 2011 (or nearest year)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932917655
4.9.2. Trends in number of cataract surgeries, inpatient and day cases, 2000 to 2011 (or nearest year)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932917674
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4. HEALTH CARE ACTIVITIES4.10. Pharmaceutical consumptionGrowth in pharmaceutical spending slowed down in many
OECD countries in recent years (see Indicator 7.4 “Pharma-
ceutical expenditure”). However, for many categories of
pharmaceutical drugs, the quantities consumed continue
to increase, partly driven by growing demand for drugs to
treat ageing-related and chronic diseases.
This section discusses the volume of consumption of four
categories of pharmaceuticals: antihypertensives, choles-
terol-lowering drugs, antidiabetics and antidepressants.
Indicator 5.2 in Chapter 5 presents data on the consump-
tion of antibiotics. Consumption of these drugs is mea-
sured through the defined daily dose (DDD) unit (see the
box on “Definition and comparability” below).
Hypertension is an important public health problem. It has
been estimated that one in three adults worldwide is
affected by hypertension, and 13% of mortality is associ-
ated with high blood pressure (WHO, 2012). Hypertension is
an important risk factor for cardiovascular and other dis-
eases. The consumption of antihypertensive medications
has nearly doubled on average in OECD countries over the
past decade, and it has more than tripled in Estonia and
Luxembourg (Figure 4.10.1). Consumption is the highest in
Germany, Hungary and the Czech Republic, and the lowest
in Korea.
The use of cholesterol-lowering drugs has more than tri-
pled across OECD countries from fewer than 30 DDDs per
1 000 people per day in 2000 to over 90 DDDs in 2011
(Figure 4.10.2). Both the epidemiological context – for
instance, growing obesity – and increased screening and
treatment explain the very rapid growth in the consump-
tion of cholesterol-lowering medications. Australia, the
United Kingdom and the Slovak Republic had the highest
consumption per capita in 2011, with levels that were over
40% higher than the OECD average. While these cross-
country differences may partly reflect differences in the
prevalence of cholesterol levels in the population, differ-
ences in clinical guidelines for the control of bad choles-
terol also play a role.
The use of antidiabetic medications has almost doubled on
average across OECD countries between 2000 and 2011
(Figure 4.10.3). This growth can be explained by a rising
prevalence of diabetes, largely linked to increases in the
prevalence of obesity (Indicator 2.7), a major risk factor for
the development of Type-2 diabetes. In 2011, the consump-
tion of antidiabetics was highest in Finland, Germany and
the United Kingdom, and lowest in Chile and Iceland.
The consumption of antidepressants has also increased
significantly in most OECD countries since 2000
(Figure 4.10.4). Guidelines for the pharmaceutical treat-
ment of depression vary across countries, and there is also
great variation in prescribing behaviors among general
practitioners and psychiatrists in each country. Iceland
reported the highest level of consumption of antidepres-
sants in 2011, followed by Australia, Canada, Denmark and
Sweden. In 2008, almost 30% of women aged 65 and over
had an antidepressant prescription in Iceland, compared
with less than 15% in Norway (NOMESCO, 2010).
Greater intensity and duration of treatments are some of
the factors explaining the general increase in antidepres-
sant consumption across countries. In England, for exam-
ple, the increase in antidepressant consumption has been
associated with a longer duration of drug treatment (Moore
et al., 2009). In addition, rising consumption levels can also
be explained by the extension of the set of indications of
some antidepressants to milder forms of depression, gen-
eralised anxiety disorders or social phobia (Hollingworth et
al., 2010; Mercier et al., 2011). These extensions have raised
concerns about appropriateness. Changes in the social
acceptability and willingness to seek treatment during
episodes of depression may also contribute to increased
consumption.
Some of the increases in the use of antidepressants may
also be linked to the insecurity created by the economic
crisis (Gili et al., 2012). In Spain, the consumption of antide-
pressants per capita has increased by 23% between 2007
and 2011, although this increase was slightly lower than in
the preceding four-year period (28% between 2003 and
2007). In Portugal, antidepressant consumption went up by
20% between 2007 and 2011. The consumption of antide-
pressants rose even more quickly in countries such as
Germany (a rise of 46% between 2007 and 2011) which were
less affected by the economic crisis and have experienced a
more rapid economic recovery.
Definition and comparability
Defined daily dose (DDD) is the assumed average
maintenance dose per day for a drug used for its main
indication in adults. DDDs are assigned to each active
ingredient(s) in a given therapeutic class by interna-
tional expert consensus. For instance, the DDD for
oral aspirin equals 3 grams, which is the assumed
maintenance daily dose to treat pain in adults. DDDs
do not necessarily reflect the average daily dose actu-
ally used in a given country. DDDs can be aggregated
within and across therapeutic classes of the Anatomic-
Therapeutic Classification (ATC). For more detail, see
www.whocc.no/atcddd.
The volume of hypertension drugs consumption pre-
sented in Figure 4.10.1 refers to the sum of five ATC2
categories which can all be prescribed against hyper-
tension (Antihypertensives, Diuretics, Beta-blocking
agents, Calcium channel blockers and Agents acting
on the Renin-Angiotensin system).
Data generally refer to outpatient consumption only,
except for the Czech Republic, Estonia, Italy and
Sweden where data also include hospital consump-
tion. The data for Canada relate to two provinces only
(Manitoba and Saskatchewan). The data for Spain
refer to outpatient consumption for prescribed
drugs covered by the National Health System (public
insurance).HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013102
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4.10. Pharmaceutical consumption4.10.1. Hypertension drugs consumption, 2000 and 2011
(or nearest year)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932917693
4.10.3. Antidiabetics consumption, 2000 and 2011
(or nearest year)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932917731
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4.10.2. Anticholesterols consumption, 2000 and 2011
(or nearest year)
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4.10.4. Antidepressants consumption, 2000 and 2011
(or nearest year)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932917750
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4. HEALTH CARE ACTIVITIES4.11. Pharmaceutical generic market shareAll OECD countries see the development of generic markets
as a good opportunity to increase efficiency in pharmaceu-
tical spending, by offering cheaper products than on-
patent drugs for an equivalent health outcome. However, in
2011, generics accounted for about three-quarter of the vol-
ume of pharmaceuticals covered by basic health coverage
in Germany, the United Kingdom, New Zealand and
Denmark, while they represented less than one-quarter of
the market in Luxembourg, Italy, Ireland, Switzerland,
Japan and France (Figure 4.11.1).
The share of the generic market has increased significantly
over the past decade in some countries that had low levels
in 2000 (Figure 4.11.2). In Portugal, the generic market grew
from virtually zero in 2000 to 30% in volume and 23% in
value in 2011. In Spain, the generic market share reached
34% in volume and 15% in value in 2011, up from 3% in
2000. While this growth in the generic market share in
Portugal and Spain preceded the 2008-09 economic reces-
sion, these efforts have been extended by policies recently
implemented in these two countries to reduce their bud-
getary deficits.
Some of the differences in the share of the generic market
across countries can be explained by market structures,
notably the number of off-patent medicines or the prefer-
ences of doctors (who may be influenced by pharmaceuti-
cal representatives) for new on-patent medicines, but the
generic take-up also very much depends on policies imple-
mented by countries (OECD, 2010b; Vogler, 2012).
A majority of OECD countries allow physicians to prescribe
in International Non-proprietary Names (INN), but profes-
sional behaviour is not only shaped by laws. While English
doctors write 80% of their prescriptions in INN, French doc-
tors do so for only 12% (OECD, 2010b). Similarly, pharma-
cists are allowed to substitute generics for brand-name
drugs in a majority of OECD countries, and even mandated
to do so in some countries (e.g., Denmark, Sweden). How-
ever, a mandate is not necessary for high generic penetra-
tion since countries like New Zealand and the United
Kingdom have high penetration rates without mandate.
Financial incentives for physicians, pharmacists and
patients have been implemented to foster the development
of generic markets. For instance, in England, Primary Care
Trusts were financially responsible for all health care
spending for their patients and therefore had a direct inter-
est to contain pharmaceutical costs. In France, social
health insurance pays bonuses to physicians for high rates
of generic prescription through a pay-for-performance
scheme.
Patients have a financial interest to choose cheaper drugs
when their co-payment is expressed as a percentage of the
price or when fixed co-payments are lower for generics or
in “reference price” systems. For example, in 2006,
Switzerland increased the co-payment rate for brand-
name drugs for which cheaper generics are available from
10 to 20%. In France, patients have to pay in advance for
their drugs and be reimbursed later when they refuse
generic substitution.
Pharmacists margins are set in relation to the price of med-
icines and are therefore higher (in absolute terms) for more
expensive products. With such an incentive, pharmacists
are penalised when they substitute a generic for a more
expensive drug. Several countries have reversed or at least
neutralised this incentive (e.g., France). Other countries
have created positive incentives: in Switzerland for
instance, pharmacists receive a fee for generic substitution.
In several countries (e.g., Norway), pharmacists have the
obligation to inform patients about the possibility of a
cheaper alternative.
Beyond encouraging generic take-up, it is also important to
promote the lowest possible price for generics if the pur-
pose is to contain cost. Figure 4.11.1 suggests, for instance,
that the differential between brand-name prices and
generic prices is much higher in the United Kingdom than
in Germany, since the generic share in value is much lower
in the United Kingdom than in Germany while the generic
share in volume is similar. One possible way to put pres-
sure on generic prices is tendering. New Zealand intro-
duced competitive tendering for generic drugs in 1997,
which resulted in up to 84% to 96% price reductions within
five years for a few products (OXERA, 2001).
Definition and comparability
A generic is defined as a pharmaceutical product
which has the same qualitative and quantitative
composition in active substances and the same phar-
maceutical form as the reference product, and whose
bioequivalence with the reference product has been
demonstrated.
Generics can be classified in branded generics (generics
with a specific trade name) and unbranded generics
(which use the international non-proprietary name
and the name of the company).
In most countries, the data cover all pharmaceutical
consumption. However, in some countries, it only
covers pharmaceuticals that are reimbursed by public
insurance. In Chile, data refer only to sales in commu-
nity pharmacies. In several countries, data only cover
reimbursed pharmaceutical consumption.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013104
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4.11. Pharmaceutical generic market share4.11.1. Share of generics in the total pharmaceutical market, 2011 (or nearest year)
1. Reimbursed pharmaceutical market.
2. Community pharmacy market.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932917769
4.11.2. Trend in share of generics in the pharmaceutical market, selected countries, 2000 to 2011
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932917788
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5.1. Avoidable hospital admissions
5.2. Prescribing in primary care
5.3. Mortality following acute myocardial infarction (AMI)
5.4. Mortality following stroke
5.5. Surgical complications
5.6. Obstetric trauma
5.7. Unplanned hospital re-admissions for patients with mental
disorders
5.8. Excess mortality from mental disorders
5.9. Screening, survival and mortality for cervical cancer
5.10. Screening, survival and mortality for breast cancer
5.11. Survival and mortality for colorectal cancer
5.12. Childhood vaccination programmes
5.13. Influenza vaccination for older people
5.14. Patient experience with ambulatory care
The statistical data for Israel are supplied by and under the responsibility of the relevant
Israeli authorities. The use of such data by the OECD is without prejudice to the status of the
Golan Heights, East Jerusalem and Israeli settlements in the West Bank under the terms of
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5. QUALITY OF CARE5.1. Avoidable hospital admissionsMost health systems have developed a “primary level” of
care whose functions include managing new health com-
plaints that pose no immediate threat to life, managing
long-term conditions and supporting the patient in decid-
ing when referral to hospital-based services is necessary. A
key aim is to keep people well, by providing a consistent
point of care over the longer term, tailoring and co-ordinating
care for thosewithmultiple health care needs and supporting
the patient in self-education and self-management (Kringos,
2010). In the context of increasing prevalence of chronic
illnesses in many OECD countries (see Indicators 1.3, 1.4
and 1.10) achieving high quality primary care is a key prior-
ity in nearly every health system.
Asthma, chronic obstructive pulmonary disease (COPD)
and diabetes are three widely prevalent long-term condi-
tions. Both asthma and COPD limit the ability to breathe:
asthma symptoms are usually intermittent and reversible
with treatment, whilst COPD is a progressive disease that
almost exclusively affects current or prior smokers.
Asthma affects between 150 to 300 million people world-
wide and causes some 250 000 deaths each year (WHO,
2011b). COPD affects around 64 million worldwide and cur-
rently is the fourth leading cause of death worldwide,
responsible for around 3 million deaths each year (WHO,
2011c). Diabetes is a condition in which the body’s ability to
regulate excessive glucose levels in the blood is lost. This
can lead to many complications over the longer term such
as kidney failure or loss of sight; in the shorter term, loss of
consciousness or coma can occur. Globally, around
180 million people are known to have diabetes (a similar
number remain undiagnosed). The condition is estimated
to have been responsible for 4.6 million deaths and 11% of
total health expenditure in 2011 (IDF, 2011).
Common to all three conditions is the fact that the evi-
dence base for effective treatment is well established and
much of it can be delivered at a primary care level. A high-
performing primary care system can, to a significant
extent, avoid acute deterioration in people living with
asthma, COPD or diabetes and prevent their admission to
hospital. Avoiding hospital admission is not only cost-saving
but often preferable to the patient as well. Many health care
systems continue to struggle, however, in reducing use of
the hospital sector for conditions which are largely man-
ageable in primary care.
Figures 5.1.1 and 5.1.2 show hospital admission rates for
asthma and COPD. Admission rates for the former vary
14-fold across countries. The Slovak Republic, the United
States and Korea report rates two or three times greater
than the OECD average; Italy, Canada andMexico report the
lowest rates. International variation in admission rates for
COPD is similar, around 16-fold, with Hungary, Ireland and
New Zealand reporting the highest rates and Japan, Portugal
and Italy the lowest. Hospital admission rates for diabetes
vary 8-fold, as shown in Figure 5.3.1. Italy, Iceland and
Switzerland have the lowest rates, while Hungary, Mexico
and Korea report rates at least double the OECD average.
Although disease prevalence may explain some, but not all,
cross-country variation in admission rates, it is particularly
noteworthy that the majority of countries report a reduc-
tion in admission rates for each of the three conditions
over recent years. This may represent an improvement in
access to and the quality of primary care. The approaches
countries are taking to improve the quality of primary care,
and the challenges faced, are described in a series of coun-
try reviews currently being undertaken by OECD. Israel’s
Quality Indicators for Community Health Care programme, for
example, is one instance of how publicly reported informa-
tion on the patterns and outcomes of care is used to incen-
tivise providers to develop better services (OECD, 2012a).
Definition and comparability
The asthma and COPD indicators are defined as the
number of hospital discharges of people aged 15 years
and over per 100 000 population. The indicator for
diabetes is based on the sum of three indicators:
admissions for short-term and long-term complica-
tions and for uncontrolled diabetes without compli-
cations.
Rates were age-sex standardised to the 2010 OECD
population aged 15 and over. Differences in coding
practices among countries and the definition of an
admission may affect the comparability of data. Dif-
ferences in disease classification systems, for exam-
ple between ICD-9-CM and ICD-10-AM, may also
affect data comparability.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013108
5. QUALITY OF CARE
5.1. Avoidable hospital admissions5.1.1. Asthma hospital admission in adults, 2006 and 2011 (or nearest year)
Note: 95% confidence intervals represented by |—|.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932917807
5.1.2. COPD hospital admission in adults, 2006 and 2011 (or nearest year)
Note: 95% confidence intervals represented by |—|.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932917826
5.1.3. Diabetes hospital admission in adults, 2006 and 2011 (or nearest year)
Note: 95% confidence intervals represented by |—|.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932917845
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5. QUALITY OF CARE5.2. Prescribing in primary careBeyond consumption and expenditure (see Indicators 4.10
“Pharmaceutical consumption” and 7.4 “Pharmaceutical
expenditure”), information on prescribing can be used as
an indicator of health care quality. Two related indicators
are shown: the total volume of antibiotics and, more specif-
ically, the volume of quinolones and cephalosporins pre-
scribed as a proportion of all antibiotics.
There is a clear correlation between the volume of antibiot-
ics prescribed at community level and prevalence of resis-
tant bacterial strains (Bronzwaer et al., 2002; Goosens et al.,
2005). Infections caused by resistant microorganisms often
fail to respond to conventional treatment, resulting in pro-
longed illness, greater risk of death, and higher costs.
Reduced prescribing in primary care has been associated
with reductions in antibiotic resistance (Butler et al., 2007).
Antibiotics, therefore, should only be prescribed where
there is an evidence-based need, avoiding use in mild
throat infections, for example, which are nearly always
viral (Cochrane Collaboration, 2013). Whilst an optimal
level of prescribing is difficult to establish, variations in
prescribing volume are a good indicator of health care
quality in the primary care setting (Coenen et al., 2007).
Quinolones and cephalosporins are considered second-line
antibiotics in most prescribing guidelines. Their use should
be restricted to ensure availability of effective second-line
therapy should first-line antibiotics fail. Again, although an
optimal level of prescribing of these antibiotics is difficult
to establish, there is widespread evidence that these antibi-
otics are prescribed unnecessarily where no, or a more
standard, antibiotic would suffice. Their volume as a pro-
portion of the total volume of antibiotics prescribed has
also been validated as a marker of quality in the primary
care setting (Adriaenssens et al., 2011).
Figure 5.2.1 shows volumes of antibiotics prescribed in pri-
mary care at national level. Volumes vary more than three-
fold across countries, with Chile, Estonia and the Netherlands
reporting the lowest volumes and Greece, Luxembourg and
Belgium reporting volumes around 1.5 times the OECD
average. Variation is likely to be explained, on the supply
side, by differences in the regulation, guidelines and incen-
tives that govern primary care prescribers and, on the
demand side, by cultural differences in attitudes and
expectations regarding the natural history and optimal
treatment of infective illness (Akkerman et al., 2005; Koller
et al., 2013).
Figure 5.2.2 shows the volume of quinolones and cephalo-
sporins as a proportion of all antibiotics prescribed in pri-
mary care. The ten-fold variation across countries is much
greater than for total antibiotic prescribing volume;
Denmark, Norway and the United Kingdom report the low-
est proportions, whilst Greece, Germany and the Slovak
Republic report volumes approaching double that of the
OECD average. There is some association in countries’
ranking across these two indicators: Greece and Luxembourg
report high volumes and the Nordic countries relatively low
volumes, for example. Germany, Austria and Hungary,
however, report low total prescribing volumes but relatively
high proportions of quinolone and cephalosporin use.
Total use may well exceed the volumes reported here given
that, in some countries, self-medication is prevalent
(Grigoryan et al., 2006). Reducing use is a pressing, yet com-
plex problem, likely to require multiple co-ordinated initia-
tives including surveillance, regulation and education of
professionals and patients. Many such programmes are
underway, including a European Union Joint Programme
launched in 2008 (JPIAMR) and the World Health Organisa-
tion’s Global Strategy for the Containment of Antimicrobial
Resistance, as well as initiatives at national level, many of
which have been shown to be effective (Huttner et al.,
2010).
Definition and comparability
See Indicator 4.10 for a description of the defined
daily dose (DDD). Data generally refer to outpatient
consumption except for Chile, Canada, Greece, Korea,
Israel, Iceland where data also include consumption
in hospitals and other institutions beyond primary
care. Data are from 2010 except for the United States
(2004), Israel (2009) and the Slovak Republic (2009).
Data for Chile only include drugs dispensed by private
pharmacies. Data for Canada only cover Manitoba
and Saskatchewan, provinces for which population
level data were available, representing 6.7% of the
population.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013110
5. QUALITY OF CARE
5.2. Prescribing in primary care5.2.1. Overall volume of antibiotics prescribed, 2010 (or nearest year)
1. Data refer to all sectors (not only primary care).
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en, IMS for United States.
1 2 http://dx.doi.org/10.1787/888932917864
5.2.2. Cephalosporins and quinolones as a proportion of all antibiotics prescribed, 2010 (or nearest year)
1. Data refer to all sectors (not only primary care).
Source: European Centre for Disease Prevention and Control 2013 and IMS for United States.
1 2 http://dx.doi.org/10.1787/888932917883
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5. QUALITY OF CARE5.3. Mortality following acute myocardial infarction (AMI)Mortality due to coronary heart disease has declined sub-
stantially since the 1970s (see Indicator 1.3 “Mortality from
cardiovascular disease”). This reduction can, in part, be
attributed to better treatments, particularly in the acute
phases of myocardial infarction (AMI). Care for AMI has
changed dramatically in recent decades, with the introduc-
tion of coronary care units and treatments aimed at rapidly
restoring coronary blood flow (Khush et al., 2005). Clinical
practice guidelines provide clinicians with information on
how to optimise treatments and studies have shown that
greater compliance with guidelines improve health out-
comes (e.g., Schiele et al., 2005; Eagle et al., 2005). However,
some AMI patients do not receive recommended care, rais-
ing concerns over the quality of care in some countries
(Brekke and Gjelsvik, 2009; Kotseva et al., 2009).
A good indicator of acute care quality is the 30-day AMI
case-fatality rate. This indicator measures the percentage
of people who die within 30 days following admission to
hospital for AMI. The measure reflects the processes of
care, such as timely transport of patients and effective
medical interventions. The indicator is influenced by not
only the quality of care provided in hospitals but also dif-
ferences in hospital transfers, average length of stay and
AMI severity.
Figure 5.3.1 shows the case-fatality rates within 30 days of
admission for AMI. The panel on the left reports the in-hos-
pital case-fatality rate when the death occurs in the same
hospital as the initial AMI admission. The lowest rate is
found in Denmark (3%) and the highest rate is in Mexico
(27%). Although Mexican case-fatality data only refer to
public sector hospitals, the quality of pre-hospital emer-
gency medical services is reportedly poor (Peralta, 2006).
The high rate of uncontrolled diabetes in Mexico, Korea and
Hungary may also be a contributing factor in explaining the
high AMI case-fatality rates (see Indicators 1.10 “Diabetes
prevalence and incidence” and 5.1 “Avoidable hospital
admissions”). Patients with diabetes have worse outcomes
after AMI compared to those without diabetes, particularly
if the diabetes is poorly controlled (Norhammar et al., 2007;
Ouhoummane et al., 2010; Yan et al., 2006). In Korea and
Japan, people are less likely to die of heart disease overall,
but are more likely to die once admitted into hospital for
AMI compared to many other OECD countries. One possible
explanation for this is that the severity of patients admit-
ted to hospital with AMI may be more advanced among a
smaller group of people across the population, but could
also reflect underlying differences in emergency care, diag-
nosis, treatment patterns and even disease coding prac-
tices (OECD, 2012b).
The right-hand-side panel of Figure 5.3.1 shows 30-day AMI
case-fatality rates where fatalities are recorded regardless
of where they occur. This is a more robust indicator
because it records deaths more widely than the same-
hospital indicator, but it requires linked data which is not
available in all countries. The average AMI case-fatality rate
is 10.8% and ranges from 8.2% (Norway) to 18.8% (Hungary).
The degree of cross-country variation is considerably less
with the in- and out-of-hospital indicator compared to the
same-hospital indicator. One potential reason for this is
that patients may be more commonly transferred to other
facilities in countries such as Denmark compared to coun-
tries such as Hungary.
Same-hospital case-fatality rates for AMI have decreased
substantially over the ten year period between 2001 and
2011 (Figure 5.3.2). Across the OECD, case fatalities fell from
11.2% to 7.9%. Between 2006 and 2011, the rate of decline
was particularly striking in Denmark, the Slovak Republic,
Poland and Canada, where case-fatality rates fell by more
than 30%. The improvements can at least be partially
attributed to better and more reliable processes of care.
Definition and comparability
The admission-based case-fatality rate following AMI
is defined as the number of people aged 45 and over
who die within 30 days of being admitted to hospital
with an AMI, where the death occurs in the same
hospital as the initial AMI admission. The in- and out-
of-hospital case-fatality rate is defined as the number
of people who die within 30 days of being admitted to
hospital with an AMI, where the death may occur
in the same hospital, a different hospital, or out of
hospital.
Rates were age-sex standardised to the 2010 OECD
population aged 45+ admitted to hospital for AMI.The
change in the population structure in this edition of
Health at a Glance compared with previous editions
(where rates were standardised using the 2005 OECD
population of all ages) has led to a general increase in
the standardised rates for all countries.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013112
5. QUALITY OF CARE
5.3. Mortality following acute myocardial infarction (AMI)5.3.1. Case-fatality in adults aged 45 and over within 30 days after admission for AMI, 2011 (or nearest year)
Note: 95% confidence intervals represented by |—|.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932917902
5.3.2. Reduction in admission-based (same hospital) case-fatality in adults aged 45 and over within 30 days after
admission for AMI, 2001-11 (or nearest year)
Note: 95% confidence intervals represented by |—|.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932917921
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5. QUALITY OF CARE5.4. Mortality following strokeStroke and other cerebrovascular diseases accounted for
over 8% of all deaths in OECD countries. Ischemic stroke
represents around 85% of all cerebrovascular disease cases.
It occurs when the blood supply to a part of the brain is
interrupted, leading to a necrosis (i.e. the cells that die) of
the affected part. Treatment for ischemic stroke has
advanced dramatically over the last decade. Clinical trials
have demonstrated clear benefits of thrombolytic treat-
ment for ischemic stroke as well as receiving care in dedi-
cated stroke units to facilitate timely and aggressive
diagnosis and therapy for stroke victims (Hacke et al., 1995;
Seenan et al., 2007). Despite their clear clinical benefit,
there is widespread variability in access to stroke units
across and within countries (AIHW, 2013; Kapral et al., 2011;
Indredavik, 2009).
Figure 5.4.1 shows the age-sex standardised case-fatality
rates within 30 days of admission for ischemic stroke as an
indicator of the quality of acute care received by patients.
The left-hand-side panel reports the in-hospital case-fatality
rate when the death occurs in the same hospital as the
initial stroke admission. The panel on the right shows the
case-fatality rate where deaths are recorded regardless of
whether they occurred in or out of hospital. The indicator
on the right hand side is more robust because it captures
fatalities more comprehensively. Although more countries
can report the more partial same-hospital measure, an
increasing number of countries are investing in their data
infrastructure and are able to provide more comprehensive
measures.
Across OECD countries, 8.5% of patients died within 30
days in the same hospital in which the initial admission for
ischemic stroke occurred. The case-fatality rates were
highest in Mexico (19.6%), Slovenia (12.8%) and Turkey
(11.8%). Rates were less than 5% in Japan, Korea, Denmark
and the United States. With the exception of Japan and
Korea, countries that achieve better results for ischemic
stroke also tend to report good case-fatality rates for acute
myocardial infarction (AMI). This suggests that certain
aspects of acute care may be influencing outcomes for both
stroke and AMI patients. By contrast, Japan and Korea
report the lowest rates for ischemic stroke but high case-
fatality rates for AMI. This somewhat paradoxical result
requires further investigation but may be associated with
the severity of disease in these two countries that is not
captured in the data (see Indicator 5.3 “Mortality following
acute myocardial infarction” for more details).
Across the 15 countries that reported in- and out-of-hospital
case-fatality rates, 11.2% of patients died within 30 days of
being admitted to hospital for stroke. This figure is higher
than the same-hospital based indicator because it captures
deaths that occur not just in the same hospital but also in
other hospitals and out of hospital. The cross-country vari-
ation is substantially smaller for the in- and out-of-hospital
measure compared to the same-hospital measure. This
may be due to systematic differences between countries in
the way that patients are transferred between hospitals
and rehabilitative care facilities following stroke.
Between 2001 and 2011, same-hospital case-fatality rates
for ischemic stroke declined by almost 25% across 19 OECD
countries for which data were available over the entire
period (Figure 5.4.2). However, the rate of decline was not
uniform across countries. Between 2001 and 2011, improve-
ments in case-fatality rates in Australia and Belgium, for
example, were not as great as the OECD average. On the
other hand, the Czech Republic, the Netherlands and
Norway were able to reduce their case fatality rates in
excess of 40% between 2001 and 2011. The improvements
in case-fatality rates can at least be partially attributed to
the degree of access to dedicated stroke units and the high
quality of care provided there.
Definition and comparability
The admission-based case-fatality rates is defined as
the number of people aged 45 and over who died
within 30 days of being admitted to hospital for isch-
emic stroke, where the death occurs in the same hos-
pital as the initial stroke admission. The in- and out-
of-hospital case-fatality rate is defined as the number
of people who die within 30 days of being admitted to
hospitalwith a stroke,where the deathmay occur in the
same hospital, a different hospital or out of hospital.
Rates were age-sex standardised to the 2010 OECD
population aged 45+ admitted to hospital for stroke.
The change in the population structure in this edition
of Health at a Glance compared with previous editions
(where rates were standardised using the 2005 OECD
population of all ages) has led to a general increase in
the standardised rates for all countries.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013114
5. QUALITY OF CARE
5.4. Mortality following stroke5.4.1. Case-fatality in adults aged 45 and over within 30 days after admission for ischemic stroke, 2011 (or nearest year)
Note: 95% confidence intervals represented by |—|.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932917940
5.4.2. Reduction in admission-based (same hospital) case-fatality in adults aged 45 and over within 30 days after
admission for ischemic stroke, 2001-11 (or nearest year)
Note: 95% confidence intervals represented by |—|.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932917959
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5. QUALITY OF CARE5.5. Surgical complicationsPatient safety remains one of the most prominent issues in
health policy and public debate. High rates of errors during
the delivery of medical care have been demonstrated
repeatedly, including the landmark report by the Institute
of Medicine which estimated that more people die from
medical errors than from traffic injuries or breast cancer
(Kohn et al., 2000). Two types of patient safety event can be
distinguished: sentinel events that should never occur such
as failure to remove surgical foreign bodies (e.g. gauze
swabs) at the end of a procedure; and adverse events, such
as post-operative sepsis, which can never be fully avoided
given the high-risk nature of some procedures, although
increased incidence at an aggregate level may indicate a
systemic failing.
Figures 5.5.1 and 5.5.2 show rates of two adverse events,
post-operative pulmonary embolism (PE) or deep vein
thrombosis (DVT) and post-operative sepsis. PE or DVT
cause unnecessary pain and in some cases death, but can
be prevented by anticoagulants and other measures before,
during and after surgery. Likewise, sepsis after surgery,
which may lead to organ failure and death, can in many
cases be prevented by prophylactic antibiotics, sterile sur-
gical techniques and good postoperative care. Figure 5.5.3
illustrates a sentinel event – rates of foreign body left in
during procedure. The most common risk factors for this
“never event” are emergencies, unplanned changes in pro-
cedure, patient obesity and changes in the surgical team;
preventive measures include methodical wound explora-
tion and effective communication among the surgical team
(Gawande et al., 2003).
International variation in post-operative PE or DVT rates
(all surgeries) varies more than 10-fold. Belgium, Portugal
and Spain report the lowest rates, whilst Slovenia and
Australia report rates approaching double the OECD aver-
age. Rates following hip and knee replacement surgery are
also shown. These are high risk procedures and higher
rates would be expected (Heit, 2012; Januel et al., 2012), yet
this pattern is observed in relatively few countries. Several
explanations are possible, including more careful care after
hip and knee surgery. Differences in emergency/elective
case mix across countries, in the mix of procedures across
the public and private sectors if countries vary in the
volume of hip and knee replacements undertaken in each
sector, in how national databases link secondary complica-
tions back to the primary procedure, or in how secondary
complications are reported to the national database, across
surgical specialities within a country, are also possible
explanations.
Variation in post-operative sepsis (all surgeries) is even
greater, at around 20-fold. Rates following abdominal sur-
gery, a high risk procedure (Bateman et al., 2010; Vogel et
al., 2010) are higher, as expected, in almost all countries.
Variation in rates for the sentinel event is around 10-fold
(Figure 5.5.3). Belgium, Denmark and Israel report the low-
est rates and Switzerland, New Zealand and Australia the
highest rates.
Caution is needed in interpreting the extent to which these
indicators accurately reflect international differences in
patient safety rather than differences in the way that coun-
tries report, code and calculate rates of adverse events (see
Definition and comparability box). In some cases, higher
adverse event rates may signal more developed patient
safety monitoring systems rather than worse care. Never-
theless, these figures demonstrate how large numbers of
patients suffer adverse events during medical care. Interna-
tional initiatives tomakemedical care safer, such as the Euro-
pean Union JointAction on Patient Safety and Quality of Care,
include efforts to improve the comparability of how countries
document and report the occurrence of adverse events.
Definition and comparability
Surgical complications are defined as the number of
discharges with ICD codes for the complication in any
secondary diagnosis field, divided by the total num-
ber of discharges for patients aged 15 and older. The
rates have been adjusted by the average number of
secondary diagnoses (Drösler et al., 2011) in order to
improve inter-country comparability. Despite this
adjustment, results for countries that report less than
1.5 diagnoses per record may be underestimated.
Rates have not been age-sex standardised, since this
makes a marginal difference to countries’ reported
rate or ranking relative to other countries.
A fundamental challenge in international compari-
son of patient safety indicators centres on the quality
of the underlying data. The indicators are typically
derived from administrative databases, rather than
systems specifically designed to monitor adverse
events, hence differences in how countries record
diagnoses and procedures and define hospital epi-
sodes can affect calculation of rates. Countries which
rely on clinicians to report adverse events may record
them less completely than countries which employ
specially trained administrative staff to identify and
code adverse events from patients’ clinical records,
for example. The extent to which national databases
facilitate recording of secondary diagnoses or to
which payments are determined by diagnosis or pro-
cedure lists may also influence recording.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013116
5. QUALITY OF CARE
5.5. Surgical complications5.5.1. Postoperative pulmonary embolism or deep vein
thrombosis in adults, 2011 (or nearest year)
1. The average number of secondary diagnoses is < 1.5.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932917978
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5.5.2. Postoperative sepsis in adults, 2011
(or nearest year)
1. The average number of secondary diagnoses is < 1.5.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932917997
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5.5.3. Foreign body left in during procedure in adults, 2011 (or nearest year)
Note: Some of the variations across countries are due to different classification systems and recording practices.
1. The average number of secondary diagnoses is < 1.5.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932918016
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5. QUALITY OF CARE5.6. Obstetric traumaPatient safety during childbirth can be assessed by looking
at potentially avoidable tearing of the perineum during
vaginal delivery. Such tears extend to the perineal muscles
and bowel wall and require surgery. They are more likely to
occur in the case of first vaginal delivery, high baby’s birth
weight, labour induction, occiput posterior baby position,
prolonged second stage of labour and instrumental deliv-
ery. Possible complications include continued perineal pain
and incontinence. A recent study found that around 10% of
women who had such tears will suffer from faecal inconti-
nence initially and almost 45% of women will have on-
going symptoms after four to eight years (Sundquist, 2012).
These types of tears are not possible to prevent in all cases,
but can be reduced by employing appropriate labour man-
agement and high quality obstetric care. For example, find-
ings from a recent study showed that enhanced midwifery
skills in managing vaginal delivery reduce the risk of
obstetric anal sphincter injuries (Hals et al., 2010). Hence,
the proportion of deliveries involving higher degree lacera-
tions is a useful indicator of the quality of obstetric care.
Obstetric trauma indicators have been used by the US Joint
Commission as well as by different international quality
initiatives seeking to assess and improve obstetric care
(AHRQ, 2006).
“Obstetric trauma with instrument” refers to deliveries
using forceps or vacuum extraction. As the risk of a peri-
neal laceration is significantly increased when instruments
are used to assist the delivery, rates for this patient popula-
tion are reported separately. Obstetric trauma indicators
are considered as relatively reliable and comparable across
countries. Nevertheless, differences in the consistency
with which obstetric units report these complications may
complicate international comparison. Fear of litigation, for
example, may cause under-reporting; conversely, systems
which facilitate recording of secondary diagnoses or rely on
specially trained administrative staff to identify and code
adverse events from patients’ clinical records rather than
clinicians to report procedures may produce more reliable
data.
The rate of obstetric trauma after vaginal delivery with
instrument (Figure 5.6.1) shows high variation across coun-
tries. Reported rates vary from below 2% in Poland, Israel,
Italy, Slovenia and Portugal to more than 15% in Canada
and Denmark. Rates of obstetric trauma after vaginal deliv-
ery without instrument (Figure 5.6.2) are considerably less
but display equally large variation, from less than 0.5%
in Poland, Israel, Italy and Slovenia to 3.5% or above in
Sweden and Switzerland. There is a strong relationship
between the two indicators: Poland, Israel, Italy, Slovenia,
Portugal and Belgium report the lowest rates and Sweden,
Canada and Denmark the highest rates for both indicators.
Definition and comparability
The two obstetric trauma indicators are defined as
the proportion of instrument assisted/non-assisted
vaginal deliveries with third- and fourth-degree
obstetric trauma codes in any diagnosis and proce-
dure field. Any differences in the definition of princi-
pal and secondary diagnoses have no influence on the
calculated rates.
Differences in data reporting across countries may
influence the calculated rates of obstetric patient
safety indicators. These relate primarily to differ-
ences in coding practice and data sources. Some
countries report obstetric trauma rates based on
administrative hospital data and others based on
obstetric register. There is some evidence that regis-
tries produce higher quality data and report a greater
number of obstetric trauma events compared to
administrative datasets (Baghestan et al., 2007).HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013118
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5.6. Obstetric trauma5.6.1. Obstetric trauma, vaginal delivery with instrument, 2011 (or nearest year)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932918035
5.6.2. Obstetric trauma, vaginal delivery without instrument, 2011 (or nearest year)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932918054
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5. QUALITY OF CARE5.7. Unplanned hospital re-admissions for patients with mental disordersThe burden of mental illness is substantial. Mental and
behavioural disorders, including major depressive disorder,
anxiety disorders, and schizophrenia accounted for 7.4% of
healthy years lost due to disability worldwide in 2010.
Furthermore, the burden attributable for this group of dis-
eases grew by 5.9% between 1990 and 2010, with schizo-
phrenia and bipolar disorders among the major
contributors to this growth (Murray et al., 2013).
Improving mental health care is a policy priority in many
OECD countries, with countries seeking the most effective
and efficient ways to deliver care to patients. Most OECD
countries are moving away from hospital care as the main
way of delivering care and towards community-based inte-
grated care that involves a multidisciplinary team (OECD,
forthcoming). Patients with severe mental disorders still
receive specialised care at hospitals but, if deemed appro-
priate, coordinated follow-up is provided after discharge
and patients are not usually re-admitted to hospital within
30 days without any prior plan to do so. The proportion of
patients with within 30-day re-admissions is therefore
used as an indicator of the lack of proper management of
mental health conditions outside of hospital.
Over 15% of patients with schizophrenia were re-admitted
to hospital within 30 days in 2011 in Israel, Korea, Australia,
Denmark and Sweden, while the rate was around 5% in
Mexico and Portugal (Figure 5.7.1). Relative positions of
countries are similar between schizophrenia and bipolar
disorder and the difference in re-admission rates was less
than 3% in all countries except for Korea (Figure 5.7.2).
Countries show diverging trends over time for both schizo-
phrenia and bipolar disorder re-admissions. The United
Kingdom experienced an increase in re-admissions,
whereas in Italy rates declined for both disorders between
2006 and 2011. In Italy, efforts have been made to reduce
inappropriate use of inpatient services for patients with
mental disorders, and re-admissions are monitored and
used to improve organisation and clinical effectiveness of
mental health care.
Mental health care systems have developed new organisa-
tional and delivery models over the past few decades.
For example, community-based “crisis teams” are used to
stabilise patients in outpatient settings in a number of
countries such as Italy, Norway and the United Kingdom.
Other countries, such as Denmark, use interval care proto-
cols to place unstable patients in hospital for short periods,
whilst being proactive in identifying patients in need of
care through outreach teams following discharges. A more
patient-centred approach is becoming commonplace, with
patients involved in care and service plan development
(OECD, forthcoming). The differences in mental health care
delivery models may be a contributor to the cross-country
variation in the proportion of re-admissions that are
planned and unplanned, with only the latter indicating
poor quality. However, our ability to identify between
planned and unplanned re-admissions in the data is lim-
ited. At this stage, only a few countries have the capacity to
distinguish between the two types of re-admissions in their
administrative data.
Definition and comparability
The indicator uses within 30-day re-admissions as a
proxy for unplanned re-admissions as many coun-
tries cannot differentiate these re-admissions. The
denominator is the number of patients with at least
one hospital admission during the year for schizo-
phrenia or bipolar disorder as principal diagnosis or
as one of the first two listed secondary diagnosis. The
numerator is the number of these patients with at
least one re-admission for any mental disorder to the
same hospital within 30 days of discharge in the year.
Patients with same-day admissions (less than
24 hours) are not included in the numerator. The data
have been age-sex standardised based on the 2010
OECD population structure, to remove the effect of
different population structures across countries.
Data presented in Health at a Glance 2009 and 2011
refer to the number of within 30-day readmissions
per 100 patients, which were slightly different from
those presented in this edition of Health at a Glance
which refer to the proportion of patients with at least
one re-admission.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013120
5. QUALITY OF CARE
5.7. Unplanned hospital re-admissions for patients with mental disorders5.7.1. Schizophrenia re-admissions to the same hospital, 2006 and 2011 (or nearest year)
Note: 95% confidence intervals represented by |—|.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932918073
5.7.2. Bipolar disorder re-admissions to the same hospital, 2006 and 2011 (or nearest year)
Note: 95% confidence intervals represented by |—|.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932918092
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5. QUALITY OF CARE5.8. Excess mortality from mental disordersExcess mortality is a ratio of the mortality rate for patients
with a mental disorder compared with the mortality rate of
the general population. A ratio value that is greater than
one implies that people withmental disorders face a higher
risk of death than the rest of the population.
There are a number of reasons why people withmental dis-
orders have higher mortality rates than the general popula-
tion. These include higher rates of suicide and accidents as
well as a higher prevalence of co-morbidities or risk factors
such as smoking, the abuse of alcohol and illicit drugs and
side effects of psychotropic treatment (de Hert et al., 2011;
Nordentoft et al., 2013; Björkenstam et al., 2012). Excess
mortality among people with mental health disorders may
also be partly due to lower access and use of health care as
well as poorer quality of care provided to them. The quality
of care may be compromised because these patients may
have difficulties in effectively communicating their physi-
cal problems and providers may prioritise patient’s psychi-
atric problem over their physical problems.
In 2011, excess mortality from schizophrenia and bipolar
disorder ranges from 2.1 to 8.8 times greater than in the
general population (Figures 5.8.1 and 5.8.2). Data are not
available for all the United Kingdom. In England, data are
not available for specific diagnostic categories of mental
disorders, but excess mortality among all patients with
serious mental illness is 3.3 times greater than in the gen-
eral population in 2010.
For patients with schizophrenia, excess mortality ranges
from 3.6 in Korea to 8.8 in Sweden (Figure 5.8.1). For
patients with bipolar disorder, excess mortality is slightly
lower in all countries, ranging from 2.1 in Denmark to 6.8 in
Sweden in 2011 (Figure 5.8.2). The Swedish results are con-
sistent with previous research which showed that death by
suicide or other external causes, particularly among Swed-
ish men with a mental disorder, are very high (Wahlbeck et
al., 2011). For both disorders, Denmark, Korea and Slovenia
have lower excess mortality than the OECD averages.
Previous studies have shown that excess mortality has
increased across countries over the past decades (Saha et
al., 2007). For schizophrenia, this trend has continued in
most countries over recent years (Figure 5.8.1). The excep-
tion to this trend is in New Zealand where excess mortality
has fallen between 2006 and 2011. New Zealand has
strengthened mental health care systems in the past two
decades by focusing on early intervention and assisting
people to improve their own health and wellness and to
live independent lives. It has improved access to specialist
care and community-based services and involved patients
and family in service planning and delivery (Ministry of
Health, 2012).
Trends in excess mortality attributable to bipolar disorder
vary across countries. Between 2006 and 2011, the ratio
increased in Korea and Sweden, stayed fairly stable in
Denmark and fell in the other countries (Figure 5.8.2). Similar
to the schizophrenia indicator, the decrease in excess mor-
tality from bipolar disorder was large in New Zealand.
Compared to a decade earlier, the rate for Israel also
declined substantially.
Despite some improvements over recent years, mortality
rates among those with mental disorders remain well
above the rates observed in the general population, sug-
gesting that those with mental disorders have not fully
benefited from improvements in health outcomes attained
by the general population and the availability and quality
of mental health care may be lagging behind (Saha et al.,
2007; Tidemalm et al., 2008). Ensuring physical health and
well-being in people with serious mental illness presents
many challenges, and health services must proactively
seek to address both the physical and mental health needs
of this group.
Definition and comparability
The numerator for the excess mortality ratio is the
overall mortality rate in a given year for persons aged
between 15 and 74 years old diagnosed with schizo-
phrenia/bipolar disorder. For Israel, New Zealand and
Sweden, it refers to the mortality of person diagnosed
in the same year but diagnosis year is not known for
others. These differences may relate to variations
shown in the figures to some extent. The denomina-
tor is the overall mortality rate for the general popula-
tion aged between 15 and 74 years old in a given year.
Data coverage varies according to the place where
mental disorders are diagnosed. In Israel and Korea
patients can be identified in the data regardless of
where diagnosis occurs while in New Zealand only
diagnoses within the secondary care sector are
included in the data, hence excess mortality appears
to be high compared to other countries. For Finland
and Sweden, data include only diagnosis within the
hospital sector. The data have been age-sex stan-
dardised based on the 2010 OECD population struc-
ture, to remove the effect of different population
structures across countries.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013122
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5.8. Excess mortality from mental disorders5.8.1. Excess mortality from schizophrenia, 2006 and 2011 (or nearest year)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932918111
5.8.2. Excess mortality from bipolar disorder, 2006 and 2011 (or nearest year)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932918130
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5. QUALITY OF CARE5.9. Screening, survival and mortality for cervical cancerCervical cancer is highly preventable if precancerous
changes are detected and treated before progression
occurs. The main cause of cervical cancer, which accounts
for approximately 95% of all cases, is sexual exposure to
the human papilloma virus (HPV) (IARC, 1995; Franco et al.,
1999). Countries follow different policies with regards to
the prevention and early diagnosis of cervical cancer.
About half of OECD countries have cervical cancer screen-
ing organised through population-based programmes but
the periodicity and target groups vary (OECD, 2013e). Some
countries with low cervical cancer incidence such as Israel
and Switzerland do not have an organised screening pro-
gramme, but in both countries women in the eligible age
group can have a Pap smear test performed every three
years for free. Since the development of a vaccine against
some HPV types, vaccination programmes have been
implemented in around half of OECD countries (Brotherton
et al., 2011), although there is an ongoing debate about the
impact of the vaccine on cervical cancer screening strate-
gies (Goldhaber-Fiebert et al., 2008;Wheeler et al., 2009).
Screening rates for cervical cancer range from 15.5% in
Turkey to 85.0% in the United States in 2011 (Figure 5.9.1).
Austria, Germany, Sweden, Norway and New Zealand also
achieved coverage above 75%. Screening rates in Iceland
and the United Kingdom declined substantially over the
decade. However, in each of these cases changes to pro-
gramme eligibility and data capturemay account for part of
this decrease. On the other hand, Korea increased the
screening coverage by four-fold, although the rate still
remains well below the OECD average.
Cancer survival is one of the key measures of the effective-
ness of cancer care systems, taking into account both early
detection of the disease and the effectiveness of treatment.
In recent years, five-year relative survival for cervical
cancer improved in many countries, possibly due to
improved effectiveness of screening and treatment
(Figure 5.9.2). The most notable increase of almost 16% was
observed in Iceland in recent years. Cross-country differ-
ences in cervical cancer range from 52.7% in Poland to
76.8% in Korea in the most recent period. Some countries
with relatively high screening coverage such as the United
States, Germany and New Zealand have lower survival.
Mortality rates reflect the effect of cancer care over the past
years and the impact of screening, as well as changes in
incidence (Dickman and Adami, 2006). The mortality rates
for cervical cancer declined in most OECD countries
between 2001 and 2011 (Figure 5.9.3), following the broad
trend of an overall reduction in mortality from all types of
cancer (see Indicator 1.4 “Mortality from cancer”). The
decline was large in Denmark, Iceland, New Zealand and
Norway. Mexico also experienced a sharp decrease in cervical
cancer mortality, although it still has the highest rate
among OECD countries. However, in some countries, such
as Greece and Estonia, mortality rates from cervical cancer
increased.
Definition and comparability
Screening rates reflect the proportion of women who
are eligible for a screening test and actually receive
the test. Some countries ascertain screening based on
surveys and other based on encounter data, which
may influence the results. Survey-based results may
be affected by recall bias. Programme data are often
calculated for monitoring national screening pro-
grammes, and differences in target population and
screening frequency may also lead to variations in
screening coverage across countries.
Relative survival is the ratio of the observed survival
experienced by cancer patients over a specified
period of time after diagnosis to the expected survival
in a comparable group from the general population in
terms of age, sex and time period. Relative survival
captures the excess mortality that can be attributed
to the diagnosis. For example, relative survival of 80%
mean that 80% of the patients that were expected to
be alive after five years, given their age at diagnosis
and sex, are in fact still alive. Survival data for
Germany and Portugal are based on a sample of
patients, representing 27% and 44% of the population
respectively.
Cancer survival calculated through period analysis is
up-to-date estimate of cancer patient survival using
more recent incidence and follow-up periods than
cohort analysis which uses survival information of a
complete five-year follow-up period. In the United
Kingdom, cohort analysis was used for 2001-06 data
while 2006-11 data are calculated through period
analysis.The reference periods vary slightly across
countries. All the survival estimates presented here
have been age-standardised using the International
Cancer Survival Standard (ICSS) population (Corazziari
et al., 2004). The survival is not adjusted for tumour
stage at diagnosis, hampering assessment of the rela-
tive impact of early detection and better treatment.
See Indicator 1.4 “Mortality from cancer” for defini-
tion, source andmethodology underlying cancer mor-
tality rates.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013124
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5.9. Screening, survival and mortality for cervical cancer5.9.1. Cervical cancer screening in women aged 20-69,
2001 to 2011 (or nearest year)
1. Programme.
2. Survey.
* Three-year average.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932918149
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5. QUALITY OF CARE5.10. Screening, survival and mortality for breast cancerBreast cancer is the most prevalent form of cancer in
women. One in nine women will acquire breast cancer at
some point in their life and one in thirty will die from the
disease. Risk factors that increase a person’s chance of get-
ting this disease include, but are not limited to, age, family
history of breast cancer, oestrogen replacement therapy,
lifestyle, diet, and alcohol.
Most OECD countries have adopted breast cancer screening
programmes as an effective way for detecting the disease
early. The periodicity and population target groups vary
across countries and are still the subjects of debate. EU
guidelines (European Commission, 2006) suggest a desir-
able target screening rate of at least 75% of eligible women
in European countries. Screening rates vary widely across
OECD countries in 2011, ranging from less than 10% in
Chile to over 80% in Finland, the Netherlands, the United
States and Austria (Figure 5.10.1). Some countries that had
high screening rates ten years ago experienced some
reductions over the past decade, including Finland, the
United States, the United Kingdom, Norway, Ireland and
Canada. On the other side, Korea, Poland and the Czech
Republic showed substantial increases, although they still
remain below the OECD average.
Breast cancer survival reflects advances in improved treat-
ments as well as public health interventions to detect the
disease early through screening programmes and greater
awareness of the disease. The introduction of combined
breast conserving surgery with local radiation and neoad-
juvant therapy, for example, have increased survival as well
as the quality of life of survivors (Mauri et al., 2008). The
availability and use of newer and more effective chemo-
therapy agents for metastatic breast cancer have also been
shown to improve survival among women (Chia et al.,
2007).
The relative five-year breast cancer survival has improved
in many countries in recent periods (Figure 5.10.2), attain-
ing over 80% in all OECD countries except Poland. In part,
this may be related to the access of care in Poland where
the numbers of cancer care centres and radiotherapy facil-
ities are limited (OECD, 2013e). Five-year survival for breast
cancer has increased considerably in central and eastern
European countries, where survival has historically been
low, as well as in Belgium and Ireland (Verdecchia et al.,
2007). Recent studies suggest that some of the differences
in cancer survival could be due to variations in the imple-
mentation of screening programmes (Rosso et al., 2010).
Countries such as Chile, Greece and the Slovak Republic
have non-population-based breast cancer screening pro-
grammes.
In addition to well organised screening programmes, a
recent OECD report on cancer care showed that shorter
waiting times and the provision of evidence-based best
practice are also associated with improved survival in
OECD countries. Developing comprehensive cancer control
plans, setting national targets with a specified time frame,
having guidelines, using case management and having
mechanisms for monitoring and quality assurance were
found to be associated with improved cancer survival
(OECD, 2013e).
Mortality rates have declined in most OECD countries over
the past decade (Figure 5.10.3). The reduction in mortality
rates are a reflection of improvements in early detection
and treatment of breast cancer, and are also influenced by
the incidence of the disease. Improvements were substan-
tial in Norway, Ireland and the Czech Republic. Denmark
also reported a considerable decline over the last decade,
but its mortality rate was still the highest in 2011. In Korea
and Japan, the mortality rate from breast cancer increased
over the decade, although it remains the lowest among
OECD countries.
Definition and comparability
Screening rates and survival are defined in
Indicator 5.9 “Screening, survival and mortality for
cervical cancer”. See Indicator 1.4 “Mortality from
cancer” for definition, source and methodology
underlying cancer mortality rates.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013126
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5.10. Screening, survival and mortality for breast cancer5.10.1. Mammography screening in women aged 50- 69,
2001 to 2011 (or nearest year)
1. Programme.
2. Survey.
* Three-year average.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932918206
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5. QUALITY OF CARE5.11. Survival and mortality for colorectal cancerColorectal cancer is the third most commonly diagnosed
form of cancer worldwide, after lung and breast cancers,
with over 1.2 million new cases diagnosed annually. Inci-
dence rates are significantly higher for males than females
(IARC, 2011). There are several factors that place certain
individuals at increased risk for the disease, including age,
the presence of polyps, ulcerative colitis, a diet high in fat
and genetic background. The disease is more common in
the United States and Europe, and is rare in Asia. But in
countries where people have adopted western diets, such
as Japan, the incidence of colorectal cancer is increasing.
Total spending on the treatment of colorectal cancer in the
United States is estimated at USD 14 billion per year (Mariotto
et al., 2011).
Following screening for breast and cervical cancers,
colorectal cancer screening has become available, and an
increasing number of countries have introduced free popu-
lation-based screening, targeting people in their 50s
and 60s (OECD, 2013e). Partly because of uncertainties
about the cost-effectiveness of screening (Lansdorp-
Vogelaar et al., 2010), countries are using different methods
(i.e. faecal occult blood test, colonoscopy and flexible sig-
moidoscopy). Multiple methods are also available within
the screening programme in some countries. In most coun-
tries that provide faecal occult blood test, screening is
available every two years. The screening periodicity sched-
ule is less frequent with colonoscopy and flexible sigmoid-
oscopy, generally every ten years, making it difficult to
compare screening coverage across countries.
Advances in diagnosis and treatment of colorectal cancer
have increased survival over the last decade. There is com-
pelling evidence in support of the clinical benefit of
improved surgical techniques, radiation therapy and com-
bined chemotherapy. Most countries showed improvement
in survival over recent periods (Figure 5.11.1). Across OECD
countries, five-year survival improved from 58.0% to 61.3%
for people with colorectal cancer during 2001-06 and 2006-11
respectively. Korea, Japan, Israel and Australia have
attained five-year relative survival of over 65%. Poland and
the Czech Republic, although having the lowest survival
among OECD countries, improved considerably from 42.5%
to 47.7% and from 48.2% to 53.4% respectively between
2001-06 and 2006-11.
Improvement in survival was observed for both men and
women across countries. In all OECD countries, colorectal
cancer survival is higher for women except in Korea and
Japan where men have a slightly higher survival
(Figure 5.11.2). The gender difference is the largest in
Slovenia with the five-year relative survival of 58.9% for
males and 67.2% for females. Denmark and Finland also
have a comparatively large difference.
Most countries experienced a decline in mortality of
colorectal cancer between 2001 and 2011, with the average
rate across OECD countries falling from 28.3 to 25.0 deaths
per 100 000 population over this period (Figure 5.11.3). The
decline was particularly large in Australia, the Czech
Republic and Austria. The main exceptions from the gen-
eral trend were Brazil and Korea, where the mortality rate
from colorectal cancer increased by about 20% in the last
decade. Central and eastern European countries tend to
have higher mortality rates than other OECD countries.
Despite a decrease over time, Hungary and the Slovak
Republic continue to have the highest mortality rate.
Further gains in colorectal cancer mortality could be
achieved through the strengthening of screening pro-
grammes and improving participation rates.
Definition and comparability
Survival and mortal ity rates are defined in
Indicator 5.9. “Screening, survival and mortality for
cervical cancer”. See Indicator 1.4 “Mortality from
cancer” for definition, source and methodology
underlying cancer mortality rates. Survival and mor-
tality rates of colorectal cancer are based on ICD-10
codes C18-C21 (colon, rectosigmoid junction, rectum,
and anus).HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013128
5. QUALITY OF CARE
5.11. Survival and mortality for colorectal cancer5.11.1. Colorectal cancer, five-year relative survival,
2001-06 and 2006-11 (or nearest period)
Note: 95% confidence intervals represented by |—|.
1. Period analysis.
2. Cohort analysis.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932918263
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5. QUALITY OF CARE5.12. Childhood vaccination programmesAll OECD countries have established vaccination pro-
grammes based on their interpretation of the risks and
benefits of each vaccine. There is strong evidence that vac-
cines provide safe and effective protection against diseases
such as diphtheria, tetanus, pertussis (whooping cough),
measles and hepatitis B. The percentage of children pro-
tected from these diseases can be considered as a quality of
care indicator for such childhood vaccination programmes.
Vaccination against diphtheria, tetanus and pertussis (DTP)
and measles are part of all national vaccination schedules
in OECD countries. Figures 5.12.1 and 5.12.2 show that the
overall vaccination of children against measles and DTP is
high in OECD countries. On average, 96% of children receive
the recommended DTP vaccination and 94% receive mea-
sles vaccinations in accordance with national immunisa-
tion schedules. Rates for DTP and/or measles vaccinations
are below 90% only in Austria, Denmark, France, South
Africa, India and Indonesia.
While national coverage rates are high, some parts of the
population remain exposed to certain diseases. In 2013, for
example, there was a measles outbreak in the north of
England as well as parts of Wales. The outbreak has been
linked to a time in the early 2000s when vaccination rates
fell to 80% among a cohort of children. During this period
there was intense media coverage of the safety of the mea-
sles, mumps and rubella (MMR) vaccine, leading many par-
ents to decide not to immunise their child. Although these
safety concerns have since been refuted, large numbers of
children in this age cohort remain unimmunised, raising
the likelihood of outbreaks such as the one experienced in
2013 (Elliman and Bedford, 2013; Sengupta et al., 2004).
Figure 5.12.3 shows the percentage of children aged one
year who are vaccinated for hepatitis B. The hepatitis B
virus is transmitted by contact with blood or body fluids of
an infected person. A small proportion of infections
become chronic, and these people are at high risk of death
from cancer or cirrhosis of the liver. A vaccination has been
available since 1982 and is considered to be 95% effective in
preventing infection and its chronic consequences. Since a
high proportion of chronic infections are acquired during
early childhood, the WHO recommends that all infants
should receive their first dose of hepatitis B vaccine as soon
as possible after birth, preferably within 24 hours (WHO,
2009).
Most countries have followed theWHO recommendation to
incorporate hepatitis B vaccine as an integral part of their
national infant immunisation programme (WHO/Unicef,
2013). For these countries, the immunisation coverage is
averaging 93%. However, a number of countries do not cur-
rently require children to be vaccinated and consequently
the rates for these countries are significantly lower than in
other countries. For example, in Denmark and Sweden,
vaccination against hepatitis B is not part of the general
infant vaccination programme, but is provided to high risk
groups such as children with mothers who are infected by
the hepatitis B virus. Other OECD countries that do not
include vaccination against hepatitis B in their infant pro-
grammes are Iceland, Finland, Hungary, Japan, Slovenia,
Switzerland and the United Kingdom. In Canada,
hepatitis B vaccination is universally included for adoles-
cents but not all provinces and territories include it in their
infant vaccine schedules (Public Health Agency of Canada,
2009; Mackie et al., 2009). In the Netherlands, hepatitis B
vaccines were recently added to the schedule for children
born after August 2011 (WHO/Unicef, 2013).
Definition and comparability
Vaccination rates reflect the percentage of children
that receive the respective vaccination in the recom-
mended timeframe. The age of complete immunisa-
tion differs across countries due to different
immunisation schedules. For those countries recom-
mending the first dose of a vaccine after age one, the
indicator is calculated as the proportion of children
less than two years of age who have received that vac-
cine. Thus, these indicators are based on the actual
policy in a given country.
Some countries administer combination vaccines
(e.g. DTP for diphtheria, tetanus and pertussis) while
others administer the vaccinations separately. Some
countries ascertain vaccinations based on surveys
and others based on encounter data, which may
influence the results.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013130
5. QUALITY OF CARE
5.12. Childhood vaccination programmes5.12.1. Vaccination against diphteria, tetanus
and pertussis, children aged 1, 2011
Source: WHO/Unicef, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932918320
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5.12.2. Vaccination against measles, children aged 1,
2011
Source: WHO/Unicef, http://dx.doi.org/10.1787/health-data-en.
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5. QUALITY OF CARE5.13. Influenza vaccination for older peopleInfluenza is a common infectious disease that affects
between 5 and 15% of the population each year (WHO,
2009). Most people with the illness recover quickly, but
elderly people and those with chronic medical conditions
are at higher risk of complications and even death. Influ-
enza can also have a major impact on the health care sys-
tem. In the United Kingdom, an estimated 779 000 general
practice consultations and 19 000 hospital admissions were
attributable to influenza per year (Pitman et al., 2006). At
certain times of the year, influenza can place health sys-
tems under enormous stress. For example, in Toronto,
Canada, every 100 local cases of influenza resulted in an
increase of 2.5 hours per week of ambulance diversion; this
is a clear sign of emergency department overcrowding
(Hoot et al., 2008; Schull et al., 2004).
Vaccines have been used for more than 60 years and pro-
vide a safe means of preventing influenza.While influenza
vaccines have shown positive results in clinical trials and
observational studies, there is a need for more high quality
studies on the effectiveness of influenza vaccines for the
elderly (Jefferson et al., 2010). Nevertheless, appropriate
influenza vaccines have been shown to reduce the risk of
death by up to 55% among healthy older adults as well as
reduce the risk of hospitalisation by between 32% and 49%
among older adults (Lang et al., 2012; Nichols et al., 2007).
In 2003, countries participating in theWorld Health Assem-
bly committed to the goal of attaining vaccination coverage
of the elderly population of at least 50% by 2006 and 75% by
2010 (WHA, 2003). Figure 5.13.1 shows that in 2011 the aver-
age influenza vaccination rate for people aged 65 and over
was 50%.Vaccination rates range from 1% in Estonia to 94%
in Mexico. Whilst there is still some uncertainty about the
reasons for the cross-national differences, personal contact
with a doctor, better communication, patient and provider
education initiatives, and recall and reminder systems as
well as insurance coverage can play important roles in
improving vaccination rates (Kohlhammer et al., 2007;
Mereckiene et al., 2008; Kroneman et al., 2003; Kunze et al.,
2007). In Estonia, for example, influenza vaccination is not
publicly covered.
Figure 5.13.2 indicates that between 2005 and 2011, the
average vaccination rates across all OECD countries fell
marginally from 58.2% to 56.6% of the elderly population
among the group of countries that have data for these two
years, with no uniform trend among countries. Only
Mexico and Korea attained the 75% coverage target in 2011,
and targets were nearly met in Australia, the Netherlands
and the United Kingdom. Changes over time should be
interpreted with some caution because of changes to the
way vaccination rates were calculated in some countries
(see box on “Definition and comparability”).
In June 2009, the WHO declared an influenza pandemic
(WHO, 2009c). The H1N1 influenza virus (also referred to as
“swine flu”) infected an estimated 11% to 18% of the
population (Kelly et al., 2011). Mexico was at the centre of
the pandemic, being among the first countries where swine
flu was detected and also where mortality rates were
reportedly higher than those in many other countries
(Echevarría-Zuno et al., 2010). The high rate of seasonal
vaccinations that are still being observed in Mexico may be
the result of the H1N1 experiences in that country. In other
countries, however, the take-up rate of H1N1 vaccine was
lower than expected, despite the vaccine being included in
most 2009-10 vaccination programmes (Valenciano et al.,
2011; Poland, 2011; Mereckiene et al., 2012). In part, this
may be due to the easing of concerns about the threat of
H1N1 amongst the general population by the time the vac-
cine became available. Studies have shown that the most
important determinant for individuals to take-up H1N1
vaccine was previous exposure to seasonal flu vaccine,
leading some researchers to argue that higher vaccination
rates for seasonal flu may help uptake during potential
future pandemics (Poland, 2011; Nguyen et al., 2011).
Definition and comparability
Influenza vaccination rate refers to the number of
people aged 65 and older who have received an
annual influenza vaccination, divided by the total
number of people over 65 years of age. The main lim-
itation in terms of data comparability arises from the
use of different data sources, whether survey or pro-
gramme, which are susceptible to different types of
errors and biases. For example, data from population
surveys may reflect some variation due to recall
errors and irregularity of administration. A number of
countries changed the way in which influenza vacci-
nation rates were calculated between 2005 and 2011.
These countries are: Chile, Denmark, Germany, Israel,
Luxembourg, New Zealand, Slovenia, Switzerland and
the United Kingdom.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013132
5. QUALITY OF CARE
5.13. Influenza vaccination for older people5.13.1. Influenza vaccination coverage, population aged 65 and over, 2011 (or nearest year)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932918377
5.13.2. Influenza vaccination coverage, population aged 65 and over, 2005-11 (or nearest year)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932918396
0
10
20
30
40
50
60
70
80
90
100
94 80 75 74 74 67 66 65 64 64 63 62 61 58 56 56 55 53 50 48 46 46 46 41 39 36 30 22 22 16 14 13 1
%
Me
xic
o
Ko
rea
Au
str
ali
a
Ne
the
rla
nd
s
Un
ite
d K
ing
do
m
Un
ite
d S
tat
es
Ne
w 
Ze
ala
nd
Be
lgi
um
Ca
na
da
Sw
ed
en Ita
ly
Ch
ile
Isr
ae
l
Sp
ain
Ire
lan
d
Ge
rm
an
y
Fra
nc
e
Ja
pa
n
OE
CD
32
Po
rtu
ga
l
Sw
itz
erl
an
d
Lu
xe
mb
ou
rg
De
nm
ark
Gr
ee
ce
Fin
lan
d
Au
str
ia
Hu
ng
ary
Cz
ec
h R
ep
.
Slo
va
k R
ep
.
Slo
ve
nia
No
rw
ay
Po
lan
d
Es
ton
ia
0
10
20
30
40
50
60
70
80
90
100
2005 2011%
Me
xic
o
Ko
rea
Au
str
ali
a
Ne
the
rla
nd
s
Un
ite
d K
ing
do
m
Un
ite
d S
tat
es
Ne
w 
Ze
ala
nd
Be
lgi
um
Ca
na
da Ita
ly
Ch
ile
Isr
ae
l
Sp
ain
OE
CD
25
Ire
lan
d
Ge
rm
an
y
Fra
nc
e
Ja
pa
n
Po
rtu
ga
l
Sw
itz
erl
an
d
Lu
xe
mb
ou
rg
De
nm
ark
Fin
lan
d
Hu
ng
ary
Slo
va
k R
ep
.
Slo
ve
niaHEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013 133
5. QUALITY OF CARE5.14. Patient experience with ambulatory careDelivering health care that is responsive and patient-cen-
tered is playing a greater role in health care policy across
OECD countries. Measuring and monitoring patient experi-
ences empowers patients and the public, involves them in
decisions on health care delivery and governance, and pro-
vides insight to the extent that they are health-literate and
have control over the treatment they receive.
Since the mid-1990s, there have been efforts to institutio-
nalise measurement and monitoring of patient experi-
ences. A number of countries have developed survey
instruments for regular data collection and monitoring and
in several countries, including the United Kingdom, the
Netherlands and Norway, responsible organisations have
recently been established. In these countries, patient expe-
riences are reported in periodic national health system
reports or on public websites, demonstrating differences
across providers, regions and over time. There is evidence
that such reporting has actually triggered improvements by
providers (Iversen et al., 2011). In the United Kingdom, it is
also used in the payment mechanism to reward providers
for delivering patient-centered care (Department of Health,
2011).
Patients generally report positive experiences when it
comes to communication and autonomy in the ambulatory
health care system. Patients report positively on time spent
with the doctor (Figure 5.14.1), explanations given
(Figure 5.14.2), opportunities to ask questions or raise con-
cerns (Figure 5.14.3), as well as involvement in care and
treatment decisions (Figure 5.14.4). But there are some dif-
ferences across countries, and the proportion of patients
reporting positive experiences ranges from around 75% in
Sweden to over 95% in certain countries, depending on the
indicator. There is no clear gender difference in patient
experiences across countries, but in the Netherlands
higher proportions of men consistently report positive
experiences than women. The proportion of patients with
positive experiences has increased in recent years in coun-
tries such as Australia, Canada and New Zealand. The
improvement was large in the United States while it was
modest in the United Kingdom (Commonwealth Fund, 2004,
2007, 2010).
Generally, when a country scores relatively well on one
dimension of patient experience, it scores relatively well on
others. For example, Luxembourg scores high for all four
aspects of patient experiences. However, the Czech Republic
is an exception with relatively low scores on patient
involvement in decision-making, but high scores on all the
communication indicators.
Various health system characteristics and policies influ-
ence doctors’ behaviour towards patients and hence have
an impact on patient experiences, including the organisation
of health care delivery, remuneration methods, systematic
monitoring and reporting of patient experiences and the
medico-legal policies for protecting patients’ interests.
Based on the data currently available, it is not yet possible
to conclude that a particular policy is associated with
improved patient experiences. There is a need for more
comparable data from countries on measures of patient
experiences across a broader array of health services.
Definition and comparability
Since the late 1990s, international efforts have been
made to collect patient experience measures through
surveys developed by the Picker Institute, and Con-
sumer Assessment of Healthcare Providers and
Systems (CAHPS) surveys by the US Agency for
Healthcare Research and Quality (AHRQ).WHO also col-
lected different dimensions of patient experience in its
2000/01 World Health Survey, and the Commonwealth
Fund’s International Health Policy Survey has been
collecting patient experience data every three years
since 1998.
Since 2006, the OECD has been involved in developing
and validating a tool to measure patient experiences
systematically. In order to measure general patient
experiences in health care system, the OECD recom-
mends monitoring patient experiences with any
doctor rather than asking patients about their experi-
ences with their regular doctor.
For most of the countries, the Commonwealth Fund’s
International Health Policy Survey 2010 was used as the
data source, even though there are a number of cri-
tiques relating to the sample size, representativeness
and response rates. Further efforts are needed to
improve international comparability of these indica-
tors. Data presented refer to patient experiences with
their regular doctor rather than any doctor. Data col-
lected through other national surveys were reported
here forAustralia (for Figure 5.14.1), the Czech Republic,
Israel , Luxembourg and New Zealand ( for
Figures 5.14.1, 5.14.2 and 5.14.4). Reference periods
are sometimes different across countries. For exam-
ple, New Zealand data are for doctors’ visits in previ-
ous threemonths only. For all countries, rates are age-
sex standardized to the 2010 OECD population, to
remove the effect of different population structures
across countries.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013134
5. QUALITY OF CARE
5.14. Patient experience with ambulatory care5.14.1. Regular doctor spending enough timewith patient
in consultation, 2010 (or nearest year)
Note: 95% confidence intervals represented by |—|.
1. Patient experience with any doctor.
Source: The Commonwealth Fund International Health Policy Survey
2010 and other national sources.
1 2 http://dx.doi.org/10.1787/888932918415
5.14.3. Regular doctor giving opportunity to ask
questions or raise concerns, 2010 (or nearest year)
Note: 95% confidence intervals represented by |—|.
1. Patient experience with any doctor.
Source: The Commonwealth Fund International Health Policy Survey
2010 and other national sources.
1 2 http://dx.doi.org/10.1787/888932918453
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5.14.2. Regular doctor providing easy-to-understand
explanations, 2010 (or nearest year)
Note: 95% confidence intervals represented by |—|.
1. Patient experience with any doctor.
Source: The Commonwealth Fund International Health Policy Survey
2010 and other national sources.
1 2 http://dx.doi.org/10.1787/888932918434
5.14.4. Regular doctor involving patient in decisions
about care and treatment, 2010 (or nearest year)
Note: 95% confidence intervals represented by |—|.
1. Patient experience with any doctor.
Source: The Commonwealth Fund International Health Policy Survey
2010 and other national sources.
1 2 http://dx.doi.org/10.1787/888932918472
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6. ACCESS TO CARE6.1. Coverage for health careHealth care coverage through public or private health
insurance promotes access to medical goods and services,
and provides financial security against unexpected or seri-
ous illness (OECD, 2004a). However, the percentage of the
population covered does not provide a complete indicator
of accessibility, since the range of services covered and the
degree of cost-sharing applied to those services also affects
access to care.
Most OECD countries have achieved universal (or near-
universal) coverage of health care costs for a core set of ser-
vices, which usually include consultations with doctors
and specialists, tests and examinations, and surgical and
therapeutic procedures (Figure 6.1.1). Generally, dental care
and pharmaceutical drugs are partially covered, although
there are a number of countries where these services are
not covered at all (Paris, Devaux andWei, 2010).
Two OECD countries do not have universal health coverage.
In Mexico, the “Seguro Popular” voluntary health insurance
scheme was introduced in 2004 to provide coverage for the
poor and uninsured, and has grown rapidly so that by 2011,
nearly 90% of the population was covered. In the United
States, coverage is provided mainly through private health
insurance, and 53% of the population had this for their
basic coverage in 2011. Publicly financed coverage insured
32% of the population (the elderly, people with low income
or with disabilities), leaving 15% of the population without
health coverage. The problem of persistent un-insurance is
a major barrier to receiving health care, and more broadly,
to reducing health inequalities among population groups
(AHRQ, 2011b). The Affordable Care Act, adopted in 2010,
will expand health insurance coverage in the United States,
which will become mandatory for nearly all citizens and
legal residents from January 2014.
Basic primary health coverage, whether provided through
public or private insurance, generally covers a defined “bas-
ket” of benefits, in many cases with cost-sharing. In some
countries, additional health coverage can be purchased
through private insurance to cover any cost-sharing left
after basic coverage (complementary insurance), add addi-
tional services (supplementary insurance) or provide faster
access or larger choice to providers (duplicate insurance).
Among the 34 OECD countries, ten have private coverage
for over half of the population (Figure 6.1.2).
Private health insurance offers 96% of the French popula-
tion complementary insurance to cover cost-sharing in the
social security system. The Netherlands has the largest
supplementary market (89% of the population), followed by
Israel (80%), whereby private insurance pays for prescrip-
tion drugs and dental care that are not publicly reimbursed.
Duplicate markets, providing faster private-sector access to
medical services where there are waiting times in public
systems, are largest in Ireland (48%) and Australia (45%).
The population covered by private health insurance has
increased in some OECD countries over the past decade. It
has doubled in Belgium to reach 80%. It has also increased
in Mexico and Turkey, although it remains at a very low
level. On the other hand, private health insurance coverage
has decreased at least slightly in Chile and the United
States, two countries where it plays a significant role in pri-
mary coverage for health care (Figure 6.1.3).
The importance of private health insurance is not linked to
a countries’ economic development. Other factors are more
likely to explain market development, including gaps in
access to publicly financed services, the way private pro-
viders are financed, government interventions directed at
private health insurance markets, and historical develop-
ment (OECD, 2004b).
Definition and comparability
Coverage for health care is defined here as the share
of the population receiving a core set of health care
goods and services under public programmes and
through private health insurance. It includes those
covered in their own name and their dependents.
Public coverage refers both to government pro-
grammes, generally financed by taxation, and social
health insurance, generally financed by payroll taxes.
Take-up of private health insurance is often volun-
tary, although it may be mandatory by law or compul-
sory for employees as part of their working
conditions. Premiums are generally non-income-
related, although the purchase of private coverage
can be subsidised by government.
Private health insurance can be both complementary
and supplementary in Denmark, Korea and New
Zealand.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013138
6. ACCESS TO CARE
6.1. Coverage for health care6.1.1. Health insurance coverage for a core set of services,
2011
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932918491
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6. ACCESS TO CARE6.2. Out-of-pocket medical expenditureFinancial protection through public or private health insur-
ance substantially reduces the amount that people pay
directly for medical care, yet in some countries the burden
of out-of-pocket spending can still create barriers to health
care access and use. Households that have difficulties pay-
ing medical bills may delay or forgo needed health care
(Banthin et al., 2008). On average across OECD countries,
20% of health spending is paid directly by patients (see
Indicator 7.6 “Financing of health care”).
In contrast to publicly funded care, out-of-pocket payments
rely on people’s ability to pay. If the financing of health care
becomes more dependent on out-of-pocket payments, the
burden shifts, in theory, towards those who use services
more, and possibly from high to low-income households,
where health care needs are higher. In practice, many
countries have policies in place to protect vulnerable popu-
lations from excessive out-of-pocket payments. These con-
sist of partial or total exemptions for social assistance
beneficiaries, seniors, or people with chronic conditions,
and in caps on out-of-pocket payments, defined in absolute
terms or as a share of income (Paris, Devaux andWei, 2010).
The burden of out-of-pocket medical spending can be mea-
sured either by its share of total household income or its
share of household consumption. In 2011, the share of
household consumption allocated to medical spending
represented only 1.5% of total household consumption in
countries such as the Netherlands, Turkey, the United
Kingdom and France, but more than 4% in Portugal, Korea,
Mexico and Chile (Figure 6.2.1). The United States, with
2.9% of household consumption spent on medical care, is
on the OECD average.
Health systems in OECD countries differ in the degree of
coverage for different health services and goods. In most
countries, the degree of coverage for hospital care and doc-
tor consultations is generally higher than for pharmaceuti-
cals, dental care and eye care (Paris et al., 2010). Taking into
account these differences as well as the relative impor-
tance of these different spending categories, it is not sur-
prising to note some significant variations between OECD
countries in the breakdown of the medical costs that
households have to bear themselves.
In most OECD countries, curative care (including both inpa-
tient and outpatient care) and pharmaceuticals are the two
main spending items for out-of-pocket expenditure
(Figure 6.2.2). On average, these two components account
for 70% of all medical spending by households. In Belgium,
Switzerland, New Zealand and Korea, household payments
for inpatient and outpatient curative care account for about
50% or more of total household outlays. In other countries
such as Poland, Estonia and the Czech Republic, half of out-
of-pocket payments or more are for pharmaceuticals. In
these countries, in addition to co-payments for prescribed
pharmaceuticals, spending on over-the-counter medicines
for self-medication has historically been high.
Payments for dental treatment also play a significant part
in household medical spending. Around 19% of all out-of-
pocket expenditure across OECD countries goes on dental
care. In Denmark and Spain, this figure reaches 30%. This
can be explained at least partly by the relatively low public
coverage for dental care in these countries (see
Indicator 6.5). The significance of therapeutic appliances
(eye-glasses, hearing aids, etc.) in households’ total medi-
cal spending is around 30% in the Netherlands and in the
Slovak Republic. The average across OECD countries is 12%.
More than half of this relates to eye-care products. In many
countries, public coverage is limited to a contribution to the
cost of lenses. Frames are often exempt from public cover-
age, leaving private households to bear the full cost if they
are not covered by complementary private insurance.
Definition and comparability
Out-of-pocket payments are expenditures borne
directly by a patient where neither public nor private
insurance cover the full cost of the health good or ser-
vice. They include cost-sharing and other expendi-
ture paid directly by private households, and also
include estimations of informal payments to health
care providers in some countries. Only expenditure
for medical spending (i.e. current health spending
less expenditure for the health part of long-term care)
is presented here, because the capacity of countries to
estimate private long-term care expenditure varies
widely.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013140
6. ACCESS TO CARE
6.2. Out-of-pocket medical expenditure6.2.1. Out-of-pocket medical spending as a share of final household consumption, 2011 (or nearest year)
Note: This indicator relates to current health spending excluding long-term care (health) expenditure.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932918548
6.2.2. Shares of out-of-pocket medical spending by services and goods, 2011 (or nearest year)
Note: This indicator relates to current health spending excluding long-term care (health) expenditure.
1. Including rehabilitative and ancillary services.
2. Including eye care products, hearing aids, wheelchairs, etc.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932918567
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6. ACCESS TO CARE6.3. Geographic distribution of doctorsAccess to medical care requires an adequate number and
proper distribution of physicians in all parts of the country.
Shortages of physicians in certain regions can increase
travel times or waiting times for patients, and result in
unmet care needs. The uneven distribution of physicians is
an important concern in most OECD countries, especially
in those countries with remote and sparsely populated
areas, and those with deprived urban regions which may
also be underserved.
The overall number of doctors per capita varies across
OECD countr ies from lows of about two per
1 000 population in Chile, Turkey and Korea, to highs of
four and more in Greece, Austria and Italy (Indicator 3.1).
Beyond these cross-country differences, the number of
doctors per capita also often varies widely across regions
within the same country (Figure 6.3.1). A common feature
in many countries is that there tends to be a concentration
of physicians in capital cities. In the Czech Republic, for
example, the density of physicians in Prague is almost
twice the national average.Austria, Belgium, Greece, Portugal,
the Slovak Republic and the United States also have amuch
higher density of physicians in their national capital
region.
The density of physicians is consistently greater in urban
regions, reflecting the concentration of specialised services
such as surgery and physicians’ preferences to practice in
urban settings. Differences in the density of doctors
between predominantly urban regions and rural regions in
2011 was highest in the Slovak Republic, Czech Republic
and Greece, driven to a large extent by the strong concen-
tration of doctors in their national capital region. The dis-
tribution of physicians between urban and rural regions
was more equal in Japan and Korea (Figure 6.3.2).
Doctors may be reluctant to practice in rural and disadvan-
taged urban regions due to various concerns about their
professional life (e.g. income, working hours, opportunities
for career development, isolation from peers) and social
amenities (such as educational opportunities for their chil-
dren and professional opportunities for their spouse).
A range of policy levers may influence the choice of prac-
tice location of physicians, including: 1) the provision of
financial incentives for doctors to work in underserved
areas; 2) increasing enrolments in medical education pro-
grammes of students coming from specific social or geo-
graphic background, or decentralising medical schools;
3) regulating the choice of practice location of doctors (for all
newmedical graduates or possibly targetingmore specifically
international medical graduates); and 4) re-organising health
service delivery to improve the working conditions of
doctors in underserved areas and find innovative ways to
improve access to care for the population.
In many OECD countries, different types of financial incen-
tives have been provided to doctors to attract and retain
them in underserved areas, including one-time subsidies
to help them set up their practice and recurrent payments
such as income guarantees and bonus payments.
In Canada, the province of Ontario provides an example of
an attempt to decentralise medical schools. A new medical
school was created in the Northern part of the province in
2005, far from the main urban centres, with the objective of
increasing access to physician services in rural and remote
parts (NOSM, 2012).
In Germany, the number of practice permits for new ambu-
latory care physicians in each region is regulated, based on
a national service delivery quota (Federal Joint Committee,
2012).
In France, new multi-disciplinary medical homes (Maisons
de Santé Pluridisciplinaires) were introduced a few years
ago as a new form of group practices in underserved areas,
allowing physicians and other health professionals to work
in the same location while remaining self-employed.
The effectiveness and costs of different policies to promote
a better distribution of doctors can vary significantly, with
the impact likely to depend on the characteristics of each
health system, the geography of the country, physician
behaviours, and the specific policy and programme design.
Policies should be designed with a clear understanding of
the interests of the target group in order to have any signif-
icant and lasting impact (Ono et al., forthcoming).
Definition and comparability
Indicators 3.1 provides information on the definition
of doctors.
The OECD classifies regions in two territorial levels.
The higher level (Territorial Level 2) consists of large
regions corresponding generally to national adminis-
trative regions. These broad regions may contain a
mixture of urban, intermediate and rural areas. The
lower level (Territorial level 3) is composed of smaller
regions which are classified as predominantly urban,
intermediate or predominantly rural regions (OECD,
2011a).HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013142
6. ACCESS TO CARE
6.3. Geographic distribution of doctors6.3.1. Physician density, by Territorial Level 2 regions, 2011 (or nearest year)
Source: OECD Regions at a Glance 2013.
1 2 http://dx.doi.org/10.1787/888932918586
6.3.2. Physicians density in predominantly urban and rural regions, selected countries, 2011 (or nearest year)
Source: OECD Regions at a Glance 2013.
1 2 http://dx.doi.org/10.1787/888932918605
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6. ACCESS TO CARE6.4. Inequalities in doctor consultationsProblems of access to health care can be measured by the
actual utilisation of health care services and reported
unmet health care needs. Any inequalities in health care
utilisation and unmet care needs may result in poorer
health status and increase health inequalities.
Inequalities in the probability and the number of doctor
consultations across different socio-economic groups must
take into account differences in need, because health prob-
lems are more frequent and more severe among lower
socio-economic groups. The adjustment for need provides
a better measure of inequity.
Figure 6.4.1 shows the degree of inequities for the probabil-
ity of a doctor visit in the past year in 17 OECD countries
and Brazil through the horizontal inequity index. If this
index is greater than zero, then high income groups access
doctors more than low income groups, after adjusting for
relative need. Doctor visits were more likely among higher
income persons in 15 out of 18 countries, although in most
countries the degree of inequity is low. This is not the case
in the United States, Brazil, Chile and Mexico, where richer
people are significantly more likely to visit doctors.
In many countries, there are significant differences in the
probability of GP and specialist visits. While the probability
of a GP visit tends to be equally distributed in most coun-
tries, a different pattern emerges for specialist visits. In
nearly all countries, higher income people are more likely
to see a specialist than those with low income, and also
more frequently. The only exceptions were the United
Kingdom, the Czech Republic and Slovenia, where there
was no statistically significant difference (Devaux and de
Looper, 2012).
Consistent with these findings, an earlier European study
found that people with higher education tend to use
specialist care more, and the same was true for GP use in
several countries (France, Portugal and Hungary) (Or et al.,
2008). The study suggests that, beyond the direct cost of
care, other health system characteristics are important in
reducing social inequalities in health care utilisation, such
as the role given to the GP and the organisation of primary
care. Social inequalities in specialist use are less in coun-
tries with a National Health System and where GPs act as
gatekeepers. Countries with established primary care net-
works may place greater emphasis on deprived popula-
tions, and gatekeeping often provides simpler access and
better guidance for people in lower socio-economic posi-
tions (Or et al., 2008).
Unmet health care needs, as reported in population-based
health surveys, is another way of assessing any access
problems for certain population groups. A European-wide
survey, conducted on an annual basis, provides informa-
tion on the proportion of people reporting having some
unmet needs for medical examination for different rea-
sons. In all countries, people with low incomes are more
likely to report unmet care needs than people with high
incomes (Figure 6.4.2). The gap was particularly large in
Hungary, Italy and Greece. The most common reason
reported by low income people for unmet needs formedical
examination is cost. In contrast, high income people report
that their unmet care needs are due to a lack of time and a
willingness to wait and see if the problem would simply go
away.
It is important to consider self-reported unmet care needs
in conjunction with other indicators of potential barriers to
access, such as the extent of health insurance coverage and
the amount of out-of-pocket payments. Germany, for
example, reports above average levels of unmet care needs,
yet it has full insurance coverage, low out-of-pocket pay-
ments, and a high density of doctors (Indicators 6.1, 6.2
and 3.1).
Definition and comparability
Consultations with doctors refer to the probability of
visiting a doctor in the past 12 months, including both
generalists and specialists. Data for Brazil, Chile and
Mexico come from different studies. They relate to
the probability of a doctor visit in the past three
months in Chile and the past two weeks in Mexico.
Estimates of the horizontal inequity indices are
derived from health interview or household surveys
conducted around 2009. Inequalities in doctor consul-
tations are assessed in terms of household income.
The probability of doctor visits is adjusted for need,
based on self-reported information about health
status.
Differing survey questions and response categories
may affect cross-national comparisons, and the mea-
sures used to grade income can also vary.
Data on unmet health care needs come from the
European Union Statistics on Income and Living Con-
ditions survey (EU-SILC). Survey respondents are
asked whether there was a time in the previous
12 months when they felt they needed a medical
examination but did not receive it, followed by a
question as to why the need for care was unmet. The
reasons include that care was too expensive, the wait-
ing time was too long, the travelling distance to
receive care was too far, a lack of time, or that they
wanted to wait and see if the problem got better on its
own. Figures presented here cover unmet care needs
for any reason. Cultural factors, public expectations
and policy debates may affect attitudes to unmet
care. Caution is needed in comparing the results
across countries.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013144
6. ACCESS TO CARE
6.4. Inequalities in doctor consultations6.4.1. Horizontal inequity indices for probability of a doctor visit in the past 12 months (with 95% confidence interval),
selected OECD countries, 2009 (or nearest year)
Note: The probability of a doctor, GP or specialist visit is inequitable if the horizontal inequity index is significantly different from zero. It favours high
income groups when it is above zero. The index is adjusted for need.
1. Any physician visits in the past thee months in Chile and in the past two weeks in Mexico.
Source: Devaux and de Looper (2012); Almeida et al. (2013); Vasquez et al. (2013); Barraza-Lloréns et al. (2013).
1 2 http://dx.doi.org/10.1787/888932918624
6.4.2. Unmet care needs for medical examination by income level, European countries, 2011
Source: EU-SILC 2011.
1 2 http://dx.doi.org/10.1787/888932918643
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6. ACCESS TO CARE6.5. Inequalities in dentist consultationsProblems in access to dentists persist in many countries,
most commonly among disadvantaged and low income
groups. For example, in the United States, over 40% of low
income persons aged 20-64 years had untreated dental car-
ies in 2005-08, compared with only 16% of high income per-
sons (NCHS, 2011).
Oral health care is mostly provided by private dental prac-
titioners. Treatment is costly, averaging 5% of total health
expenditure across OECD countries, with most of the
spending paid for privately in many countries. On average
across OECD countries, out-of-pocket payment for dental
care represented 55% of total dental care expenditure in
2011, ranging from 18% in the Netherlands to 97% in Spain
(Figure 6.5.1). In countries such as Spain, Israel and
Switzerland, adult dental care is generally not part of the
basic package of public health insurance, although some
care may be provided for certain population groups. In
most other countries, prevention and treatment are
covered, but a significant share of the costs is borne by
patients, and this may create access problems for low-
income groups.
Recent OECD findings show that high income persons were
more likely to visit a dentist within the last 12 months than
low income persons (Figure 6.5.2). Inequalities are larger in
countries with a lower probability of a dental visit such as
Hungary, Poland, and the United States. Denmark and
France have different recall periods, which affect the aver-
age probability of a dental visit but not the level of inequal-
ity. Both countries are among the most equitable for the
probability of a dental visit, although the share of out-of-
pocket payments in Denmark is much greater than in
France.
There are also differences in the types of dental care received
across different socio-economic groups. A Canadian study
showed that access to preventive care is more common
among higher income persons (Grignon et al., 2010).
Income-related inequalities in dental service utilisation
have also been found among Europeans aged 50 years and
over, mostly due to inequalities in preventive dental visits
(Listl, 2011).
A significant proportion of the population in different
countries reports some unmet needs for dental care.
Iceland (13.7%), Italy (11.5%) and Portugal (11.4%) reported
the highest rates among EU countries in 2011, according to
the European Union “Statistics on Income and Living Con-
ditions survey” (Figure 6.5.3). In these three countries, there
were large inequalities in unmet dental care needs
between high and low income groups. On average across
those European countries covered under this survey,
slightly more than 10% of low income people reported
having some unmet care needs for dental care, compared
with 3.4% for high income people. The most common rea-
son reported by low income people for unmet needs for
dental care was cost (for 68% of respondents), followed by
fear of dentists (9%). A much lower proportion of high
income people reported that their unmet needs for dental
care was due to cost (30%), while a higher share responded
that this was due to a lack of time (17%), fear (15%) or wait-
ing times to get an appointment (13%).
Strategies to improve access to dental care for disadvan-
taged or underserved populations need to include both
reducing financial and non-financial barriers, as well as
promoting an adequate supply of dentists and other dental
care practitioners to respond to the demand.
Definition and comparability
Data on the probability of a dentist visit come from
health interview or household surveys, and rely on
self-report. Inequalities in dental consultations are
here assessed in terms of household income.
Differing survey questions and response categories
may affect cross-national comparisons, and the mea-
sures used to grade income level can also vary. Most
countries refer to dental consultations during the
past 12 months, except for France (past 24 months)
and Denmark (past three months). The difference in
recall periods is likely to have an impact on the aver-
age probability of dentist visits, but not on the level of
inequality.
Data on unmet health care needs come from the
European Union Statistics on Income and Living
Conditions survey (EU-SILC). No single survey or
study on unmet care needs has been conducted
across all OECD countries. To determine unmet dental
care, EU-SILC asks whether there was a time in the
previous 12 months when people felt they needed
dental examinations but did not receive them.
Cultural factors and policy debates may affect atti-
tudes to unmet care. Caution is needed in comparing
the magnitude of inequalities in unmet dental care
needs across countries.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013146
6. ACCESS TO CARE
6.5. Inequalities in dentist consultations6.5.1. Out-of-pocket dental expenditure, 2011
(or nearest year)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932918662
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1. Visits in the past two years.
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Source: Devaux and de Looper (2012).
1 2 http://dx.doi.org/10.1787/888932918681
0 20 40 60 80 100
%
France1
Czech Rep.
United Kingdom
Slovak Rep.
Canada
Austria
Finland
Belgium
Slovenia
New Zealand
Estonia
Spain
United States
Poland
Hungary
Denmark2
Low income High incomeAverage
6.5.3. Unmet need for a dental examination, by income quintile, European countries, 2011
Source: EU-SILC 2011.
1 2 http://dx.doi.org/10.1787/888932918700
%
0
5
10
15
20
Highest income National average Lowest income
Ice
lan
d
Ita
ly
Po
rtu
ga
l
Po
lan
d
Sw
ed
en
Es
ton
ia
Gr
ee
ce
Fra
nc
e
OE
CD
24
No
rw
ay
Hu
ng
ary
Sp
ain
Ire
lan
d
Sw
itz
erl
an
d
Be
lgi
um
Fin
lan
d
De
nm
ark
Cz
ec
h R
ep
.
Au
str
ia
Slo
va
k R
ep
.
Ge
rm
an
y
Lu
xe
mb
ou
rg
Un
ite
d K
ing
do
m
Ne
the
rla
nd
s
Slo
ve
niaHEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013 147
6. ACCESS TO CARE6.6. Inequalities in cancer screeningCancer is the secondmost common cause of death in OECD
countries, responsible for 26% of all deaths in 2011. The
early detection of breast, cervical, and colorectal cancers
through screening programmes has contributed to
increased survival rates over the past five years (see
Indicators 5.9 to 5.11), and many countries have opted to
make screening widely available. In most countries, more
than half of women in the target age groups have had a
recent mammogram, and a pelvic exam or Pap smear (see
Indicators 5.9 and 5.10).
Screening rates vary widely by education and socio-economic
groups in OECD countries. Even in those countries where
the practice is common, women in lower income groups
are generally less likely to undergo breast and cervical
screening (Figures 6.6.1 and 6.6.2). Income-related inequal-
ities in cervical cancer screening are significant in 15 of the
16 countries studied. However, pro-rich inequalities in
breast cancer screening are significant in fewer countries
(Belgium, Canada, Estonia, France, New Zealand, Poland
and the United States).
In the United States, low-income women, women who are
uninsured or receiving Medicaid (health insurance cover-
age for the poor, disabled or impoverished elderly) or
women with lower educational levels report much lower
use of mammography and Pap smears (NCHS, 2011). There
is additional evidence in European countries for significant
social inequalities in utilisation of early detection and pre-
vention services (von Wagner et al., 2011). In particular,
women in higher socio-economic groups are more likely to
havemammograms (Sirven and Or, 2010). However, in most
OECD countries, income should not be a barrier to access-
ing screening mammography or Pap smears, since the ser-
vices are provided free of charge, or at the cost of a doctor
consultation.
Rates of colorectal cancer screening for people aged 50-75
vary by education level (Figure 6.6.3). On average across
ten European countries, 22% of people with high education
level have once participated in colorectal cancer screening
whereas this proportion goes down to 14% for people with
low education. These inequalities are particularly large in
the Czech Republic, although the screening rates for people
with low education is higher than the screening rates for
people with high education in most other countries. The
gap is much smaller in France. Rates of colorectal cancer
screening vary across countries, with the highest rates in
the Czech Republic and France. The Czech Republic and
France completed nationwide rollout of colorectal cancer
screening earlier than other countries (OECD, 2013e).
The utilisation of cancer screening services may largely
depend on the availability of national public screening pro-
grammes. For instance, findings in Europe highlight that
inequalities are larger in countries without population-
based screening programmes (Palència et al., 2010). In addi-
tion, a number of demographic and socio-economic char-
acteristics – such as income, ethnicity, younger age, higher
level of education, employment status – as well as having a
usual source of care are all important predictors of partici-
pation in screening.
Given the variety of factors affecting the use of different
cancer screening, no single action can be expected to over-
come the barriers for all population groups (Gakidou et al.,
2008). In countries with sufficient health system capacity,
increased screening can be encouraged by ensuring ser-
vices are free and available where needed. Some policy
interventions may also need to be better targeted in order
to overcome inequalities. As a complementary tool, the
promise of new cancer preventing vaccines also has impor-
tant implications for resource-poor settings where main-
taining screening programmes is challenging.
Definition and comparability
Breast and cervical screening rates measure the pro-
portion of women of a given age who have received a
recent mammogram, breast exam, pap smear or pel-
vic exam. Rates by income group were derived from
national health surveys. For cervical cancer, women
aged 20-69 years were asked whether they had been
screened in the three years prior to the survey, and for
breast cancer, women aged 50-69 years in the past
two years. The exceptions were Mexico and Denmark
(for breast only), where screening was reported for the
past 12 months. Screening estimates based on self-
reported health surveys should be used cautiously,
since respondents tend to overestimate desirable
behaviours.
Rates of colorectal cancer screening by education
level were derived from the European Health Inter-
view Survey (carried out in some EU countries
between 2006 and 2009). Screening rate was collected
for people aged 50-75, based on the following ques-
tion: “Have you ever had a faecal occult blood test
(FOBT)?”. However, in some countries, other types of
tests (e.g. colonoscopy, flexible sigmoidoscopy) may
be used (see Indicator 5.11).HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013148
6. ACCESS TO CARE
6.6. Inequalities in cancer screening6.6.1. Cervical cancer screening in past three years
by income level, selected OECD countries, 2009
(or nearest year)
Note: The data source for some countries may be different to that used
for reporting breast and cervical cancer screening in Chapter 5.
1. Visits in the past 12 months.
Source: Devaux and de Looper (2012).
1 2 http://dx.doi.org/10.1787/888932918719
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6.6.2. Breast cancer screening in past two years by income
level, selected OECD countries, 2009
(or nearest year)
Note: The data source for some countries may be different to that used
for reporting breast and cervical cancer screening in Chapter 5.
1. Visits in the past 12 months.
Source: Devaux and de Looper (2012).
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6.6.3. Colorectal cancer screening once in lifetime by educational level, European countries, 2009 (or nearest year)
Source: Eurostat Statistics Database 2013.
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6. ACCESS TO CARE6.7. Waiting times for elective surgeryLong waiting times for health services is an important
health policy issue in many OECD countries (Siciliani et al.,
2013). Long waiting times for elective (non-emergency) sur-
gery, such as cataract surgery, hip and knee replacement,
generates dissatisfaction for patients because the expected
benefits of treatments are postponed, and the pain and dis-
ability remains. While long waiting times is considered an
important policy issue in many countries, this is not the
case in others (e.g., Belgium, France, Germany, Japan,
Korea, Luxembourg, Switzerland, United States).
Waiting times is the result of a complex interaction
between the demand and supply of health services, where
doctors play a critical role on both sides. The demand for
health services in general and elective surgery specifically
is determined by the health status of the population, prog-
ress in medical technologies (including the increase ease of
many procedures like cataract which can now be per-
formed as day surgery), patient preferences (including their
weighting of the expected benefits and risks), and the
extent of cost-sharing for patients. However, doctors play a
crucial role in converting the demand for better health
from patients in a demand for medical care. On the supply
side, the availability of different categories of surgeons,
anaesthesists and other staff involved in surgical proce-
dures, as well as the supply of the required medical and
hospital equipment is likely to influence surgical activity
rates.
Themeasure presented here focuses on waiting times from
the time that a medical specialist adds a patient to the
waiting list to the time that the patient receives the treat-
ment. Both the average waiting time and the median are
presented. Because some patients wait for very long times,
the average is usually greater than the median.
In 2012, the average waiting times for cataract surgery was
just over 30 days in the Netherlands, but more than three-
times higher in Finland and Spain (Figure 6.7.1). Within the
United Kingdom (in England), the average waiting times for
cataract surgery was slightly over 60 days in 2011 (latest
year available).Waiting times for cataract surgery has come
down over the past few years in some countries, but not all.
In Portugal and Spain, waiting times fell significantly
between 2006 and 2010, but has increased since 2010. In the
United Kingdom (England), waiting times for cataract sur-
gery came down between 2006 and 2008, but has gone up
slightly since then.
In 2012, the average waiting times for hip replacement was
about 40 days in the Netherlands, but above 120 days in
Spain, Portugal and Finland (Figure 6.7.2). Themedian wait-
ing times was between 80 to 90 days in the United Kingdom
(England) and Canada, but above 100 days in Estonia,
Australia, Finland and Portugal. As was the case for cata-
ract surgery, waiting times for hip replacement fell sharply
in the United Kingdom (England) between 2006 and 2008,
but has gone up slightly since then. Similarly, following sig-
nificant reduction between 2006 and 2010, waiting times
for hip replacement in Portugal and Spain has increased
since 2010. It has also increased slightly in Canada, and
more so in New Zealand.
Waiting times for knee replacement has come down over
the past few years in the Netherlands, Finland and Estonia,
although it remains very long in Estonia (Figure 6.7.3). In
the United Kingdom (England), it fell between 2006 and
2008, but has risen slightly since then. In Canada, New
Zealand and Australia, waiting times for knee replacement
has also increased at least slightly between 2008 and 2012.
Over the past decade, waiting time guarantees have
become themost common policy tool to tackle long waiting
times in several countries. This has been the case for
instance in Finland where a National Health Care Guaran-
tee was introduced in 2005 and led to a reduction in waiting
times for elective surgery (Jonsson et al., 2013). However,
these guarantees are only effective if they are enforced.
There are two main approaches to enforcement: setting
waiting time targets and holding providers accountable for
achieving these targets; or allowing patients to choose
alternative health providers (including the private sector) if
they have to wait beyond a maximum amount of time
(Siciliani et al., 2013).
Definition and comparability
There are at least two ways of measuring waiting
times for elective procedures: 1) measuring the wait-
ing times for patients treated in a given period; or
2) measuring waiting times for patients still on the
list at a point in time. The data reported here relate to
the first measure (data on the second measure are
available in the OECD health database). The data
come from administrative databases (not surveys).
Waiting times are reported both in terms of the aver-
age and the median. The median is the value which
separates a distribution in two equal parts (meaning
that half the patients have longer waiting times and
the other half lower waiting times). Compared with
the average, the median minimises the influence of
outliers (patients with very long waiting times). The
data for the United Kingdom relate only to England.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013150
6. ACCESS TO CARE
6.7. Waiting times for elective surgery6.7.1. Cataract surgery, waiting times from specialist assessment to treatment, 2006 to 2012 (or 2011)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en. 1 2 http://dx.doi.org/10.1787/888932918776
6.7.2. Hip replacement, waiting times from specialist assessment to treatment, 2006 to 2012 (or 2011)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en. 1 2 http://dx.doi.org/10.1787/888932918795
6.7.3. Knee replacement, waiting times from specialist assessment to treatment, 2006 to 2012 (or 2011)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en. 1 2 http://dx.doi.org/10.1787/888932918814
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7. HEALTH EXPENDITURE AND FINANCING7.1. Health expenditure per capitaHow much OECD countries spend on health and the rate at
which it grows reflects a wide array of market and social
factors, as well as countries’ diverse financing and organ-
isational structures of their health systems.
In 2011, the United States continued to outspend all other
OECD countries by a wide margin, with the equivalent of
USD 8 508 for each person (Figure 7.1.1). This level of health
spending is two-and-a-half times the average of all OECD
countries and 50% higher than Norway and Switzerland,
which were the next biggest spending countries. Compared
with large European economies such as France and
Germany, the United States spends around twice as much
on health care per person. Around half of OECD countries
fall within a per capita spending of between USD 3 000 and
USD 4 500 (adjusted for countries’ different purchasing
powers – see Definition and Comparability). Countries
spending below USD 3 000 include most of the southern
and central European members of the OECD, together with
Korea and Chile. The lowest per capita spenders on health
in the OECD were Mexico and Turkey with levels of less
than a third of the OECD average. Outside of the OECD,
among the key emerging economies, China and India spent
13% and 4% of the OECD average on health per capita in
2011.
Figure 7.1.1 also shows the breakdown of per capita spend-
ing on health into public and private sources (see also
Indicator 7.6 “Financing of health care”). In general, the
ranking according to per capita public expenditure remains
comparable to that of total spending. Even if the private
sector in the United States continues to play the dominant
role in financing, public spending on health per capita is
still greater than that in all other OECD countries, with the
exception of Norway and the Netherlands.
Since 2009, health spending has slowed markedly or fallen
in many OECD countries after years of continuous growth.
However, health spending patterns across the 34 OECD
countries have been affected to varying degrees. On aver-
age across the OECD, per capita health spending over the
period 2000-09 is estimated to have grown, in real terms, by
4.1% annually (Figure 7.1.2). In stark contrast, over the sub-
sequent two years (2009-11), average health spending
across the OECD grew at only 0.2% as the effects of the eco-
nomic crisis took hold.
The extent of the slowdown has varied considerably across
the OECD. While a number of European countries have
experienced drastic cuts in spending, other countries out-
side of Europe have continued to see health spending grow
albeit in many cases at a reduced pace.
Some of the European countries hardest hit by the eco-
nomic downturn saw dramatic reversals in health spend-
ing compared with the period before the crisis. Greece, for
example, saw per capita health spending falling by 11% in
2010 and 2011 after a yearly growth rate of more than 5%
between 2000 and 2009. Ireland and Estonia also suffered
significant falls in per capita health spending after previ-
ously strong growth.
Away from Europe, health spending growth also slowed sig-
nificantly in most countries between 2009 and 2011, nota-
bly in Canada (0.8%) and the United States (1.3%). Only two
OECD countries – Israel and Japan – saw the rate of health
spending growth accelerate since 2009 compared with the
period before. Health spending in Korea has continued to
grow at more than 6% per year since 2009, albeit at a slower
rate than in previous years.
Definition and comparability
Total expenditure on health measures the final con-
sumption of health goods and services (i.e. current
health expenditure) plus capital investment in health
care infrastructure. This includes spending by both
public and private sources on medical services and
goods, public health and prevention programmes and
administration.
To compare spending levels between countries, per
capita health expenditures are converted to a com-
mon currency (US dollar) and adjusted to take
account of the different purchasing power of the
national currencies, in order to compare spending
levels. Economy-wide (GDP) PPPs are used as themost
available and reliable conversion rates.
To compare spending over time, figures are deflated
using the economy-wide GDP implicit deflator for
each country. In the case of Chile, the Consumer Price
Index (CPI) is preferred since it is considered more
representative of price changes in the health sector in
recent years.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013154
7. HEALTH EXPENDITURE AND FINANCING
7.1. Health expenditure per capita7.1.1. Health expenditure per capita, 2011 (or nearest year)
1. In the Netherlands, it is not possible to clearly distinguish the public and private share related to investments.
2. Current health expenditure.
3. Data refers to 2010.
4. Data refers to 2008.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en; WHO Global Health Expenditure Database.
1 2 http://dx.doi.org/10.1787/888932918833
7.1.2. Annual average growth rate in per capita health expenditure, real terms, 2000 to 2011 (or nearest year)
1. CPI used as deflator.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932918852
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7. HEALTH EXPENDITURE AND FINANCING7.2. Health expenditure in relation to GDPChanges in the health spending to GDP ratio are the result
of both fluctuations in the rate of health spending as well
as growth in the economy as a whole. The economic crisis
that began in 2008 ended a long period during which health
spending had grown faster than GDP in many OECD coun-
tries. This has resulted in very different trends in the
health-spending-to-GDP ratio across OECD countries.
Health spending accounted for 9.3% of GDP on average
across OECD countries in 2011, compared with 9.4% in 2010
(Figure 7.2.1). Excluding capital spending, current expendi-
ture on health as a share of GDP dropped from 9.1% on
average in 2010 to 8.9% in 2011. The health spending to GDP
ratio reached a peak in 2009 (9.6% total expenditure and
9.2% current expenditure) as overall economic conditions
rapidly deteriorated but health spending continued to grow
or was maintained in many countries. In the subsequent
context of reducing public deficits and falling incomes, the
reductions in (public) spending on health have resulted in
the share of GDP falling since 2009.
In 2011, the United States spent 17.7% (17.0% for current
expenditure on health) of GDP on health, remaining well
above the OECD average and around six percentage points
above the next group of countries, which include the
Netherlands, France, Germany, Canada and Switzerland.
The health spending to GDP ratio in the United States has
remained at the same level since 2009, after years of con-
tinuous increases. It is not clear yet whether this levelling-
off reflects cyclical factors andmay start to grow again once
the economy picks up, or whether it reflects more struc-
tural changes such as a slower diffusion of new technolo-
gies and pharmaceuticals, and changes in provider
payments resulting in greater efficiency. Of the OECD coun-
tries, Mexico, Turkey and Estonia devoted only around 6%
of GDP to health – around two-thirds of the OECD average.
Outside of the OECD, China and India spent 5.2% and 3.9%
of GDP respectively in 2011, while Brazil devoted 8.9% of
GDP to health – close to the OECD average.
During the pre-crisis period up to 2009, all OECD countries
saw health spending outpace economic growth resulting in
an increasing share of GDP allocated to health (Figures 7.2.2
and 7.2.3). Average annual growth in health spending in
real terms between 2000 and 2009 was 4.1% compared to
GDP growth of only 1.5%. For example, Ireland saw health
spending grow much more rapidly than the rate of eco-
nomic growth during this period, resulting in the share of
GDP rising from just over 6% in 2000 to 10% by 2009. France
also, where economic growth in this period was more slug-
gish, continued to see a trend increase in the health share
to GDP ratio between 2000 and 2009.
In 2009, health spending as a share of GDP jumped in many
OECD countries as overall economic conditions deterio-
rated while health spending was essentially maintained in
many countries. Since then, OECD countries have typically
seen their share of health spending to GDP stabilise or fall.
Some European countries, such as Estonia, Greece and
Ireland saw health spending growth decline much more
than GDP, resulting in a rapidly decreasing health spending
to GDP ratio.
Away from Europe, Japan has continued to see its ratio to
GDP grow such that by 2010 (latest figure available), the
health spending to GDP ratio in Japan climbed above the
OECD average for the first time. In Canada, after a sharp
increase in 2009, the share of GDP devoted to health
remained stable in 2010 and declined slightly in 2011.
Definition and comparability
See Indicator 7.1 “Health expenditure per capita” for a
definition of total and current expenditure on health.
Gross Domestic Product (GDP) = final consumption +
gross capital formation + net exports. Final consump-
tion of households includes goods and services used
by households or the community to satisfy their indi-
vidual needs. It includes final consumption expendi-
ture of households, general government and non-
profit institutions serving households.
In countries such as Ireland and Luxembourg, where
a significant proportion of GDP refers to profits
exported and not available for national consumption,
GNI may be a more meaningful measure than GDP.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013156
7. HEALTH EXPENDITURE AND FINANCING
7.2. Health expenditure in relation to GDP7.2.1. Health expenditure as a share of GDP, 2011 (or nearest year)
1. Total expenditure only.
2. Data refers to 2010.
3. Data refers to 2008.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en; WHO Global Health Expenditure Database.
1 2 http://dx.doi.org/10.1787/888932918871
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7. HEALTH EXPENDITURE AND FINANCING7.3. Health expenditure by functionSpending on inpatient care and outpatient care combined
accounts for a large proportion of health expenditure
across OECD countries – around 62% of current health
expenditure on average in 2011 (Figure 7.3.1). A further 20%
of health spending was allocated to medical goods (mainly
pharmaceuticals, which accounted for 17% of total health
spending), 12% on long-term care and the remaining 6% on
collective services, such as public health and prevention
services and administration.
Spending on inpatient care (including day care in hospitals)
was the biggest costing component for a number of coun-
tries, including France and Greece where it accounted for
37% of total spending.While the United States consistently
reports the highest share of outpatient care (and by conse-
quence the lowest inpatient share), it should be noted that
this figure includes remunerations of physicians who inde-
pendently bill patients for hospital care. Other countries
with a high share of outpatient spending include Israel and
Portugal (48% and 45%).
The other major category of health spending is medical
goods. In the Slovak Republic and Hungary, medical goods
represent the largest spending category at 38% and 37% of
current health expenditure respectively. In Denmark, New
Zealand, Norway and Switzerland, on the other hand,
spending on medical goods represents only 11% of total
health spending. Differences in the consumption pattern of
pharmaceuticals and relative prices are some of the main
factors explaining the variations between countries.
There are also differences between countries in their
expenditure on long-term care (see Indicator 8.9). Coun-
tries such as Norway, Denmark and the Netherlands, which
have established formal arrangements for the elderly and
the dependent population, allocate more than 20% of cur-
rent health spending to long-term care. In countries with
less comprehensive formal long-term care services such as
Portugal, the expenditure on long-term care accounts for a
much smaller share of total spending.
The slowdown in health spending experienced in many
OECD countries in recent years has affected all spending
categories, but to varying degrees (Figure 7.3.2). In more
than half of OECD countries, total pharmaceutical spend-
ing fell in 2011 (see also Indicator 7.4). Many OECD coun-
tries have reduced their spending on prevention and public
health services, with the reduction averaging 1.5% in 2010
and 1.7% in 2011 across all OECD countries. Whereas the
decrease in 2010 can to some extent be explained by the
H1N1 influenza pandemic in 2009 which led to significant
one-off expenditures for the purchase of large stocks of
vaccines in many countries, the reduction in 2011 is mainly
due to more general cuts to public health budgets. Expendi-
ture growth for administration also slowed down. It was
negative in 2010 and went up slightly in 2011, but the
growth rate was lower than in 2008 and 2009. Cuts in
administrative budgets were frequently an initial response
to the financial crisis in many countries, such as in the
Czech Republic where the budget of the Ministry of Health
was reduced by 30% between 2008 and 2010.
Although remaining positive, growth rates for inpatient
care, outpatient care and long-term care spending
decreased significantly in 2010 and 2011 compared to 2008
and 2009. Many governments introduced measures to curb
public spending on these health care functions, such as
cuts in salaries of health workers and the reduction of
health workforce, reductions in the fees to health providers
and increases in co-payments for patients to ease mount-
ing budget pressures (Morgan and Astolfi, 2013).
Definition and comparability
The System of Health Accounts (OECD, 2000; OECD,
Eurostat, WHO, 2011) defines the boundaries of the
health care system. Current health expenditure com-
prises personal health care (curative care, rehabilita-
tive care, long-term care, ancillary services and
medical goods) and collective services (prevention
and public health services as well as health adminis-
tration). Curative, rehabilitative and long-term care
can also be classified by mode of production (inpa-
tient, day care, outpatient and home care). Concern-
ing long-term care, only the health aspect is normally
reported as health expenditure, although it is difficult
in certain countries to separate out clearly the health
and social aspects of long-term care. Some countries
with comprehensive long-term care packages focus-
ing on social care might be ranked surprisingly low
based on SHA data because of the exclusion of their
social care. Thus, estimations of long-term care
expenditure are one of the main factors limiting com-
parability across countries.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013158
7. HEALTH EXPENDITURE AND FINANCING
7.3. Health expenditure by function7.3.1. Current health expenditure by function of health care, 2011 (or nearest year)
Note: Countries are ranked by curative-rehabilitative care as a share of current expenditure on health.
* Refers to curative-rehabilitative care in inpatient and day care settings.
** Includes home-care and ancillary services.
1. Inpatient services provided by independent billing physicians are included in outpatient care for the United States.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932918928
7.3.2. Average annual growth rates of health spending for selected functions, in real terms, OECD average, 2008 to 2011
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932918947
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7. HEALTH EXPENDITURE AND FINANCING7.4. Pharmaceutical expenditureSpending on pharmaceuticals accounted for more than a
sixth (17%) of all health expenditure on average across
OECD countries in 2011, making it the third largest spend-
ing component after inpatient and outpatient care.
The total pharmaceutical bill across OECD countries was
around USD 800 billion in 2011. However, there are wide
variations in pharmaceutical spending per capita across
countries, reflecting differences in volume, structure of
consumption and pharmaceutical prices (Figure 7.4.1, left
panel). At almost USD 1 000 in 2011, the United States
spent far more on pharmaceuticals than any other OECD
country on a per capita basis. Canada (USD 701) and Greece
(USD 673) also spent significantly more on medicines than
the OECD average. At the other end of the scale, Chile and
Mexico had relatively low spending levels.
Pharmaceutical spending accounted for 1.5% of GDP on
average across OECD countries with around 0.8% of GDP
financed publicly and the rest from private sources. Across
OECD countries, the share of pharmaceutical spending in
GDP ranges from less than 1% in Luxembourg, Norway,
Denmark and Chile, to more than 2.5% in Hungary and
Greece (Figure 7.4.1, right panel).
The economic crisis has had a significant effect on the
growth in pharmaceutical spending in many OECD coun-
tries (Figure 7.4.2). Between 2000 and 2009, annual pharma-
ceutical expenditure per capita grew by 3.5% in real terms
on average in OECD countries, but in the two years since
2009, the average growth became negative (-0.9%). Annual
growth rates in pharmaceutical spending were lower
between 2009 and 2011 than in the 2000-09 period in all
OECD countries, apart from Chile and Australia. The reduc-
tion was particularly steep in those countries that were hit
hardest by the recession. In Greece, pharmaceutical spend-
ing per capita decreased by 10% in both 2010 and 2011,
following high growth rates in the preceding years. Estonia
(-7.2%), Portugal (-5.9%), Iceland (-4.7%) and Ireland (-4.4%)
also experienced substantial reductions in pharmaceutical
spending between 2009 and 2011. In some of the larger
OECD economies, spending growth per capita was also neg-
ative: annual growth rates decreased on average in Ger-
many (-0.7%), France (-0.6%), the United States (-0.5%) and
Canada (-0.3%) between 2009 and 2011.
OECD countries have introduced a series of measures to
reduce pharmaceutical spending, including: price cuts
(achieved through negotiations with pharmaceutical man-
ufacturers, introduction of reference pricing, application of
compulsory rebates, decrease of pharmacy margins, reduc-
tions of the value added tax applicable for pharmaceuti-
cals), centralized public procurement of pharmaceuticals,
promoting the use of generics, reduction in coverage
(excluding pharmaceuticals from reimbursement) and
increases in co-payments by households.
For example, Spain introduced a general rebate applicable
for all medicines prescribed by NHS physicians in 2010. In
addition, it mandated price reductions for generics which
is one of the factors explaining the growth in the consump-
tion of generics in that country (see Indicator 4.11). In
Germany, compulsory rebates for manufacturers were
raised in 2011 and prices frozen until 2013. From 2011 on,
pharmaceutical companies were also mandated to enter
into reimbursement price negotiations based on benefit
evidence with the national association of health insurance
funds for innovative drugs, which put an end to the previ-
ous free-pricing regime. In the United States, the Medicaid
drug rebate percentage was increased and an annual fee
imposed on manufacturers and importers of branded phar-
maceuticals (OECD, 2010b). In Canada, the spending halt
was due partly to patent expirations of brand name drugs
for cholesterol and hypertension and the reduction of
generic prices in many provinces (CIHI, 2012).
Definition and comparability
Pharmaceutical expenditure covers spending on pre-
scription medicines and self-medication, often
referred to as over-the-counter products, as well as
other medical non-durable goods. It also includes
pharmacists’ remuneration when the latter is sepa-
rate from the price of medicines. Pharmaceuticals
consumed in hospitals are excluded (data available
suggests that their inclusion would add another 15%
to pharmaceutical spending approximately). Final
expenditure on pharmaceuticals includes wholesale
and retail margins and value-added tax.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013160
7. HEALTH EXPENDITURE AND FINANCING
7.4. Pharmaceutical expenditure7.4.1. Expenditure on pharmaceuticals per capita and as a share of GDP, 2011 (or nearest year)
1. Includes medical non-durables.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en. 1 2 http://dx.doi.org/10.1787/888932918966
7.4.2. Average annual growth in pharmaceutical expenditure per capita, in real terms, 2000 to 2011 (or nearest year)
1. CPI used as deflator.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en. 1 2 http://dx.doi.org/10.1787/888932918985
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7. HEALTH EXPENDITURE AND FINANCING7.5. Expenditure by disease and ageAttributing health care expenditure by disease and age is
important for health policy makers in order to analyse
resource allocations in the health care system. This infor-
mation can also play a role in assessing the recent and pos-
sible future impact of ageing populations and changing
disease patterns on spending. Furthermore, the linking of
health expenditure by disease to appropriate measures of
outputs (e.g. hospital discharges by disease) and outcomes
(e.g. survival rates after heart attack or cancer) helps in
monitoring the performance of health care systems at a
disease-based level (Heijink et al., 2006).
Figure 7.5.1 shows the distribution of hospital acute inpa-
tient expenditure according to six main diagnostic catego-
ries. These categories account for between 51% and 73% of
all acute inpatient care expenditure in this group of coun-
tries. Circulatory diseases account for the highest share of
inpatient spending in each of the countries except for
Korea and the Netherlands, where spending on cancer and
mental and behavioural disorders is the largest category,
respectively. The differences between countries can be
influenced by a number of factors, including demographic
structure and disease patterns, as well as institutional
arrangements and clinical guidelines for treating different
diseases. Japan allocates more than 22% of hospital inpa-
tient expenditure to the treatment of circulatory diseases,
which is somewhat surprising given that discharges related
to circulatory diseases only account for 12% of all dis-
charges – a proportion similar to other countries. The high
share of expenditure allocated to circulatory diseases may
be explained by longer than average lengths of stay in
Japan, particularly for some specific circulatory diseases such
as cerebrovascular disease (stroke). In the Netherlands, men-
tal and behavioral disorders account for 19% of all inpatient
spending – around twice the level of the other countries
shown. This may be partly explained by the large number
of acute mental health hospitals with very long average
lengths of stay.
Figure 7.5.2 compares expenditure per hospital discharge
for circulatory diseases and cancer. Generally, the cost per
discharge between these two main disease categories is
similar in all countries, apart from Japan where spending
per discharge for circulatory diseases is more than twice
that of cancer. Japan also has the highest expenditure per
discharge compared to the other countries, again likely due
to the much longer lengths of stay, while Australia and the
Netherlands have the highest expenditure per discharge
for cancer treatment.
The different cost patterns may also be due partly to demo-
graphic factors. Figure 7.5.3 shows the share of hospital
spending for people aged 65 and over compared with the
share of the population aged 65 and over. As expected, this
age group consumes proportionally more hospital
resources compared to their share of the population. Japan
allocates the greatest share of hospital expenditure to peo-
ple aged 65 and over (64%), associated with the fact that it
also has the highest share of people in that age group (23%).
By contrast, Israel, Korea, and the Netherlands allocate
only a third of all expenditure to those aged 65 and over,
reflecting, at least partly, the fact that the proportion of the
population in this age-group in these countries is only
between 10% and 15%.
Definition and comparability
Expenditure by disease and age allocates current
health expenditure by patient characteristics. Disease
categories are based on ICD-10.To ensure comparabil-
ity between countries, expenditures are linked to the
System of Health Accounts (SHA) framework and a
common methodology is proposed advocating pri-
marily a top-down allocation of expenditure based on
principal diagnosis.
Themain comparability issues relate to the treatment
of non-allocated and non-disease-specific expendi-
ture. In the former case this is due to data limitations
(often in outpatient and pharmaceutical expenditure)
and in the latter case mainly prevention and adminis-
tration expenditure. For more meaningful compari-
sons a subset of expenditure can be used, such as
acute inpatient hospital care – an area where admin-
istrative records are generally complete with the nec-
essary diagnostic and patient information.
The data presented here come primarily from data
provided by countries as part of the OECD project of
Estimating Expenditures by Disease, Age and Gender,
supplemented by additional country data where
similar methodologies have been used. Note that
Figures 7.5.1-7.5.3 represent allocated spending only,
and the following limitations apply: Canada excludes
acute inpatient hospitalisations in Quebec and all
inpatient hospitalisations in designated psychiatric
hospitals; the Czech Republic refers to expenditure by
the Health Insurance Fund only; Germany refers to
total hospital expenditure; and the Netherlands
refers to curative care in general and specialty
hospitals.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013162
7. HEALTH EXPENDITURE AND FINANCING
7.5. Expenditure by disease and age7.5.1. Share of hospital inpatient expenditure by main diagnostic category, 2011 (or nearest year)
Source: Australia: AIHW (2012); Canada, Czech Republic, Finland, Israel, Korea, Slovenia and Sweden: unpublished data; Germany: Federal Statistical
Office (2013); Japan, Netherlands: OECD calculations using published data.
1 2 http://dx.doi.org/10.1787/888932919004
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7. HEALTH EXPENDITURE AND FINANCING7.6. Financing of health careAcross all OECD countries, health care is financed by a mix
of public and private spending. In some countries, public
health spending is generally confined to spending by the
government using general revenues. In others, social insur-
ance funds finance the bulk of health expenditure. Private
financing of health care consists mainly of payments by
households (either as standalone payments or as part of
co-payment arrangements) as well as various forms of pri-
vate health insurance intended to replace, complement or
supplement publicly financed coverage.
In nearly all OECD countries, the public sector is the main
source of health care financing. Around three-quarters of
health care spending was publicly financed in 2011. In
Denmark, the United Kingdom and Sweden, the central,
regional or local governments finance more than 80% of all
health spending. In the Czech Republic, the Netherlands,
Luxembourg, Japan, France, Slovenia and Germany, social
insurance finances 70% or more of all health expenditure
making it the dominant financing scheme. Only in Chile
(45%), Mexico (47%) and the United States (49%) was the
share of public spending on health below 50%. In these
countries, a great proportion of health spending is financed
either directly by households (Chile and Mexico) or by pri-
vate insurance (United States).
Although public funds are the main source of financing for
health spending in the majority of OECD countries, this
does not imply that the public sector plays the dominant
financing role for all health services and goods. On average
across OECD countries, the public sector covered a much
higher proportion of the costs of medical services (78%)
compared with medical goods (54%) in 2011 (Figure 7.6.2).
This is true for all countries with the exception of
Switzerland, Greece and Korea where public coverage for
medical goods is greater. For medical services, public
sources covered 90% or more of total spending in the Czech
Republic, the Netherlands and Estonia. Concerningmedical
goods, Luxembourg and Greece were the countries with the
highest public spending shares (above 70%).
After public financing, the main source of funding tends to
be out-of-pocket payments. On average it financed 20% of
health spending across OECD countries in 2011. The share
of out-of-pocket payments was above 30% in Mexico, Chile,
Korea and Greece. It was the lowest in the Netherlands
(6%), France (8%) and the United Kingdom (10%).
The share of out-of-pocket spending has changed in many
countries over the past decade (Figure 7.6.3). While out-of-
pocket spending decreased overall in Iceland and Spain
between 2000 and 2011, the share has increased by nearly
2 percentage points since 2009 as public coverage for certain
services was reduced as a result of the crisis and a growing
share of payments was transferred to households. In
Ireland, the private spending share remained flat between
2000 and 2009 but has since grown by 2 percentage points.
In Portugal, the share grew by 1.5 percentage points
between 2000 and 2009 and recorded the same growth
between 2009 and 2011. The Slovak Republic has seen the
biggest increase in the household share of health spending,
with a rise of 15 percentage points between 2000 and 2010.
This increase took place prior to the economic crisis, and
was due to a combination of increased co-payments on
prescribed pharmaceuticals and higher spending on non-
prescribed drugs, greater use of private providers as well as
informal payments to public providers (Szalay et al., 2011).
Out-of-pocket payments also increased substantially in the
Czech Republic between 2000 and 2008 with a slight drop
since.
In a number of other countries, spending by private house-
holds has fallen sharply in the last decade as more services
were covered by public sources or private insurance
schemes. In Turkey, the reliance on private spending has
been significantly reduced in the past decade as universal
health care coverage has been expanded. In Switzerland
the share of out-of-pocket spending also fell notably
between 2000 and 2011 by around 7 percentage points, with
most of this drop occurring between 2000 and 2008.
Definition and comparability
The financing of health care can be analysed from the
point of view of the sources of funding (households,
employers and the state), financing schemes (e.g.,
compulsory or voluntary insurance), and financing
agents (organisations managing the financing
schemes). Here “financing” is used in the sense of
financing schemes as defined in the System of Health
Accounts (OECD, 2000; OECD, Eurostat andWHO, 2011).
Public financing includes expenditure by the general
government and social security funds. Private financ-
ing covers households’ out-of-pocket payments,
private health insurance and other private funds
(NGOs and private corporations). Out-of-pocket pay-
ments are expenditures borne directly by patients.
They include cost-sharing and, in certain countries,
estimations of informal payments to health care
providers.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013164
7. HEALTH EXPENDITURE AND FINANCING
7.6. Financing of health care7.6.1. Expenditure on health by type of financing, 2011 (or nearest year)
1. Data refer to total health expenditure.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932919061
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7. HEALTH EXPENDITURE AND FINANCING7.7. Trade in health servicesTrade in health services and its most high-profile compo-
nent, medical tourism, has attracted a great deal of media
attention in recent years. The growth in “imports” and
“exports” has been fuelled by a number of factors. Techno-
logical advances in information systems and communica-
tion allow patients or third party purchasers of health care
to seek out quality treatment at lower cost and/or more
immediately from health care providers in other countries.
An increase in the portability of health coverage, whether
as a result of regional arrangements with regard to public
health insurance systems, or developments in the private
insurance market, are also poised to further increase
patient mobility. All this is coupled with a general increase
in the temporary movement of populations for business,
leisure or specifically for medical reasons between coun-
tries.
While the major part of international trade in health ser-
vices does involve the physical movement of patients
across borders to receive treatment, to get a full measure of
imports and exports, there is also a need to consider goods
and services delivered remotely such as pharmaceuticals
ordered from another country or diagnostic services pro-
vided from a doctor in one country to a patient in another.
The magnitude of such trade remains small, but advances
in technology mean that this area also has the potential to
grow rapidly.
Data on imports of health services and goods are available
for most OECD countries and amounted to more than
USD 7 billion in 2011. The vast majority of the trade
recorded is between OECD countries. However, due to data
gaps and under-reporting, this is likely to be a significant
underestimate. With health-related imports of nearly
USD 2.3 billion, Germany is the greatest importer in abso-
lute terms, followed by the United States and the
Netherlands. Nevertheless, in comparison to the size of the
health sector, trade in health goods and services remains
marginal for most countries. Even in the case of Germany,
reported imports represent only around 0.6% of Germany’s
current health expenditure. The share rises above 1% of
health spending only in Iceland and Portugal, as these
smaller countries see a higher level of cross-border move-
ment of patients. Luxembourg is a particular case because
a large part of its insured population is living and consum-
ing health services in neighbouring countries. In the major-
ity of OECD countries reporting imports of health care
goods and services, these have been increasing in the last
five years, in many cases with double-digit annual growth
rates.
A smaller number of countries can quantify total exports of
health-related travel expenditure and other health services
totalling around USD 6.9 billion in 2011 (Figure 7.7.2). For
many countries these figures are, again, likely to be signifi-
cant underestimates. In absolute values, the United States
reported exports around USD 3 billion, while the exports of
France and the Czech Republic exceeded USD 500 million.
In relation to overall health spending, health-related
exports remain marginal in most countries, except for the
Czech Republic where they account for 3.6%. Slovenia,
Poland and Hungary have also recorded shares above 1%.
These countries have become popular destinations for
patients from other European countries, particularly for
services such as dental surgery. The growth rate in health-
related exports has been around 20% per year over the past
five years in Slovenia and Poland, but also in Korea.
Patient mobility in Europemay see further growth since the
adoption of a EU directive in 2011 (Directive 2011/24/EU).
The directive supports patients in exercising their right to
cross border health care and promotes co-operation
between health systems.
Definition and comparability
The System of Health Accounts includes imports within
current health expenditure, defined as imports of
medical goods and services for final consumption. Of
these the purchase of medical services and goods, by
resident patients while abroad, is currently the most
important in value terms.
In the balance of payments, trade refers to goods and
services transactions between residents and non-
residents of an economy. According to the Manual on
Statistics of International Trade in Services, “Health-
related travel” is defined as “goods and services
acquired by travellers going abroad for medical
reasons”. This category has some limitations in that it
covers only those persons travelling for the specific
purpose of receiving medical care, and does not
include those who happen to require medical services
when abroad. The additional item “Health services”
covers those services delivered across borders but can
include medical services delivered between providers
as well as to patients.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013166
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7.7. Trade in health services7.7.1. Imports of health care services as share of health expenditure, 2011 and annual growth rate in real terms,
2006-2011 (or nearest year)
1. Refers to balance of payments concept of health-related travel plus health services within personal, recreational and cultural services.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en; OECD-Eurostat Trade in Services Database.
1 2 http://dx.doi.org/10.1787/888932919118
7.7.2. Exports of health-related travel or other services as share of health expenditure, 2011 and annual growth rate
in real terms, 2006-2011 (or nearest year)
Note: Health-related exports occur when domestic providers supply medical services to non-residents.
Source: OECD-Eurostat Trade in Services Database; Hungarian Central Statistical Office – Tourism Statistics.
1 2 http://dx.doi.org/10.1787/888932919137
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8. AGEING AND LONG-TERM CARE8.1. Demographic trendsPopulation ageing is characterised by a rise in the share of
the elderly population resulting from longer life expectancy
(see Indicator 1.1) and declining fertility rates (OECD,
2011b).
On average across OECD countries, the share of the popula-
tion aged over 65 years has increased from less than 9% in
1960 to 15% in 2010 and is expected to nearly double in the
next four decades to reach 27% in 2050 (Figure 8.1.1, left
panel). In about two-thirds of OECD countries, at least one-
quarter of the population will be over 65 years of age by
2050. This proportion is expected to be especially large in
Japan, Korea and Spain where nearly 40% of the population
will be aged over 65 years by 2050. Population ageing will
also occur rapidly in China where the share of the popula-
tion over 65 is expected to more than triple between 2010
and 2050, to reach the same level as the OECD average.
Conversely, Israel and the United States will see a more
gradual increase in the share of the elderly population due
to significant inflows of migrants and higher fertility rates.
The increase in the share of the population aged 80 years
and over will be even more dramatic (Figure 8.1.1, right
panel). On average across OECD countries, 4% of the popu-
lation were 80 years old and over in 2010. By 2050, the per-
centage will increase to 10%. In Japan, Spain and Germany,
the proportion of the population aged over 80 is expected to
nearly triple between 2010 and 2050 (rising from 6% to 16%
in Japan, and from 5% to 15% in Spain and Germany). The
rise will be even faster in Korea where the share of the pop-
ulation aged over 80 years will grow from 2% to 14% over
the next four decades. Similarly, in China, the share of the
population aged over 80 will rise from 1% to 8%.
Population ageing is a phenomenon affecting most coun-
tries around the world, but the speed of the process varies
(Figure 8.1.2). The speed of population ageing is particularly
rapid in the European Union, where the share of the popu-
lation aged 80 years and over increased from 1.5% in 1960 to
nearly 5% in 2010, and is expected to rise to 11% by 2050.
The pace of population ageing is slower in other parts of
the world, although it is expected to accelerate in coming
decades. In large emerging countries including Brazil,
China, India, Indonesia and South Africa, only 1% of the
population was 80 years and over in 2010, but this share is
expected to reach around 5% by 2050.
Although the pressure that this growing proportion of peo-
ple aged 65 and 80 over will put on long-term care systems
will depend on the health status of people as they reach
these ages, population ageing is likely to lead, all other
things being equal, to greater demand for elderly care. As
the share of the economically active population is expected
to decline, it will also affect the financing of social protec-
tion systems and the potential supply of labour in the econ-
omy. On average across OECD countries, there were slightly
more than four people of working age (15-64 years) for
every person 65 years and older in 2012. This rate is pro-
jected to halve from 4.2 in 2012 to 2.1 on average across
OECD countries over the next 40 years (OECD, 2013c).
Definition and comparability
Data on the population structure have been extracted
from the OECD Historical Population Data and Projec-
tions (1950-2050). The projections are based on the
most recent “medium-variant” population projec-
tions from the United Nations, World Population
Prospects – 2012 Revision.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013170
8. AGEING AND LONG-TERM CARE
8.1. Demographic trends8.1.1. Share of the population aged over 65 and 80 years, 2010 and 2050
Source: OECD Historical Population Data and Projections Database, 2013.
1 2 http://dx.doi.org/10.1787/888932919156
8.1.2. Trends in the share of the population aged over 80 years, 1960-2050
1. Emerging economies include Brazil, China, India, Indonesia and South Africa.
Source: OECD Historical Population Data and Projections Database, 2013.
1 2 http://dx.doi.org/10.1787/888932919175
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8. AGEING AND LONG-TERM CARE8.2. Life expectancy and healthy life expectancy at age 65Life expectancy at age 65 has increased significantly for
both men and women during the past 50 years across both
OECD countries and emerging economies. Some of the fac-
tors explaining these gains in life expectancy at age 65
include advances in medical care combined with greater
access to health care, healthier lifestyles and improved liv-
ing conditions before and after people reach age 65.
In 2011, women at age 65 could expect to live for another
20.9 years on average across OECD countries, while men
could expect to live 17.6 years (Figure 8.2.1). Life expectancy
at age 65 was the highest in France for both women
(23.8 years) and men (19.3 years), followed by Japan. It was
lower in Turkey (16.1 years for women and 14.1 years for
men), where life expectancy at age 65 is similar to that of
other major emerging countries such as South Africa.
On average across OECD countries, life expectancy at
age 65 has increased by six years for women and 4.8 years
for men since 1960.While the gender gap in life expectancy
at age 65 widened in many countries in the 1960s and the
1970s, it has slightly narrowed over the past 30 years. In
some countries such as Australia, New Zealand, United
Kingdom and the United States, the overall gains in life
expectancy at age 65 since 1960 have been greater for men
than for women. Japan has achieved the highest gains in
life expectancy at age 65 since 1960, with an increase of
almost ten years for women and over seven years for men,
although the increase has slowed down over the past few
years. The gains in life expectancy have been more modest
in some central and eastern European countries, such as
the Slovak Republic and Hungary, especially for men, and
in Mexico.
Countries relative position with respect to life expectancy
at age 65 mirrors closely their relative position with regard
to life expectancy at age 80. Life expectancy at age 80 is the
highest in France (11.8 for women, 9.2 for men), followed by
Japan (11.4 for women, 8.4 for men) and Italy (10.7 for
women, 8.5 for men). Turkey has the lowest life expectancy
at age 80 among OECD countries (6.7 for women and 6.2 for
men). While life expectancy at age 65 in the United Kingdom
is around the OECD average, it is much higher than the
OECD average at age 80 (10.2 for women, 8.8 for men).
Increased life expectancy at age 65 does not necessarily
mean that the extra years lived are in good health. In
Europe, an indicator of disability-free life expectancy
known as “healthy life years” is calculated regularly, based
on a general question about disability in the European Sur-
vey of Income and Living Conditions (EU-SILC). Given that
this indicator has only recently been developed, long-time
series are not yet available and efforts continue to improve
its comparability.
Among European countries participating in the survey, the
average number of healthy life years at age 65 was almost
the same for women and men, at 9.5 years for women and
9.4 years for men in 2011 (Figure 8.2.2). The absence of any
significant gender gap in healthy life years means that
women are more likely to live with some type of activity
limitation after age 65 than men. Norway and Sweden had
the highest number of healthy life years at age 65 in 2011,
with over 15 years free of disability for women and about
14 years for men.
Definition and comparability
Life expectancy measures how long on average a per-
son of a given age can expect to live, if current death
rates do not change. However, the actual age-specific
death rate of any particular birth cohort cannot be
known in advance. If rates are falling, as has been the
case over the past decades in OECD countries, actual
life spans will be higher than life expectancy calcu-
lated using current death rates. The methodology
used to calculate life expectancy can vary slightly
between countries. This can change a country’s
estimates by a fraction of a year.
Disability-free life expectancy (or “healthy life years”)
is defined as the number of years spent free of activity
limitation. In Europe, this indicator is calculated
annually by Eurostat for EU countries and some EFTA
countries using the Sullivan method (Sullivan, 1971).
The disability measure is the Global Activity Limita-
tion Indicator (GALI) which comes from the EU-SILC
survey. The GALI measures limitation in usual activi-
ties due to health problems.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013172
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8.2. Life expectancy and healthy life expectancy at age 658.2.1. Life expectancy at age 65, 2011 and years gained since 1960 (or nearest year)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en; national sources for non-OECD countries.
1 2 http://dx.doi.org/10.1787/888932919194
8.2.2. Healthy life years at age 65, European countries, 2011
Source: Eurostat Statistics Database 2013.
1 2 http://dx.doi.org/10.1787/888932919213
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8. AGEING AND LONG-TERM CARE8.3. Self-reported health and disability at age 65Most OECD countries conduct regular health surveys which
allow respondents to report on different aspects of their
health. A question that is often found among such surveys
is usually similar to: “How is your health in general?”.
Although these questions are subjective, indicators of per-
ceived general health have been found to be a good predic-
tor of people’s future health care use and mortality
(DeSalvo, 2005; Bond et al., 2006). However, cross-country
differences in perceived health status may be difficult to
interpret as survey questions may differ slightly, and cul-
tural factors can affect responses.
Keeping these limitations in mind, more than half of the
population aged 65 years and over rate their health to be
good in 12 of the 34 OECD countries (Figure 8.3.1).
New Zealand, Canada and the United States have the high-
est percentage of older people assessing their health to be
good, with at least three out of four people reporting to be
in good health. However, the response categories offered to
survey respondents in these three countries are different
from those used in most other OECD countries, introducing
an upward bias in the results (see box on “Definition and
comparability” below).
In Finland, France, Germany, Greece and Spain, only
between 35% and 40% of people aged 65 years and over rate
their health to be good. And in Portugal, Hungary, Poland,
Estonia, the Slovak Republic, Turkey, Japan and the Czech
Republic, less than 20% of people aged 65 and over report
being in good health. In nearly all countries, men over 65
were more likely than women to rate their health to be
good, the exception being Australia. On average across
OECD countries, 45.6% of men aged over 65 rated their
health to be good, while 39.5% of women did so.
The percentage of the population aged 65 years and over
who rate their health as being good has remained fairly sta-
ble over the past 30 years in most countries where long
time series are available. There has been significant
improvement however in the United States, where the
share has increased from just over 60% in 1982 to 75% in
2011.
Measures of disability are not yet standardised across
countries, limiting the possibility for comparisons across
all OECD countries. In Europe, based on the EU Statistics on
Income and Living Conditions survey (EU-SILC), 42% of peo-
ple aged between 65 and 74 years reported that they were
limited in their usual daily activities because of a health
problem in 2011. The proportion rises to almost 60% for
people aged 75 and over (Figure 8.3.2).While a large propor-
tion of the population reported only moderate activity lim-
itation, about 14% aged 65-74 years, and 25% aged 75 years
and over reported being severely limited, on average among
a group of 25 European OECD countries. Severe activity lim-
itations are more likely to create needs for long-term care,
whether formal or informal.
People in Nordic countries reported the lowest level of
moderate or severe disability, with the exception of
Finland, where self-reported disability rates are higher and
close to the European average. The highest rate of self-
reported disability is in the Slovak Republic, followed by
Estonia.
Definition and comparability
Self-reported health reflects people’s overall percep-
tion of their own health, including both physical and
psychological dimensions. Typically, survey respon-
dents are asked a question such as: “How is your
health in general? Very good, good, fair, poor, very
poor”. OECD Health Statistics provides figures related
to the proportion of people rating their health to be
“good/very good” combined.
Caution is required in making cross-country compar-
isons of perceived health status, for at least two rea-
sons. First, people’s assessment of their health is
subjective and can be affected by cultural factors. Sec-
ond, there are variations in the question and answer
categories used to measure perceived health across
surveys/countries. In particular, the response scale
used in Australia, Canada, New Zealand and the
United States is asymmetric (skewed on the positive
side), including the following response categories:
“excellent, very good, good, fair, poor”. The data
reported in OECD Health Statistics refer to respondents
answering one of the three positive responses (“excel-
lent, very good or good”). By contrast, in most other
OECD countries, the response scale is symmetric,
with response categories being: “very good, good, fair,
poor, very poor”. The data reported from these coun-
tries refer only to the first two categories (“very good,
good”). Such difference in response categories biases
upward the results from those countries that are
using an asymmetric scale.
Perceived general disability is measured in the EU-
SILC survey through the question: “For at least the
past six months, have you been hampered because of
a health problem in activities people usually do? Yes,
strongly limited/Yes, limited/No, not limited”. Persons
in institutions are not surveyed, resulting in an under-
estimation of disability prevalence. Again, the mea-
sure is subjective, and cultural factors may affect
survey responses.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013174
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8.3. Self-reported health and disability at age 658.3.1. Population aged 65 years and over reporting to be in good health, 2011 (or nearest year)
1. Results not directly comparable with other countries due to methodological differences (resulting in an upward bias).
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932919232
8.3.2. Limitations in daily activities, population aged 65-74 and 75 years and over, European countries, 2011
Source: Eurostat Database 2013.
1 2 http://dx.doi.org/10.1787/888932919251
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8. AGEING AND LONG-TERM CARE8.4. Dementia prevalenceDementia describes a variety of brain disorders which pro-
gressively lead to brain damage, and cause a gradual dete-
rioration of the individual’s functional capacity and social
relations. Alzheimer’s disease is the most common form of
dementia, representing about 60% to 80% of cases.
Currently, there is no treatment that can halt dementia, but
pharmaceutical drugs and other interventions can slow the
progression of the disease.
According to WHO, nearly 35.6 million people around the
world live with dementia. With population ageing and no
widely effective prevention options, this number is
expected to double by 2030 (65.7 million) and more than
triple by 2050 (115.4 million) (WHO and Alzheimer Disease
International, 2012).
In 2009, there were an estimated 14 million people aged
60 years and over suffering from dementia in OECD coun-
tries, accounting for more than 5% of the population in that
age group, according to estimates by Wimo et al. (2010)
(Figure 8.4.1). France, Italy, Switzerland, Spain, Sweden and
Norway had the highest prevalence rate, with 6.3% to 6.5%
of the population aged 60 years and over estimated as hav-
ing dementia. The prevalence rate was only about half
these rates in some emerging economies including South
Africa, Indonesia and India, although this in part reflects
fewer detected cases.
Clinical symptoms of dementia usually begin after the age
of 65, and the prevalence increases markedly with age
(Figure 8.4.2). The disease affects more women than men.
In Europe, 14% of men and 16% of women aged 80-84 years
were estimated as having dementia in 2009, compared to
less than 4% among those under 75 years of age (Alzheimer
Europe, 2009). For people aged 90 years and over, the figures
rise to 31% of men and 47% of women. A similar pattern is
observed in Australia (AIHW, 2012c). Early-onset dementia
among people aged younger than 65 years is rare; they
comprise less than 2% of the total number of people with
dementia.
The direct costs of dementia account for a significant share
of total health expenditure in OECD countries, greater than
the direct costs related to depression and other mental
disorders such as schizophrenia (Figure 8.4.3). In the
Netherlands, dementia accounted for nearly 6% of overall
health spending in 2007. Most of these costs were related to
caring for people with dementia in nursing homes, but part
of the costs were also related to home-based care and a
smaller proportion for hospital-based care (Slobbe et al.,
2011). In Germany, dementia accounted for 3.7% of total
health expenditure in 2008, withmost of the costs also allo-
cated for care in nursing homes (Federal Statistical Office,
2013). In Korea, nearly 3% of total health expenditure was
devoted to dementia care in 2009, but with most of the
costs in this country related to care provided in hospital
(unpublished data submitted to the OECD).
With a growing number of older persons suffering from the
disease, dementia has become a health policy priority in
many countries. National policies in Australia, Austria,
Canada, France, the United States and other countries typ-
ically involve measures to improve early diagnosis, pro-
mote quality of care for people with dementia, and support
informal caregivers (Wortmann, 2009; Juva, 2009; Ersek et
al., 2009; Kenigsberg, 2009; Alzheimer Europe, 2012; OECD
and European Commission, 2013).
Definition and comparability
Dementia prevalence rates are based on estimates of
the total number of persons aged 60 years and over
living with dementia divided by the size of the corre-
sponding population. Estimates on prevalence by
Wimo et al. (2010) are based on previous national
epidemiological studies and meta-analyses which
used the following age-specific dementia percent-
ages: 1% for ages 60-64, 1,5% for ages 65-69, 3% for
ages 70-74, 6% for ages 75-79, 13% for ages 80-84, 24%
for ages 85-89, 34% for ages 90-94 and 45% for
ages 95+.
In Figure 8.4.3, depression refers to mood disorders
and schizophrenia includes schizophrenia, schizotyp-
ical and delusional disorders.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013176
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8.4. Dementia prevalence8.4.1. Prevalence of dementia among the population aged 60 years and over, 2009
Source: Wimo et al. (2010).
1 2 http://dx.doi.org/10.1787/888932919270
8.4.2. Age- and gender- specific prevalence of dementia in Europe and Australia, 2009
Source: Alzheimer Europe (2009); AIHW (2012).
1 2 http://dx.doi.org/10.1787/888932919289
8.4.3. Share of total health expenditure allocated to dementia and other mental disorders, selected OECD countries, 2009
(or nearest year)
Source: OECD Project on Expenditure by Disease, Age and Gender (unpublished).
1 2 http://dx.doi.org/10.1787/888932919308
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8. AGEING AND LONG-TERM CARE8.5. Recipients of long-term careThe number of people receiving long-term care (LTC) ser-
vices in OECD countries is rising, mainly due to population
ageing and the growing number of elderly dependent per-
sons, as well as the development of services and facilities
in many countries.
Although long-term care services are delivered both to
elderly people and younger disabled groups, the vast
majority of LTC recipients are over 65 years of age. Among
all LTC recipients, around 60% are women because of their
higher life expectancy combined with a higher prevalence
of disabilities and functional limitations in old age.
On average across OECD countries, over 12% of the popula-
tion aged 65 and over were receiving some long-term care
services at home or in institutions in 2011 (Figure 8.5.1).
The number of LTC recipients as a share of the population
aged 65 and over was the highest in Israel and Switzerland,
with more than one-fifth of the population in that age
group receiving long-term care. On the other hand, only
about 1% of the population aged 65 and over in Poland
receives formal LTC services, with most of them receiving
them in institutions, although many more may receive
informal care from family members at home. The use of
long-term care services increases sharply with age. On
average across OECD countries, 30% of the people aged 80
and over receive LTC services.
In response to most people’s preference to receive LTC ser-
vices at home, an important trend in many OECD countries
over the past decade has been the implementation of pro-
grammes and benefits to support home-based care. In
most countries for which trend data are available, the share
of people aged 65 and over receiving long-term care at
home in the total number of LTC recipients has increased
over the past ten years (Figure 8.5.2). The proportion of LTC
recipients at home is the highest in Japan and Hungary,
with about 75% of LTC recipients receiving care at home. In
Hungary, LTC in institutions has been restricted by budget-
ary constraints and stricter admission criteria. The share of
home-based care recipients has also increased markedly in
Sweden, Korea, France and Luxembourg. The share of
home care recipients in France has increased from 40% to
over 60%, as part of a multi-year plan to increase home
nursing care capacity to 230 000 by 2025 (Colombo et al.,
2011).
While the share of home-based care recipients has
increased over the past decade in many OECD countries,
the share has declined from 69% to 60% in Finland. The
actual number of people receiving LTC at home has
remained fairly stable, while the number of people receiv-
ing care in institutions has grown at a faster rate. This may
be due to the fact that the intensity of care needs among
the more elderly people has increased.
In the Unites States, only around 40% of LTC recipients
receive care at home in 2009 (latest year available). This
may partly reflect a traditional bias in supporting institu-
tional-based care. Financial support to promote home-
based care has only been implemented by certain states.
Additional support or changes in incentives may be needed
in the United States and in other countries to further
encourage home-based care (Colombo et al., 2011).
Definition and comparability
LTC recipients are defined as persons receiving
long-term care by paid providers, including non-
professionals receiving cash payments under a social
programme. They also include recipients of cash ben-
efits such as consumer-choice programmes, care
allowances or other social benefits which are granted
with the primary goal of supporting people with long-
term care needs. LTC institutions refer to nursing and
residential care facilities which provide accommoda-
tion and long-term care as a package. LTC at home is
defined as people with functional restrictions who
receive most of their care at home. Home care also
applies to the use of institutions on a temporary
basis, community care and day-care centres and spe-
cially designed living arrangements. Concerning the
number of people aged 65 and over receiving LTC in
institutions, the estimate for Ireland is under-
reported. Data for Japan underestimate the number of
recipients in institutions because hospitals also
provide LTC. In the Czech Republic, LTC recipients
refer to recipients of the care allowance (i.e., cash
allowance paid to eligible dependent persons). Data
for Poland only refer to services in nursing homes.
Data in Spain only refer to a partial coverage of facili-
ties or services. In Australia, the data do not include
recipients who access the Veterans’ Home Care Pro-
gram and those who access services under the
National Disability Agreement, as it is currently
unknown how many of these people could be
included in LTC recipients. Australia does not directly
collect data on whether clients or consumers of
health and aged care services are receiving LTC and
data are therefore estimated. With regard to the age
threshold, data for Austria, Belgium, France and
Poland refer to people aged over 60, while they refer
to people over 62 in the Slovak Republic. This is
resulting in a slight under-estimation of the share in
these countries, given that a much smaller proportion
of people aged 60-65 or 62-65 receive LTC compared
with older age groups.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013178
8. AGEING AND LONG-TERM CARE
8.5. Recipients of long-term care8.5.1. Population aged 65 years and over receiving long-term care, 2011 (or nearest year)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932919327
8.5.2. Share of long-term care recipients aged 65 years and over receiving care at home, 2000 and 2011 (or nearest year)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932919346
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8. AGEING AND LONG-TERM CARE8.6. Informal carersFamily carers are the backbone of long-term care systems
in all OECD countries, although there are substantial varia-
tions across countries in the relative importance of infor-
mal caregiving by family members compared with the use
of more formal long-term care providers. Because of the
informal nature of care provided by family members, it is
not easy to get comparable data on the number of family
carers across countries, nor on the frequency of their
caregiving. The data presented in this section come from
national or international health surveys, and refer to peo-
ple aged 50 years and over who report providing care and
assistance to family members and friends.
On average across OECD countries, over 15% of people
aged 50 and over provided care for a dependent relative or
friend in 2010. This proportion reaches about 20% in
Belgium and Italy (Figure 8.6.1). In Italy, the high proportion
of people who provide care to a family member is associ-
ated with relatively few formal (paid) LTC workers (see
Indicator 8.7).
Most informal carers are women. On average across coun-
tries, more than 60% of carers are women.This ranges from
a high of 71% in Hungary to a low of 54% in Denmark
(Figure 8.6.2).
On average across OECD countries, 66% of informal carers
provide care on a daily basis, while the remaining 34% pro-
vide care only on a weekly basis. However, there is wide
variation across countries in the intensity in caregiving
(Figure 8.6.3). In some southern European countries (Portugal,
Spain and Italy), Poland and Slovenia where there is a
strong culture of family members providing care for their
elderly parents, three-quarter or more of informal carers
report providing care on a daily basis. By contrast, in coun-
tries such as Sweden, Switzerland and Denmark where a
greater share of LTC services is provided by paid workers,
the proportion of people providing care on a daily basis is
much lower.
Intensive caregiving is associated with a reduction in
labour force attachment for caregivers of working age,
higher poverty rates, and a higher prevalence of mental
health problems. Many OECD countries have implemented
policies to support family carers with a view to mitigate
these negative impacts. These include paid care leave (e.g.,
Belgium), allowing flexible work schedules (e.g., Australia
and the United States), providing respite care (e.g., Austria,
Denmark and Germany) as well as counselling/training ser-
vices (e.g., Sweden). Moreover, a number of OECD countries
provide cash benefits to family caregivers or cash-for-care
allowances for recipients which can be used to pay infor-
mal caregivers (Colombo et al., 2011).
The potential pool of working-age and older family carers is
likely to shrink in the coming decades as a result of declin-
ing family size, changes in residential patterns of people
with disabilities, and rising participation rates of women in
the labour market. Therefore, it is likely that a greater share
of people providing informal care may be required to pro-
vide high-intensity care. Without adequate support, infor-
mal caregiving might exacerbate employment and health
inequalities (Colombo et al., 2011).
Definition and comparability
Family carers are defined as people providing daily or
weekly help to family members, friends and people in
their social network living in their household or out-
side of the household who require help for Activities
of Daily Living (ADL) and Instrumental Activities of
Daily Living (IADL). The data relate only to the popu-
lation aged 50 and over, and are based on national or
international health surveys. Survey results may be
affected by reporting biases or recall problems.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013180
8. AGEING AND LONG-TERM CARE
8.6. Informal carers8.6.1. Population aged 50 and over reporting to be informal carers, 2010 (or nearest year)
Source: OECD estimates based on 2011 HILDA survey for Australia, 2009 BHPS survey for the United Kingdom and 2010 SHARE survey for other
European countries.
1 2 http://dx.doi.org/10.1787/888932919365
8.6.2. Share of women among all informal carers aged 50 and over, 2010 (or nearest year)
Source: OECD estimates based on 2011 HILDA survey for Australia, 2009 BHPS survey for the United Kingdom and 2010 SHARE survey for other
European countries.
1 2 http://dx.doi.org/10.1787/888932919384
8.6.3. Frequency of care provided by informal carers, 2010 (or nearest year)
Source: OECD estimates based on the 2010 SHARE survey.
1 2 http://dx.doi.org/10.1787/888932919403
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8. AGEING AND LONG-TERM CARE8.7. Long-term care workersThe provision of long-term care (LTC) is a labour-intensive
activity. Formal LTCworkers are defined as paid workers, typ-
ically nurses and personal carers, providing care and/or assis-
tance to people limited in their daily activities at home or in
institutions. Formal long-term care is complemented by
informal, usually unpaid, care by family and friends, which
accounts for a large part of care for older people in all OECD
countries (see Indicator 8.6).
Relative to the population aged 65 and over, Norway and
Sweden have the largest number of LTC workers, and Italy
the lowest share (Figure 8.7.1). The organisation of formal
care also varies across OECD countries. Care providers work
mainly in institutions in the United States, Denmark,
Switzerland, Canada and the Czech Republic, even though
most recipients may receive care at home in some of these
countries (see Indicator 8.5). People working in LTC institu-
tions often attend to people with more severe limitations.
Conversely, most formal LTC workers provide care at home
in Estonia, Israel, Korea and Japan.
Most LTC workers are women and work part-time. Over
90% of LTC workers are women in Canada, Denmark, the
Czech Republic, Ireland, Korea, New Zealand, the Slovak
Republic, the Netherlands, Norway and Sweden. Foreign-
born workers also play an important role in LTC provision,
although their presence is uneven across OECD countries.
While Germany has very few foreign-born LTC workers, in
the United States nearly one in every four care workers is
foreign-born. In other countries, foreign-born workers rep-
resent a large share of people providing home-based ser-
vices, including LTC services. This is the case, for instance,
in Italy where about 70% of people providing services at
home are foreign-born (Colombo et al., 2011). The recruit-
ment of foreign-born workers to provide LTC at home or in
institutions can help respond to growing demand, often at
a relatively low cost. But the growing inflows of LTC work-
ers coming from other countries have raised some issues in
certain countries, such as the management of irregular
migration inflows and paid work which is undeclared for
tax and social security purposes.
Employment in the LTC sector still represents only a small
share of total employment in OECD countries, averaging
just over 2% across all OECD countries. However, this share
has increased over the past decade in many countries, with
the broadening of public protection against LTC risks and
increased demand stemming from population ageing. In
Japan, the number of LTC workers has more than doubled
since the implementation of the universal LTC insurance
programme in 2000, while there was a slight decrease in
total employment in the economy over this period.
Employment has also increased in the LTC sector in
Germany and, to lesser extent, in Denmark and Norway
(Figure 8.7.2).
On average, close to 30% of formal LTC providers are
nurses, while the other 70% are personal care workers (who
may be called under different names in different countries
– nursing aides, health assistants in institutions, home-
based care assistants, etc.). Many countries are looking at
possibilities to delegate some of the tasks currently pro-
vided by nurses to lower-skilled providers to increase the
supply of services and reduce costs, while ensuring at the
same time that minimum standards of quality of care are
maintained. One of the common approaches to ensure
quality of services in OECD countries has been to set educa-
tional and training requirements for personal care workers.
Still, these requirements vary substantially across OECD
countries resulting in various qualifications level among
personal care workers, especially where home-based care
is concerned (OECD/European Commission, 2013).
Given population ageing and the expected decline in the
availability of family caregivers, the demand for LTC work-
ers as a share of the working population is expected to at
least double by 2050. A combination of policies is needed to
respond to this, including policies to improve recruitment
(e.g., encouraging more unemployed people to consider
training and working in the LTC sector); to improve reten-
tion (e.g., enhancing pay and work conditions); and to
increase productivity (e.g., through reorganisation of work
processes and more effective use of new technologies)
(Colombo et al., 2011; European Commission, 2013).
Definition and comparability
Long-term care workers are defined as paid workers
who provide care at home or in institutions (outside
hospitals). They include qualified nurses (see defini-
tion under Indicator 3.7) and personal care workers
providing assistance with ADL and other personal
support. Personal care workers include different cate-
gories of workers who may have some recognised
qualification or not. Because they may not be part of
recognised occupations, it is more difficult to collect
comparable data for this category of LTC workers. LTC
workers also include family members or friends who
are employed under a formal contract either by the
care recipient, an agency, or public and private care
service companies. The numbers are expressed as
head counts, not full-time equivalent.
The data for Germany exclude elderly care nurses,
and persons declared to social security systems as
caregivers, resulting in a substantial under-estimation.
The data for Italy exclude workers in semi-residential
long-term care facilities. The data for Japan involve
double-counting (as some workers may work in more
than one home). The data for Ireland refer only to the
public sector. The data for Australia are estimates
drawn from the 2011 National Aged Care Workforce
Census and Survey, and underrepresent the numbers
of people who could be considered LTC workers.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013182
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8.7. Long-term care workers8.7.1. Long-term care workers as share of population aged 65 and over, 2011 (or nearest year)
1. In Sweden, Spain and the Slovak Republic, it is not possible to distinguish LTC workers in institutions and at home.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932919422
8.7.2. Trends in long-term care employment and total employment, selected OECD countries, 2000-11 (or nearest year)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932919441
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8. AGEING AND LONG-TERM CARE8.8. Long-term care beds in institutions and hospitalsThe number of beds in long-term care (LTC) institutions
and in LTC departments in hospitals provides a measure of
the resources available for delivering LTC services to indi-
viduals outside of their home.
On average across OECD countries, there were 44 beds in
LTC institutions and five beds in LTC departments in hospi-
tals per 1 000 people aged 65 and over in 2011 (Figure 8.8.1).
Luxembourg had the highest number of LTC beds in 2011,
with almost 80 beds per 1 000 people aged 65 and over in
LTC institutions. On the other hand, there were fewer than
20 beds per 1 000 people aged 65 and over in LTC institu-
tions or in hospitals in Italy and Poland.
While most countries allocate very few beds for LTC in hos-
pitals, others still use hospital beds quite extensively for
LTC purposes. Although the number of beds in LTC institu-
tions in Korea has increased strongly following the imple-
mentation of a public LTC insurance programme for the
elderly in 2008, many beds in hospitals are still dedicated to
LTC services. Similarly, in Japan many hospital beds have
been traditionally used for long-term care, even if the num-
ber of beds in LTC institutions has also recently increased.
Among European countries, Finland and Hungary have
maintained a fairly large number of LTC beds in hospitals.
Finland has, however, developed institutional facilities
while reducing the use of hospital beds for long-term care,
similar to what is occurring in countries such as Iceland
and France (Figure 8.8.2).
Many other OECD countries have expanded capacity in LTC
institutions to provide care to patients who no longer need
acute care in hospitals and to free up costly hospital beds.
In most OECD countries, the number of LTC beds in institu-
tions has increased more rapidly than the number of
LTC beds in hospitals, Korea, Estonia and Hungary being
the exceptions (Figure 8.8.2). Available LTC beds in institu-
tions have increased substantially in Korea and Spain since
2000. In Sweden, the reduction in both hospital and institu-
tional beds reflects the implementation of policies
designed to promote home-based care (Colombo et al.,
2011).
Providing LTC in institutions is generally more expensive
than providing home-based care, if only because of the
additional cost of board and lodging and also because of
higher staffing ratios. LTC users generally prefer to remain
at home. However, depending on individual circumstances,
a move to LTC institutions may be the most appropriate
option, for example for people living alone and requiring
round the clock care and supervision (Wiener et al., 2009) or
people living in remote areas with limited home-care
support.
Definition and comparability
Long-term care institutions refer to nursing and resi-
dential care facilities which provide accommodation
and long-term care as a package. They include spe-
cially designed institutions or hospital-like settings
where the predominant service component is long-
term care for people with moderate to severe
functional restrictions. Beds in adapted living
arrangements for persons who require help while
guaranteeing a high degree of autonomy and self con-
trol are not included. For international comparisons,
they should not include beds in rehabilitation centers.
However, there are variations in data coverage across
countries. Several countries only include beds in pub-
licly-funded LTC institutions, while others also
include private institutions (both profit and non-for-
profit). Some countries also include beds in treatment
centers for addicted people, psychiatric units of
general or specialised hospitals, and rehabilitation
centers. Australia does not collect data on the num-
bers of beds provided for LTC. Data on Australian LTC
beds in institutions are estimated from the aged care
database.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013184
8. AGEING AND LONG-TERM CARE
8.8. Long-term care beds in institutions and hospitals8.8.1. Long-term care beds in institutions and hospitals, 2011 (or nearest year)
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932919460
8.8.2. Trends in long-term care beds in institutions and in hospitals, 2000-11 (or nearest year)
Note: The OECD average excludes Korea (due to the extremely high growth rate).
1. Australia, Germany, Luxembourg, the Netherlands, Norway and Switzerland do not report any long-term care beds in hospital.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932919479
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8. AGEING AND LONG-TERM CARE8.9. Long-term care expenditureLong-term care (LTC) expenditure has risen over the past
few decades in most OECD countries and is expected to rise
further in the coming years due mainly to population age-
ing and a growing number of people requiring health and
social care services on an on-going basis.
A significant share of LTC services is funded from public
sources. Total public spending on LTC (including both the
health and social care components) accounted for 1.6% of
GDP on average across OECD countries in 2011 (Figure 8.9.1).
The highest spenders are the Netherlands and Sweden,
where public expenditure on long-term care was two-times
greater than the OECD average (at 3.7% and 3.6% of GDP).
On the contrary, Greece, Portugal, Estonia, Hungary, the
Czech Republic and Poland allocated less than 0.5% of their
GDP to public spending on long-term care. This variation
reflects both differences in population structure but espe-
cially the development of formal long-term care systems,
as opposed to more informal arrangements based mainly
on care provided by unpaid family members. Despite the
problems of under-reporting, privately-funded LTC expen-
diture plays a relatively large role in Switzerland (0.8% of
GDP), Germany, the United States, Finland and Spain (about
0.4% of GDP). Most of the private spending comes from out-
of-pocket spending, since private health insurance for
long-term care does not play an important role in any
country.
The boundaries between health and social LTC spending
are not fully consistent across countries (see box on “Defi-
nition and comparability”), with some reporting particular
components of LTC as health care, while others view it as
social spending. The Netherlands, Denmark and Norway
spent over 2% of GDP on the health part of LTC, which is
double the OECD average. Regarding the social part of pub-
lic LTC expenditure, Sweden has the highest share, reach-
ing 3% of GDP, much higher than the OECD average of 0.7%.
The Netherlands, Finland and Japan reportedmore than 1%
of GDP on this spending component. Poland, Spain, New
Zealand and Korea reported less than 0.1% of GDP on social
public LTC spending.
Public spending on LTC has grown rapidly in recent years in
some countries (Figure 8.9.2). The annual growth rate in
public expenditures on LTC was 4.8% between 2005 and
2011 across OECD countries, which is above the growth in
health care expenditures during this period. Countries
such as Korea and Portugal, which have implemented
measures to expand the coverage of their LTC systems in
recent years, have had the highest public spending growth
rates between 2005 and 2011. On the other hand, countries
with high spending levels and those with a longer history
of public LTC coverage tend to record below-average growth
rates in recent years.
Although a high proportion of LTC expenditure continues
to be allocated for institutional care, many OECD countries
have expanded the availability of home care services.
Between 2005 and 2011, the annual growth rate of public
spending on home care was about 5% compared with 4%
for institutional care (Figure 8.9.3). There were significant
increases in home care spending in Korea, Estonia and
Spain, while public spending on institutional care was
reduced in Finland and Hungary.
Projection scenarios suggest that public resources allocated
to LTC as a share of GDP may double or more by 2060
(Colombo et al., 2011; De La Maisonneuve and Oliveira
Martins, 2013). One of the main challenges in many OECD
countries in the future will be to strike the right balance
between providing appropriate LTC protection and ensur-
ing that this protection is fiscally sustainable in the long
run.
Definition and comparability
LTC spending comprises both health and social sup-
port services to people with chronic conditions and
disabilities needing care on an on-going basis. Based
on the System of Health Accounts (SHA), the health
component of LTC spending relates to nursing and
personal care services (i.e. assistance with activities
of daily living, ADL). It covers palliative care and care
provided in LTC institutions or at home. LTC social
expenditure primarily covers assistance with instru-
mental activities of daily living (IADL). Countries’
reporting practices between the health and social
components of LTC spending may differ. In addition,
publicly-funded LTC expenditure is more suitable for
international comparisons as there is significant vari-
ation in the reporting of privately-funded LTC expen-
diture across OECD countries.HEALTH AT A GLANCE 2013: OECD INDICATORS © OECD 2013186
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8.9. Long-term care expenditure8.9.1. Long-term care public expenditure (health and social components), as share of GDP, 2011 (or nearest year)
Note: The OECD average only includes the 11 countries that report health and social LTC.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932919498
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8.9.2. Annual growth rate in public expenditure on
long-term care (health and social), in real terms, 2005-11
(or nearest year)
Note: The OECD average excludes Korea (due to the extremely high
growth rate).
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
1 2 http://dx.doi.org/10.1787/888932919517
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Additional information on demographic
and economic context, and health expenditure
and financing
The statistical data for Israel are supplied by and under the responsibility of the relevant Israeli
authorities. The use of such data by the OECD is without prejudice to the status of the Golan
Heights, East Jerusalem and Israeli settlements in the West Bank under the terms of interna-
tional law.203
ADDITIONAL INFORMATION ON DEMOGRAPHIC AND ECONOMIC CONTEXT, AND HEALTH EXPENDITURE AND FINANCINGTable A.1. Total population, mid-year, 1960 to 2011
Thousands
1960 1970 1980 1990 2000 2010 2011
Australia 10 275 12 507 14 695 17 065 19 153 22 065 22 323
Austria 7 048 7 467 7 549 7 678 8 012 8 390 8 421
Belgium 9 153 9 656 9 859 9 967 10 251 10 920 11 048
Canada 18 178 21 745 24 518 27 690 30 688 34 120 34 484
Chile 7 643 9 570 11 174 13 179 15 398 17 094 17 248
Czech Republic 9 602 9 858 10 304 10 333 10 272 10 497 10 496
Denmark 4 580 4 929 5 123 5 141 5 340 5 548 5 571
Estonia 1 211 1 359 1 477 1 569 1 369 1 340 1 340
Finland 4 430 4 606 4 780 4 986 5 176 5 363 5 388
France 45 684 50 772 53 880 56 709 59 062 62 927 63 249
Germany1 55 608 61 098 61 549 62 679 82 212 81 777 81 373
Greece 8 322 8 793 9 643 10 157 10 917 11 308 11 300
Hungary 9 984 10 338 10 711 10 374 10 211 10 000 9 993
Iceland 176 204 228 255 281 318 319
Ireland 2 829 2 957 3 413 3 514 3 805 4 520 4 575
Israel 2 150 2 958 3 878 4 660 6 289 7 624 7 749
Italy 50 200 53 822 56 434 56 719 56 942 60 483 60 724
Japan 93 419 103 721 117 061 123 613 126 927 128 058 127 799
Korea 25 012 32 241 38 124 42 869 47 008 49 410 49 779
Luxembourg 314 339 364 382 436 507 518
Mexico 37 877 50 785 67 384 83 971 98 439 108 396 109 220
Netherlands 11 487 13 039 14 150 14 952 15 926 16 615 16 718
New Zealand 2 382 2 828 3 170 3 390 3 858 4 366 4 404
Norway 3 581 3 876 4 086 4 241 4 491 4 889 4 952
Poland 29 561 32 526 35 578 38 031 38 256 38 517 38 526
Portugal 8 858 8 680 9 766 9 983 10 226 10 605 10 557
Slovak Republic 4 068 4 538 4 980 5 299 5 389 5 409 5 398
Slovenia 1 580 1 670 1 884 1998 1990 2049 2052
Spain 30 455 33 815 37 439 38 850 40 263 46 071 44 835
Sweden 7 485 8 043 8 311 8 559 8 872 9 378 9 447
Switzerland 5 328 6 181 6 319 6 712 7 184 7 828 7 912
Turkey 27 438 35 294 44 522 55 120 64 252 73 328 74 165
United Kingdom 52 371 55 633 56 331 57 238 58 888 61 344 61 760
United States 180 671 205 052 227 225 249 623 282 162 309 326 311 588
OECD (total) 768 959 870 899 965 909 1 047 508 1 149 946 1 230 391 1 235 233
1. Population figures for Germany prior to 1991 refer toWest Germany.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
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ADDITIONAL INFORMATION ON DEMOGRAPHIC AND ECONOMIC CONTEXT, AND HEALTH EXPENDITURE AND FINANCINGTable A.2. Share of the population aged 65 and over, 1960 to 2011
1960 1970 1980 1990 2000 2010 2011
Australia 8.5 8.3 9.6 11.1 12.4 13.5 13.7
Austria 12.2 14.1 15.4 14.9 15.4 17.6 17.7
Belgium 12 13.4 14.3 14.9 16.8 17.2 17.3
Canada 7.5 7.9 9.4 11.3 12.6 14.2 14.7
Chile 4.8 5 5.5 6.1 7.2 9 9.3
Czech Republic 9.5 12.1 13.5 12.6 13.8 15.4 16.2
Denmark 10.6 12.3 14.4 15.6 14.8 16.6 17.1
Estonia 10.6 11.7 12.5 11.6 15.1 17 17.2
Finland 7.3 9.2 12 13.4 14.9 17.3 17.8
France 11.6 12.9 13.9 14 16.1 16.8 17.1
Germany 10.8 13.1 15.5 15.5 16.4 20.6 20.7
Greece 8.2 11.1 13.1 13.7 16.6 19.1 19.5
Hungary 9 11.6 13.4 13.3 15.1 16.7 16.8
Iceland 8.1 8.8 9.9 10.6 11.6 12.1 12.9
Ireland 11.1 11.1 10.7 11.4 11.2 11.6 12.2
Israel 5 6.7 8.6 9.1 9.8 9.9 10
Italy 9.3 10.9 13.1 14.9 18.3 20.3 21
Japan 5.7 7.1 9.1 12.1 17.4 23.2 23.3
Korea 2.9 3.1 3.8 5.1 7.2 11 11.4
Luxembourg 10.9 12.5 13.6 13.4 14.1 13.9 13.9
Mexico 3.4 4.6 4.3 4.1 4.7 5.8 6.1
Netherlands 9 10.2 11.5 12.8 13.6 15.4 15.9
New Zealand 8.7 8.4 9.7 11.2 11.8 13 13.3
Norway 11 12.9 14.8 16.3 15.2 15 15.2
Poland 5.8 8.2 10.1 10.1 12.2 13.6 13.9
Portugal 7.9 9.4 11.3 13.4 16.2 18.4 19
Slovak Republic 6.9 9.1 10.5 10.3 11.4 12.4 12.7
Slovenia 7.8 9.9 11.7 10.7 14 16.6 16.8
Spain 8.2 9.6 11 13.6 16.8 17 17.6
Sweden 11.8 13.7 16.3 17.8 17.3 18.3 19.3
Switzerland 10.2 11.4 13.8 14.6 15.3 17.4 17.1
Turkey 3.6 4.4 4.7 5.2 6.5 7.7 7.9
United Kingdom 11.7 13 15 15.7 15.8 15.8 16.2
United States 9.2 9.8 11.3 12.5 12.4 13.1 13.2
OECD34 8.6 9.9 11.4 12.1 13.5 15.1 15.4
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
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ADDITIONAL INFORMATION ON DEMOGRAPHIC AND ECONOMIC CONTEXT, AND HEALTH EXPENDITURE AND FINANCINGTable A.3. GDP per capita in 2011 and average annual growth rates, 1970 to 2011
GDP per capita in
USD PPP
Average annual growth rate per capita, in real terms
2011 1970-80 1980-90 1990-2000 2000-10 2010-11
Australia 44 201 1.3 1.5 2.4 1.7 2.2
Austria 42 186 3.5 2.1 2.2 1.1 2.3
Belgium 38 629 3.2 1.9 1.9 0.8 0.6
Canada 40 449 2.8 1.6 1.9 0.8 1.5
Chile 20 855 .. .. 4.8 3.1 5.0
Czech Republic 26 209 .. .. 0.6 3.2 1.8
Denmark 40 933 1.9 2.0 2.2 0.2 0.7
Estonia1 21 998 .. .. .. 3.8 8.3
Finland 37 479 3.4 2.6 1.7 1.4 2.3
France 35 395 3.0 1.9 1.5 0.5 1.2
Germany2, 3 39 662 2.8 2.1 1.3 1.0 3.5
Greece 25 859 3.6 0.2 1.6 1.7 -7.0
Hungary2 21 409 .. .. .. 2.2 1.7
Iceland 36 611 5.2 1.6 1.5 0.9 2.6
Ireland 41 548 3.2 3.3 6.6 0.9 0.2
Israel 28 958 2.4 1.9 2.7 1.3 2.9
Italy 32 648 3.3 2.3 1.6 -0.2 0.0
Japan 33 843 3.2 4.1 0.9 0.7 -0.4
Korea 29 833 7.2 8.4 5.6 3.6 2.9
Luxembourg 88 781 1.9 4.5 3.6 1.2 -0.6
Mexico 17 446 3.6 -0.4 1.8 0.8 3.1
Netherlands 42 716 2.3 1.7 2.5 0.9 0.4
New Zealand 30 942 0.6 1.3 1.7 1.1 0.2
Norway 61 060 4.2 1.0 3.9 1.3 4.0
Poland 21 138 .. .. 3.7 3.8 4.5
Portugal 25 588 3.5 3.0 2.7 0.3 -1.1
Slovak Republic4 24 112 .. .. .. 4.7 3.4
Slovenia 27 351 .. .. 1.9 2.4 0.4
Spain 33 045 2.6 2.6 2.4 0.7 3.2
Sweden 41 461 1.6 1.9 1.7 1.6 2.9
Switzerland 51 227 1.0 1.6 0.4 0.9 0.8
Turkey 16 984 1.7 3.0 2.1 2.5 7.5
United Kingdom 36 158 1.8 2.6 2.5 1.3 0.3
United States 48 113 2.2 2.3 2.2 0.6 1.1
OECD 35 436 2.9 2.3 2.4 1.5 1.8
1. First year available 1993.
2. First year available 1991.
3. Data prior to 1991 refer toWestern Germany.
4. First year available 1992.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
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ADDITIONAL INFORMATION ON DEMOGRAPHIC AND ECONOMIC CONTEXT, AND HEALTH EXPENDITURE AND FINANCINGTable A.4. Total expenditure on health per capita in 2011,
average annual growth rates, 2000 to 2011
Total health
expenditure per
capita in USD PPP
Annual growth rate per capita in real terms1
2011 2007/08 2008/09 2009/10 2010/11 2000-11
Australia2 3 800 2.2 3.6 0.0 .. 2.7
Austria 4 546 3.2 2.1 0.5 0.0 1.8
Belgium3 4 061 4.3 3.1 0.4 0.7 3.1
Canada 4 522 1.8 6.8 1.8 -0.3 3.0
Chile4 1 568 3.0 12.2 4.3 6.6 7.1
Czech Republic 1 966 6.9 10.7 -4.3 2.8 4.7
Denmark 4 448 0.6 5.7 -2.4 -1.2 2.3
Estonia 1 303 12.6 -0.1 -6.9 1.2 5.3
Finland 3 374 3.1 0.5 0.8 2.5 3.5
France 4 118 0.7 2.6 0.7 0.8 1.8
Germany 4 495 3.5 4.4 2.5 1.6 2.1
Greece 2 361 2.6 -2.9 -11.4 -10.9 2.1
Hungary 1 689 -1.7 -3.2 5.4 -0.1 3.0
Iceland 3 305 -0.9 -1.4 -7.2 -0.4 0.6
Ireland 3 700 10.5 3.7 -9.0 -4.2 4.4
Israel 2 239 3.3 -1.6 3.2 3.5 1.7
Italy 3 012 2.6 -0.6 1.3 -2.0 1.2
Japan2 3 213 3.5 4.7 4.9 .. 3.0
Korea 2 198 4.7 7.7 8.6 4.0 8.7
Luxembourg5 4 246 -3.4 4.0 .. .. 0.7
Mexico2 977 1.6 2.2 0.7 .. 2.8
Netherlands 5 099 3.5 3.6 2.7 -0.7 4.7
New Zealand3 3 182 6.6 7.9 0.6 1.0 3.8
Norway 5 669 2.7 1.6 -1.4 2.5 2.4
Poland 1 452 14.3 6.3 0.2 2.2 6.0
Portugal 2 619 2.1 2.6 2.0 -6.3 1.1
Slovak Republic2 1 915 9.2 8.2 2.8 .. 10.0
Slovenia 2 421 9.6 0.6 -2.6 0.2 2.9
Spain 3 072 4.7 2.8 -0.8 -0.1 3.3
Sweden 3 925 2.1 1.4 0.7 2.9 3.1
Switzerland 5 643 1.7 3.5 0.8 2.1 1.8
Turkey6 906 -0.7 .. .. .. 5.6
United Kingdom 3 405 3.6 5.6 -2.5 -1.1 4.0
United States 8 508 1.5 2.1 1.7 1.0 3.0
OECD 3 322 3.9 3.2 -0.2 0.3 3.4
1. Using national currency units at 2005 GDP price level.
2. Most recent year 2010.
3. Excluding investment.
4. CPI is used as deflator.
5. Most recent year 2009.
6. Most recent year 2008.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
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ADDITIONAL INFORMATION ON DEMOGRAPHIC AND ECONOMIC CONTEXT, AND HEALTH EXPENDITURE AND FINANCINGTableA.5. Public expenditure on health per capita in 2011, average annual growth
rates, 2000 to 2011
Public health
expenditure per
capita in USD PPP
Annual growth rate per capita in real terms1
2011 2007/08 2008/09 2009/10 2010/11 2000-11
Australia2 2 578 2.7 4.6 -1.0 .. 2.9
Austria 3 466 3.9 2.0 -0.1 0.5 1.9
Belgium3 3 083 6.5 4.7 -0.9 1.8 3.3
Canada 3 183 2.2 7.4 1.6 -0.8 3.0
Chile4 735 5.0 21.3 3.4 5.8 6.1
Czech Republic 1 655 3.5 12.6 -4.5 3.3 4.0
Denmark 3 795 0.9 6.2 -2.3 -1.0 2.5
Estonia 1 033 15.9 -3.4 -2.5 1.8 5.6
Finland 2 545 3.3 1.4 0.2 3.4 4.0
France 3 161 0.1 2.8 0.6 0.6 1.5
Germany 3 436 3.6 4.9 2.5 1.2 1.7
Greece 1 536 1.9 10.8 -13.4 -13.3 2.9
Hungary 1 098 -2.0 -5.2 4.0 0.3 2.2
Iceland 2 656 -0.8 -2.1 -8.9 -0.4 0.5
Ireland 2 477 10.0 -0.1 -12.7 -7.7 3.3
Israel 1 362 4.4 -0.2 1.7 3.3 1.4
Italy 2 345 3.5 -0.7 0.8 -2.8 1.7
Japan2 2 638 4.8 4.9 5.6 .. 3.2
Korea 1 217 4.3 11.4 8.1 1.9 9.6
Luxembourg5 3 596 -3.4 7.7 .. .. 0.9
Mexico2 462 5.0 5.1 -1.2 .. 3.0
Netherlands6 4 055 4.4 4.5 2.8 -0.8 6.9
New Zealand3 2 631 7.2 8.1 0.8 0.5 4.4
Norway 4 813 3.0 1.8 -1.2 2.7 2.7
Poland 1 021 16.5 6.1 -0.3 0.9 6.0
Portugal 1 703 0.0 4.6 1.1 -7.6 0.9
Slovak Republic 2 1 358 10.7 4.9 0.9 .. 6.5
Slovenia 1 784 12.8 0.2 -2.3 -0.2 2.8
Spain 2 244 6.4 5.2 -1.5 -1.7 3.4
Sweden 3 204 2.2 1.4 0.7 3.1 2.7
Switzerland 3 661 12.1 4.2 0.4 1.5 3.3
Turkey7 661 6.9 .. .. .. 7.6
United Kingdom 2 821 4.7 7.6 -1.4 -1.9 4.4
United States 4 066 3.4 4.8 2.4 1.5 4.0
OECD 2 414 5.1 4.4 -0.7 -0.1 3.5
1. Using national currency units at 2005 GDP price level.
2. Most recent year 2010.
3. Excluding investment.
4. CPI is used as deflator.
5. Most recent year 2009.
6. Data refer to public current expenditure.
7. Most recent year 2008.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en.
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ADDITIONAL INFORMATION ON DEMOGRAPHIC AND ECONOMIC CONTEXT, AND HEALTH EXPENDITURE AND FINANCINGTable A.6. Total expenditure on health, percentage of GDP, 1980 to 2011
1980 1990 1995 2000 2005 2009 2010 2011
Australia 6.1 6.8 7.3 8.1 8.5 9.0 8.9 ..
Austria 7.5 | 8.4 9.6 10.0 10.4 11.2 11.0 10.8
Belgium1 6.3 7.2 | 7.6 8.1 | 10.0 10.6 10.5 10.5
Canada 7.0 8.9 9.0 8.8 9.8 11.4 11.4 11.2
Chile .. .. 5.2 6.4 6.6 7.9 7.4 7.5
Czech Republic .. 4.4 | 6.7 | 6.3 | 6.9 8.0 7.4 7.5
Denmark 8.9 8.3 8.1 8.7 | 9.8 11.5 11.1 10.9
Estonia .. .. .. 5.3 5.0 7.0 6.3 5.9
Finland 6.3 7.7 | 7.8 7.2 8.4 9.2 9.0e 9.0e
France 7.0 8.4 | 10.4 10.1 | 11.0 11.7 11.7 11.6
Germany 8.4 8.3 | 10.1 10.4 10.8 11.8 11.5 11.3
Greece 5.9 6.7 8.7 8.0 9.7 10.2 9.5 9.1
Hungary .. 7.1 1991 7.3 | 7.2 | 8.4 7.7 8.0 7.9
Iceland 6.3 7.8 8.2 9.5 9.4 9.6 9.3 9.0
Ireland 8.1 6.0 6.6 6.1 7.6 10.0 9.3 8.9
Israel 7.7 7.1 7.6 7.5 7.9 7.7 7.7 7.7
Italy .. 7.7 7.1 7.9 8.7 9.4 9.4 9.2
Japan 6.4 5.8 | 6.8 7.6 8.2 9.5 9.6 ..
Korea 3.6 3.9 3.7 4.3 5.6 7.1 7.3 7.4
Luxembourg 5.2 5.4 | 5.6 | 7.5 7.9 8.0 7.2 6.6
Mexico .. 4.4 5.1 | 5.1 | 5.9 6.4e 6.2e ..
Netherlands 7.4 8.0 8.3 | 8.0 | 10.9 11.9 12.1 11.9
New Zealand1 5.8 6.8 7.1 7.6 8.4 10.0 10.2 10.3
Norway 7.0 7.6 | 7.9 | 8.4 | 9.0 9.7 9.4 9.3
Poland .. 4.8 5.5 5.5 | 6.2 7.2 7.0 6.9
Portugal 5.1 5.7 | 7.5 | 9.3 10.4 10.8 10.8 10.2
Slovak Republic .. .. 5.8 1997 5.5 | 7.0 9.2 9.0 | 7.9
Slovenia .. .. 7.5 8.3 | 8.4 9.2 8.9 8.9
Spain 5.3 6.5 7.4 | 7.2 | 8.3 9.6 9.6 9.3
Sweden 8.9 8.2 | 8.0 8.2 9.1 9.9 9.5 9.5
Switzerland 7.2 8.0 | 9.3 9.9 10.9 11.0 10.9 11.0
Turkey 2.4 2.7 2.5 | 4.9 5.4 6.1 2008 .. ..
United Kingdom 5.6 5.8 6.8 7.0 8.3 9.9 9.6 9.4
United States 9.0 12.4 13.7 13.7 15.8 17.7 17.7 17.7
OECD2 6.6 6.9 7.5 7.8 8.7 9.62 9.42 9.32
Brasil .. .. 6.7 7.2 8.2 8.8 9.0 8.9
China .. .. 3.5 4.6 4.7 5.1 5.0 5.2
India .. .. 4.0 4.3 4.2 3.9 3.7 3.9
Indonesia .. .. 2.0 2.0 2.8 2.9 2.8 2.7
Russia .. .. 5.4 5.4 5.2 6.2 6.5 6.2
South Africa .. .. 7.4 8.3 8.8 8.7 8.7 8.5
| Break in the series.
e: Preliminary estimate
1. Excluding investment.
2. OECD average calculated with the most recent data available.
Source: OECD Health Statistics 2013, http://dx.doi.org/10.1787/health-data-en; WHO Global Health Expenditure Database.
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